consultant cme national committee

Dr. CESARE GRIDELLI
CURRICULUM VITAE
INDEX:
Iter ....................................................................................................
3
Management courses .........................................................................
5
Teaching activity ...............................................................................
6
Scientific society and cooperative group membership………………
7
Committee Membership ......................……………………………… 7
Fellowships and accademy awards .....................................................
8
Courses and Congresses Direction........................................................ 9
Chairman in national conference ......................................................... 11
Chairman in international conference .................................................. 18
Participation at Consensus Conference, Panel and Guidelines .........
20
Invited lectures in national conference ...............................................
21
Invited lectures in international conference ………………
37
Organization of national conferences and meetings …………..
44
Organization of international conferences .......................................... 47
Project leadership ..............................................................................
48
Acting as reviewer .............................................................................
49
Associate editor activity ...................................................................... 51
Abstracts at national meetings ...........................................................
52
Abstracts at international meetings ....................................................
64
Book chapters ...................................................................................
84
Books ................................................................................................... 86
Books and manuals on electronic version ........................................... 87
Articles on national journals ..............................................................
88
Articles on indexed international journals ........................................... 94
Citation index ....................................................................................
126
2
ITER
Date and Place of birth:
24-3-1961 - Naples (Italy)
M.D. Degree:
July 30, 1985
Summa cum laude
Medical School,
University "Federico II" of Naples, Italy
Medical board:
February 26, 1986
University "Federico II" of Naples, Italy
Speciality in Oncology:
July 12, 1988
Summa cum laude
Medical School,
University "Federico II" of Naples, Italy
Speciality in Internal Medicine:
July 15, 1993
Medical School,
University "Federico II" of Naples, Italy
Research Interest:
Lung Cancer
Experience:
1983 - 1985
Student fellow,
Division of Medical Oncology,
Medical School,
University "Federico II" of Naples, Italy
1985 – 1988
Resident,
Division of Medical Oncology,
Medical School,
University "Federico II" of Naples, Italy
1988 – 1993
Fellow,
Division of Medical Oncology,
Medical School,
University "Federico II" of Naples, Italy
December 1993
Assistant Professor,
Division of Medical Oncology B,
National Cancer Institute of Naples, Italy
July 1996
Vice Chief
Division of Medical Oncology B,
3
National Cancer Institute of Naples, Italy
January 2001
Chief of Day Hospital Chemotherapy Unit
National Cancer Institute of Naples, Italy
Current Position:
Since December 2001
Chief Division of Medical Oncology
“S. G. Moscati” Hospital, Avellino, Italy
Since December 2003
Director Department of
Oncology/Hematology “S.G. Moscati”
Hospital, Avellino, Italy
4
MANAGEMENT COURSES
Course of management for chief of the staff named “Ippocrate” held to the “Luigi
Bocconi” University in Milan (Italy).
February - March - April 1999.
The course has the criteria specified by Italian Ministery of Health.
5
TEACHING ACTIVITY
1. Professor post-graduated School in Oncology, Medical School, University "Federico
II" of Naples, Italy for the academic course 1996/1997, 1997/1998, 1998/1999,
1999/2000.
2. Professor in “General Physiopathology” School of Nursing, Second University of
Naples Italy, for the academic course 1999/2000 and 2000/2001.
3. Professor post-gratueted School in Oncology, Medical School, University “Federico
II” of Naples, Italy since 2002. Inclusion of the Division of Medical Oncology of
“S.G. Moscati” Hospital, Avellino, run by Dr Gridelli, in the Educational Program of
the above cited School.
4. Professor post-gratueted School in Oncology, Medical School, “Second University of
Naples” (SUN), Italy since 2004. Inclusion of the Division of Medical Oncology of
“S.G. Moscati” Hospital, Avellino, run by Dr Gridelli, in the Educational Program of
the above cited School.
5. Director of the Italian School of Thoracic Oncology (SIOT) since 2008.
6
SCIENTIFIC SOCIETY AND COOPERATIVE GROUP MEMBERSHIP
 Associazione Italiana di Oncologia Medica (A.I.O.M.) since 1988
Member of National Directory Board since 2006
 American Society of Clinical Oncology (A.S.C.O.) since 1995
 International Association for the Study of Lung Cancer (I.A.S.L.C.) since 2006
 International Society of Geriatric Oncology (SIOG) from 2003 to 2009
 Gruppo Oncologico Italia Meridionale (G.O.I.M.)
Advisor Board Member since 2001
Secretary from 2004 to 2006
 Gruppo Italiano di Geriatria Oncologica (G.I.O.Ger)
Directory Board Member from 2000 to 2008
 European Organization for Research and Treatment of Cancer
(E.O.R.T.C.) "Lung Cancer Cooperative Group" from 1996 to 2000

Clinical Trial Promoting Group (C.T.P.G.)
Advisor Board Member since 2001
Chairman of “Lung Cancer Section” since 2001

Associazione Italiana di Oncologia Toracica (A.I.O.T.)
Secretary since 2007

Euroepan Society of Medical Oncology (ESMO) since 2008

European
Thoracic
Oncology
Platform
Foundation Council Member from 2009 to 2013.
Foundation
(ETOP)
CONSULTANT CME NATIONAL COMMITTEE

Consultant of Continuing Medical Education (CME) National Committee from 2002
to 2011.
EUROPEAN EXPERT FOR EMEA

European Expert for Oncology of European Medicine Evaluation Agency (EMEA)London (UK) year 2004.
7
FELLOWSHIPS
 Fondazione Italiana Ricerca sul Cancro for the course "Medical Oncology" of the
European School of Oncology Milano, June 30 - July 5, 1986.
 Lega Italiana per la Lotta Contro i Tumori for the study: "Treatment of early stage
cutaneus T cell lymphpma with alpha2-b interferon" performed at the Division of
Medical Oncology, Medical School, University "Federico II" of Naples from April
1987 to February 1988.
ACCADEMY AWARDS
 Prize "Corrado Gallo Curcio" of the Associazione Italiana di Oncologia Medica
(AIOM) due to the original study: "Phase II study of mitomicin C, etoposide e
vindesine (MEV) in the treatment of advanced non small cell lung cancer”. Prize
given by Associazione Italiana di Oncologia Medica on November 1990 in Bologna.
 Prize of the Lega Italiana per la Lotta Contro i Tumori for the study: "Carboplatin plus
epirubicin plus VP-16, concurrent radiotherapy and adjuvant surgery for limited small
cell lung cancer (SCLC)" presented at the "Third International Conference on small
cell lung cancer". Ravenna May 6-7, 1993.
 Prize of the International Association for Study of Lung Cancer (I.A.S.L.C.) and
European Society of Medical Oncology (ESMO) for the study: “Vinorelbine plus best
supportive care vs best supportive care in the treatment of advanced non small cell
lung cancer elderly patients. Results of a phase III randomized trial”, presented at the
IV Perugia International Cancer Conference. Perugia October 11-13, 1998.
 International Prize 2004 for “Biomedical Sciences” of the Cultural International
Association Sebetia Ter. Under the auspices of the Italian President of Republic. Prize
given at the Court Theater of the Royal Palace of Naples (Italy) on April 2, 2005.
 Prize Lucio Colletti 2010 for “Medical Science” of the Studies Center Lucio
Colletti.. Prize given at Pietro da Cortona Room of Campidoglio in Rome on June 18,
2010.
 Prize “Anna Maria Di Sipio” for Oncology of the Ferdinando Palasciano Association.
Prize given at “Aula Magna” of Faculty of Economy, Second University of Naples in
Capua on December 7, 2013.
 Prize “Buona Sanità 2014” of the Buona Sanità Association given at Naples on May
8, 2014.
8
9
COURSES AND CONGRESSES DIRECTION
1) Sopravvivenza e Qualità di vita: end point a confronto in Oncologia. Naples,
February 24-25 2000.
2) II° Corso di Aggiornamento in Oncologia Geriatrica. La chemioterapia nel
paziente oncologico anziano. Naples, February 21-22, 2001.
3) Italian - German Cooperative Educational Symposium on Diagnosis and
Treatment of Non Small Cell Lung Cancer. Heidelberg (Germany), April 18-20
2002.
4) Survival and Quality of Life: Comparing End Points in Oncology: two years later.
Napoli, December 13-14 2002.
5) Italian-Spanish Educational Corse on the Diagnosis and Treatment of Lung
Cancer. Barcelona (Spain), September- October 2 2004.
6) VII Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM),
Napoli, October 18-21 2005.
7) I Conferenza Italiana di Oncologia Toracica (CIOT). Naples June 26-28 2008.
8)
Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule. Frascati (Rome), July-November, 2008.
9)
Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule.”. Frascati (Rome), March-April, 2009.
10) Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule.”. Frascati (Rome), March-May, 2009.
11) Residential Course of Italian School of Thoracic Oncology (SIOT)/European
Society of Medical Oncology (ESMO). Non small cell lung cancer: from
diagnosis to treatment in the third millennium era”. Frascati (Rome), JulySeptember, 2009.
12) Residential Course of Italian School of Thoracic Oncology (SIOT)/European
Society of Medical Oncology (ESMO). Non small cell lung cancer: from
diagnosis to treatment in the third millennium era”. Frascati (Rome), JulySeptember, 2010.
13) . Residential Course of Italian School of Thoracic Oncology (SIOT Le metastasi
ossee da NSCLC: nuovi opzioni per un approccio globale. Frascati (Rome),
January 21-22, 2011.
14) Corso residenziale della Scuola Italiana di Oncologia Toracica (SIOT)/European
Thoracic Oncology Platform (ETOP). Advanced non small cell lung cancer: new
prospective in first-line setting”. Frascati (Roma), May 13-14, 2011.
10
15) Corso residenziale della Scuola Italiana di Oncologia Toracica (SIOT)/European
Society of Medical Oncology (ESMO). Advanced non small cell lung cancer:
new prospective in Thoracic Oncology”. Frascati (Roma), October 14-15, 2011.
16) International Conference on Thoracic Oncology (CIOT). Naples, June 28-30
2012.
17) Corso residenziale della Scuola Italiana di Oncologia Toracica (SIOT) NET
INSIGHT: tumori neuroendocrini toracici. Frascati (Rome), 23 November 2012.
18) Il carcinoma polmonare: dalla diagnosi al trattamento nell’era del terzo millennio
Corso Residenziale Teorico pratico. Avellino, 15-16 May 2014.
19) International Conference on Thoracic Oncology (CIOT). Rome, June 26-28 2014.
20) Il carcinoma polmonare non a piccole cellule: dalla diagnosi al trattamento
nell’era del terzo millennio Corso Residenziale Teorico pratico. Avellino, 20-21
June 2014.
21) Strategie terapeutiche in prima e seconda linea nei pazienti con NSCLC
EGFRM+ e EGFRWT. Avellino, 7 Luglio 2014.
11
CHAIRMAN IN NATIONAL CONFERENCE
1. Scuola Superiore di Oncologia e Scienze Biomediche. "Journal Club: L'Oncologia
Medica nel 1996." Session: "BRM nei tumori solidi: quali prospettive?" Naples
September 26, 1996.
2. Società Italiana di Psicologia Oncologica. "La psicologia oncologica: problemi e
prospettive." Naples November 20, 1996.
3. XXV Congresso Nazionale SIT (Società Italiana Tumori). Session: “Il ruolo del
topotecan nel trattamento del tumore del polmone: attualità e prospettive.” Sorrento
(Na) November 19, 1999.
4. 3° Congresso Nazionale AIOM (Associazione Italiana Oncologia Medica).
Simposium: “Docetaxel: verso nuovi impieghi nel trattamento dei tumori solidi”.
Naples November 4, 2001.
5. “Incidenza e attualità diagnostiche e terapeutiche delle neoplasie pleuro-polmonari.”
Avellino February 23, 2002.
6. X Riunione Nazionale: “Update sul trattamento dei tumori polmonari”. Naples April
8, 2002.
7. GOIM (Gruppo Oncologico Italia Meridionale) Meeting: “I tumori urogenitali”.
Avellino April 9, 2002.
8. Attualità nel trattamento dei tumori della mammella e del polmone. Session II:
“Carcinoma del polmone.” Fasano (Br) April 13, 2002.
9. Patologie ematologiche ed oncologiche: percorsi diagnostici-terapeutici. Session I:
“Nuove acquisizioni nel trattamento medico dei tumori solidi.” Avellino May 31,
2002.
10. Le metastasi epatiche attualità diagnostiche e terapeutiche. Avellino June 14, 2002.
12
11. Il progetto salute e l’Oncologia nell’anziano: quale rivoluzione? III incontro.
Pozzuoli (Na) June 6, 2002.
12. Corso Nazionale di Perfezionamento in Oncologia Polmonare “Il carcinoma
polmonare non a piccole cellule.” Avellino September 11-12, 2002.
13. Terapia Medico-Nucleare del dolore oncologico scheletrico. Avellino September 20,
2002.
14. 4° Congresso Nazionale AIOM (Associazione Italiana Oncologia Medica). “I tumori
del polmone e del testa-collo”. Turin October 1, 2002.
15. Attualità e prospettive nel trattamento del carcinoma mammario: nuovi farmaci orali.
Avellino October 7, 2002.
16. Corso di Aggiornamento: “Attualità di terapia chirurgica nel trattamento delle
neoplasie polmonari.” Avellino October 12, 2002.
17. XXVII Congresso Nazionale della Società Italiana di Chirurgia Toracica: “Ruolo di
Navelbine nel carcinoma polmonare non a piccole cellule”. Rome November 25,
2002.
18. Corso Residenziale: “Trattamento del carcinoma del polmone non a piccole cellule:
stato dell’arte e prospettive future.” Avellino November 15, 2002.
19. Paclitaxol: present and future perspectives. Plenary Session, Round Table Group 4:
“NSCLC Stage III.” Naples March 21-22, 2003.
20. Stato dell’arte e prospettive nella lotta ai tumori: il carcinoma polmonare ed il
carcinoma della mammella. Recenti sviluppi nella diagnosi e nel trattamento del
tumore della mammella e del polmone. II Session: “Vinorelbine orale.” Venice
March 21-23, 2003.
21. Quando la psicologia incontra l’oncologia. Avellino April 8, 2003.
22. Il carcinoma polmonare non microcitoma III stadio: quale standard?: “Lo stato
dell’arte nel trattamento del III stadio”. Avellino May 23, 2003.
23. Corso di aggiornamento in Oncologia Medica: “Gestione clinica della tossicità da
chemioterapia e del rischio trombotico nel paziente oncologico.” Naples June 13,
2003.
24. Recenti acquisizioni in oncologia. Naples June 17, 2003.
25. Focus Group on Anemia. Naples June 24, 2003.
26. Convegno di aggiornamento: “Diagnosi e trattamento dei tumori stromali gastrointestinali (GIST).” Avellino June 26, 2003.
13
27. Attualità nella diagnosi e nella terapia del cancro del polmone non oat-cells. Avellino
October 29, 2003.
28. La qualità di vita nel paziente oncologico. Avellino November 27, 2003.
29. Carcinoma mammario, attualità e prospettive. Avellino March 18-20, 2004.
30. Incontri di Oncologia 2004: “Focus on Simposio: la conservazione degli organi in
oncologia.” Vallo della Lucania (Sa) May 11, 2004.
31. Benevento Breast Cancer. Session I: “Terapie adiuvanti.” Benevento May 28, 2004.
32. La gestione della tossicità in corso di trattamento chemioterapico. Benevento
September 28, 2004.
33. VI Congresso Nazionale AIOM (Associazione Italiana Oncologia Medica). Session:
“Tumori del polmone, pleura e testa collo.” Boulogne September 21-24, 2004.
34. La gestione della tossicità in corso di trattamento chemioterapico. Benevento
September 28, 2004.
35. Le cure palliative al servizio della qualità di vita: “Le terapie orali.” Pietrelcina (Bn)
October 8-9, 2004.
36. Aggiornamento Carcinoma mammario: attualità e prospettive. Session III:
“Trattamento medico.” Avellino April 9, 2005.
37. Il carcinoma della mammella: un approccio integrato. Session III: “La gestione della
paziente con malattia metastatica ossea.” Naples May 27, 2005.
38. Novità terapeutiche nel trattamento dei tumori toracici. Naples June 28, 2005.
39. Stage Itinerante di Oncologia: lo stato dell’arte delle terapie di supporto. Avellino
September 29, 2005.
40. 2° Congresso Oncologico Sannita: I tumori nell’anziano. “I tumori del polmone
nell’anziano.” Benevento October 6-8, 2005.
41. Attualità e prospettive nella malattia metastatica ossea: “La terapia medica.” Naples
October 4, 2005.
42. Il carcinoma colorettale dalla teoria alla pratica clinica. Benevento November 17-18,
2005.
43. Attualità e prospettive nella malattia metastatica ossea. Milan November 26, 2005.
44. Nuove opzioni terapeutiche in oncologia. Milan January 23, 2006.
45. La scomparsa del dolore da cancro: un sogno che diventa realtà. Avellino March 1,
2006.
14
46. La chemioterapia del carcinoma dl polmone non a piccole cellule early stage:
strategie a confronto. Rome March 2-3, 2006.
47. Novità sui trattamenti combinati/integrati in Oncologia. Bari March 6-8, 2006.
48. I nuovi farmaci biologici. Avellino May 18-19, 2006.
49. Recenti acquisizioni in tema di management dell’anemia indotta da chemioterapia e
profilassi della neutropenia febbrile. Vietri sul mare (Sa) May 26, 2006.
50. Il trattamento del carcinoma colo-rettale nel 2006. Napoli June 23, 2006.
51. Le patologie neoplastiche del fegato. Bacoli (NA) June 5-6, 2006.
52. Il carcinoma del colon: esperienze a confronto. Avellino September 27, 2006.
53. Nuove terapie citotossiche e molecolari nel carcinoma squamoso del distretto
cervico-cefalico. Naples October 26 2006.
54. Carcinoma polmonare e terapie biologiche: progressi e prospettive. Genoa October
20 2006.
55. VIII Congresso Nazionale di Oncologia Medica. Le neoplasie polmonari tra biologia
e nuovi farmaci. Milan November 18-21 2006.
56. VIII Congresso Nazionale di Oncologia Medica. Simposium Il percorso terapeutico
nel NSCLC: quali evidenze per poter decidere nella pratica clinica? Milan November
18-21 2006.
57. EGFR e neoplasie: il ruolo degli anticorpi monoclonali. Benevento, March 23, 2007.
58. La scomparsa del dolore da cancro: un sogno che diventa realtà. Naples, May 24
2007.
59. Terapie biologiche nel NSCLC. Naples, June 22, 2007.
60. Associazione Italiana di Oncologia Medica. “Nuovi farmaci oncologici: indicazioni,
appropriatezza e sostenibilità”. Rome, July 12, 2007.
61. Export Forum on Gastrointestinal Cancer. Naples, September 18, 2007.
62. Percorso terapeutico nel carcinoma polmonare (NSCLC). Avellino, November 5
2007.
63. IX Congresso nazionale di Oncologia Medica. Sessione Educazionale sui Tumori del
Polmone. Palermo, October 12-15, 2007.
64. Le neoplasie del torace. Naples, November 9, 2007.
15
65. Export Forum GI Cancer “Ruolo delle fluoropirimidine orali vs infusionali nel ca. del
colon-retto”. Naples, March 4 2008.
66. Expert Forum “Oncotarget nel carcinoma polmonare”. Naples, March 18 2008.
67. Carcinoma mammario:attualità e prospettive. Napoles, March 28 2008.
68. Corso Residenziale SIOT . Il carcinoma polmonare non a piccole cellule. Frascati
(Rome) July 10-11, 2008.
69. Seminari di Oncologia. Le neoplasie dell’apparato urinario e genitale. Avellino,
September 23, 2008.
70. Il carcinoma della mammella: la terapia alle soglie del terzo millennio. Naples,
September 25, 2008.
71. Il carcinoma del polmone non a piccole cellule. Ricerca, pratica, prospettive. Naples,
October 2, 2008.
72. Il carcinoma del polmone non a piccole cellule: le nuove opzioni terapeutiche. Rome,
October 4, 2008.
73. X Congresso Nazionale AIOM. Simposio Merck-Serono. Strategie attuali e future nel
trattamento dei tumori solidi: ruolo di cetuximab. Verona, October 12, 2008.
74. Associazione Italiana di Oncologia Toracica.Il carcinoma polmonare non a piccole
cellule: la terapia alle soglie del terzo millennio. Naples, November 7, 2008.
75. I Expert Forum Campano. Il carcinoma polmonare non a piccole cellule avanzato:
strategie terapeutiche. “Chemioterapia verso i farmaci a bersaglio molecolare in II
linea:quali scelte?. Avellino, November 11, 2008.
76.
Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule. Frascati (Rome), July-November, 2008.
77.
Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule.”. Frascati (Rome), March-April, 2009.
78. Residential Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma
polmonare non a piccole cellule.”. Frascati (Rome), March-May, 2009.
79. Clinical Governance. Franciacorta (BS), March 28, 2009.
80. Anchor Project “Bevacizumab nel NSCLC”. Naples, May 14, 2009.
81. Clinical Governance. Gavi (GE), June 12, 2009.
82. Anchor Project. “Bevacizumab in NSCLC”. Milan, June 16, 2009.
83. Clinical Governance. Monteporzio Catone (Rome), June 19, 2009.
16
84. Challenge Project “Erlotinib in NSCLC”. Naples, June 23, 2009.
85. Challenge Project “Erlotinib in NSCLC”. Milan, July 3, 2009.
86. II Expert Forum Campano. Il carcinoma del polmone non a piccole cellule avanzato:
strategie terapeutiche. Avellino, July 7, 2009.
87. Residential Course of Italian School of Thoracic Oncology (SIOT)/European Society
of Medical Oncology (ESMO). Non small cell lung cancer: from diagnosis to
treatment in the third millennium era”. July-September, 2009.
88. I Moving Course of Italian School of Thoracic Oncology (SIOT). Il carcinoma del
polmone non a piccole cellule: dalla diagnosi al trattamento nell’era del terzo
millennio”. Zerman di Mogliano Veneto (TV), October 2-3, 2009.
89. Il ruolo delle mutazioni di K-ras e EGFR nella scelta del tratamento nei tumori del
colon-reto e del polmone. Avellino, October 8, 2009
90. Clinical Governance. Naples, October 30, 2009.
91. Residential Course of Italian School of Thoracic Oncology (SIOT). “SCLC:
highlight nell’era del terzo millennio”. Frascati (Rome), November 6-7, 2009.
92. III Expert Forum Campano “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, October 6, 2009.
93. Expert Forum: best clinical practice nel carcinoma della mammella. Benevento,
Novembre 21, 2009.
94. La PET/TC in Oncologia. Acerra (NA), Decdember 19, 2009.
95. IV Expert Forum Campano. “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, July 8, 2010.
96. Lung Road. Percorsi di cura nel carcinoma polmonare. Naples, September 20, 2010.
97. V Expert Forum Campano. “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, September 27, 2010.
98. Il trattamento del NSCLC avanzato nell’era della mutazione dell’EGFR. Naples,
October 15, 2010.
99. I Corso Regionale GOIM Regione Campania. La programmazione terapeutica del
carcinoma mammario operabile, Avellino, October 22, 2010.
100.
13 Congresso Nazionale GOIM. I Tumori del polmone. Bari, June 20, 2011.
17
101. VI Expert Forum Campano. Up-date nella terapia del carcinoma polmonare non a
piccole cellule. Avellino, June 30, 2011.
102. XIII Congresso Nazionale di Oncologia Medica, Sessione Educazionale sul
Tumore del Polmone. Bologna, Novenber 7 2011.
103.
A-NSCLC personalized treatment. Napoli, November 24 2011.
104.
I tumori del pancreas. AORN Moscati Avellino, May 17 2012.
105. VII Expert Forum Campano. Up-date sul trattamento del carcinoma polmonare
non a piccole cellule. Avellino, July 12 2012.
106. NET INSIGTH: raccomandazioni per la pratica clinica e nuove prospettive.
Naples, July 19 2012.
107. SIOT NET INSIGHT: tumori neuroendocrini toracici. Frascati (Roma), 23
Novembre 2012.
108. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. Naples, 25 February 2013.
109. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. Bari, 14 March 2013.
110.
NSCLC: controversie nella pratica clinica. Naples, 11 April 2013.
111.
Inibizione di m-TOR in Oncologia. Pozzuoli, 7 May 2013.
112.
Carcinoma mammario avanzato: nuovi scenari. Benevento, 20 May 2013.
113.
NSCLC: controversie in Oncologia. Naples, 13 June 2013.
114.
I tumori del pancreas. Avellino, September 10, 2013.
115.
Thoracic Oncology:where are we going. Parma, September 20, 2013.
116. 15 Congresso Nazionale AIOM. Sessione Educazionale Giovani from papers to
bedside. Milan, October 12, 2013.
117. Terapia del dolore oncologico nelle provincie di Avellino e Benevento. Solofra
(AV), 17 March 2014.
118.
Focus sulla ricerca oncologica: attualità e prospettive. Naples, 17 April 2014.
18
CHAIRMAN AT INTERNATIONAL CONFERENCE
1. E.O.R.T.C. - Lung Cancer Cooperative Group Meeting. New trends in lung cancer.
Session: "Clinical approaches to SCLC." Naples May 11, 1996.
2. International Workshop on New Strategies in the Cancer Treatment. Round Table:
“Nuove prospettive nei tumori polmonari.” Naples October 2-3, 2000.
3. European Society of Medical Oncology (ESMO). Poster Symposium: “Elderly
Patients.” Hamburg October 15, 2000.
4. Italian-German Cooperative Educational Symposium on Diagnosis and Treatment of
Non-Small Cell Lung Cancer. Heidelberg December 13-15, 2001.
5. European School of Oncology: Advances in solid tumour treatment. Rome February
25-26, 2002.
6. Italian-German Cooperative Educational Symposium on Diagnosis and Treatment of
Non-Small Cell Lung Cancer. Heidelberg April 18-20, 2002.
19
7. Survival and quality of life: comparing end points in oncology. Two years later.
Naples December 13-14, 2002.
8. IRESSA Opinion Leader Summit for Non Small Cell Lung Cancer. Breakout session
on stage IV, 1st line. Washington November 3, 2002.
9. First IASLC/ASCO International Conference: “Molecular Targeted Therapies in
Lung Cancer”. Marbella January 15-19, 2003.
10. Workshop on treatment of advanced NSCLC patients with performance status 2.
Avellino April 14–15, 2003.
11. 10th World Conference on Lung Cancer. “Management of Lung Cancer in the
Elderly”. Vancouver August 11-15, 2003.
12. 1st Mediterranean Conference on Oncology. Treatment of gastrointestinal cancer.
Simposium IV: “Novità in oncologia medica.” Bari October 5-8, 2003.
13. 2nd Investigator Meeting on NSCLC and ABC. “Advanced Disease”. Dresden
October 16-18, 2003.
14. Fourth Meeting of SIOG, Geriatric Oncology: Cancer in the elderly. Session IV:
“Clinical approaches”. Rome November 20, 2003.
15. International Naples Conference: “Treatment of advanced non small cell lung cancer
in the elderly”. Naples April 20, 2004.
16. Introducing the IACT Congress: Europe and US discuss about the leading edge in
anticancer treatment: “The leading edge in lung cancer treatment.” Paris January 31 –
February 1, 2005.
17. Hematopoietic Growth Factors in Solid Tumors: Expert Panel Meeting and
Conference. Avellino April 11, 2006.
18. I World Conference on Interventional Oncology. Cernobbio June 12-16, 2006.
19. The Vesuvian Interactive Thoracic Course. First Session “The interaction between
the clinician an the researcher”. Naples September 21-22, 2006.
20. 7 Meeting of the International Society of Geriatric Oncology. “Targeted therapies and
chemotherapy: new challenge for the treatment of advanced NSCLC elderly patients.
; The Hague (Netherland), November 2-4 2006.
21. International Experts Panel Conference. “Second-line treatment of advanced
NSCLC”. Naples, April 17 2007.
22. I ESMO-IASLC Lung Cancer Conference. Poster Session “Biology”. Genere, April
23-26, 2008.
23. I Conferenza Italiana di Oncologia Toracica. Naples June 26-28 2008.
20
24. European Multidisciplinary Conference on Thoracic Oncology. Roche Satellite
Symposium “Spotlight on treatment decisions in NSCLC”. Lugano, May 2, 2009.
25. ECCO 15- ESMO 34 Congress. Specific issues in lung cancer management. Berlin,
September 22 2009.
26. II Conferenza Italiana di Oncologia Toracica. Rome, June 26-28 2010.
27. European Multidisciplinary Conference on Thoracic Oncology. “Maintenance
treatment in advanced NSCLC”. Lugano (Switzerland), February 26, 2011.
28. III International Conference of Thoracic Oncology. Rome, June 28-30 2012.
29. ESMO Congress. Latest innovations in advanced NSCLC. Vienna (Austria), 1
October 2012.
30. ECLC Congress (ESMO/IASLC). Overcoming resistance in ongogenic-driven
disease. Geneve (Switzerland), March 28, 2014.
31. IV International Conference on Thoracic Oncology. Roma,26-28 June 2014.
PARTICIPATION AT CONSENSUS CONFERENCE, PANEL AND
GUIDELINES
1. An International Consensus Panel: Improving therapeutic Outcomes. Paris May 29,
2001.
2. CECOG Consensus on medical treatment of non-small cell lung cancer. Wien
October, 2001.
3. European Consensus Panel on treatment of advanced NSCLC patients with
performance status 2. Avellino April 14, 2003.
4. International Consensus Experts Panel on the treatment of adanced non small cell
lung cancer in the elderly. Naples April 19, 2004.
5. CECOG Consensus on medical treatment of non small cell lung cancer. Wien
November, 2004.
6. Hematopoietic Growth Factors in Solid Tumors: Experts Panel Meeting and
Conference. Avellino April 10-11, 2006.
21
7. International Experts Panel Meeting.“Second-line treatment of advanced NSCLC”.
Naples, April 16, 2007
8. International Experts Panel Meeting “First-line treatment of advanced non small cell
lung cancer”. Sperlonga (LT), May 7, 2009.
9. ESMO Lung Cancer Consensus Conference “Treatment of lung cancer”. Lugano,
May 21-22, 2010.
10.International Experts Panel Meeting “Role of maintenance treatment in advanced
non small cell lung cancer”. Sperlonga (LT), May 6, 2011.
11.Third CECOG Consensus on the systemic treatment of non small cell lung cancer.
Vienna, January 2010.
12. International Experts Panel Meeting “Treatment of advanced NSCLC with EGFR
mutation or ALK rearrangement”. Sperlonga (LT), May 3, 2013.
13.International Experts Panel Meeting “Treatment of NSCLC in the elderly: 10 years
later”. Sperlonga (LT), May 9, 2014.
INVITED LECTURES IN NATIONAL CONFERENCE
1. Attualità in tema di carcinoma polmonare non microcitoma: "La chemioterapia neoadiuvante." Naples April 5, 1989.
2. Attualità in tema di carcinoma polmonare a piccole cellule aspetti biologici e
implicazioni diagnostiche-terapeutiche: "Terapie Combinate." Naples March 16,
1990.
3. Società Italiana di Endoscopia Toracica. V Convegno di Aggiornamento. Il
carcinoma del polmone e le neoplasie del mediastino. Diagnosi e indirizzi terapeutici:
"Indirizzi terapeutici nel carcinoma polmonare." Naples April 28, 1990.
4. Simposi monotematici di oncologia. Cancro del polmone: "Problematiche della
terapia del SCLC." Naples May 17, 1990.
22
5. IX Riunione Annuale di Patologia Toracica. Le metastasi toraciche: "La terapia
medica." Cava dei Tirreni (Sa) April 27, 1991.
6. I Simposio GOIM (Gruppo Oncologico Italia Meridionale). Conferenza nazionale
SIPDTT (Società Italiana di Prevenzione, Diagnosi e Terapia dei Tumori). Oncologia
Medica: nuove strategie terapeutiche. Microcitoma polmonare: "La chemioterapia."
Bari June 12-14, 1991.
7. Il trattamento della nausea e del vomito da chemioterapia antineoplastica: nuove
acquisizioni sul ruolo dei 5HT3 antagonisti: "Il controllo della nausea e del vomito in
oncologia." Verona June 18, 1991.
8. Strategie terapeutiche nelle neoplasie polmonari non operabili: "Le terapie combinate
nel carcinoma polmonare a piccole cellule." Naples October 3, 1991.
9. XVII Congresso Nazionale di Oncologia SIPDTT (Società Italiana di Prevenzione,
Diagnosi e Terapia dei Tumori): "I 5HT3 antagonisti." Catania November 13-16,
1991.
10. Associazione Umbra per la lotta Contro il Cancro (AUCC): “La chemioterapia del
carcinoma polmonare non microcitoma: attaulità e prospettive.” Terni September 18,
1992.
11. Associazione Umbra per la lotta Contro il Cancro (AUCC): "Fumo e neoplasie
polmonari." Terni September 19, 1992.
12. Terzo corso di Aggiornamento in Oncologia Clinica della sezione. Nord-Est Italia
della SIPDTT (Società Italiana di Prevenzione, Diagnosi e Terapia dei Tumori): "La
cachessia neoplastica." Passariano (Ud) November 24-25, 1993.
13. Corso di Aggiornamento in Chirurgia Toracica: "La biologia delle metastasi
polmonari." Bari December 4, 1993.
14. Corso annuale per la formazione permanente del medico: Oncologia Clinica. "La
chemioterapia del carcinoma del polmone." Naples November 11, 1994.
15. Il paziente oncologico anziano: attualità terapeutiche: “La chemioterapia nel
carcinoma polmonare non a piccole cellule nell’anziano.” Turin October 7, 1995.
16. Prima Conferenza Nazionale AIOM (Associazione Italiana di Oncologia Medica)
sulle Linee guida per il follow-up del paziente oncologico: “Il carcinoma polmonare.”
Palermo December 1-2, 1995.
17. Incontri di aggiornamento: neoplasie polmonari, aspetti clinici e terapeutici. Polla
(Sa) May 4, 1996.
18. Aggiornamenti sul trattamento dei tumori polmonari. Vallo della Lucania (Sa) June
5, 1996.
23
19. Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale): "La
chemioterapia del carcinoma polmonare non a piccole cellule nell'anziano." Vietri sul
Mare (Sa) July 5-7, 1996.
20. Attuali consensi e controversie nel trattamento dei tumori polmonari: "I risultati delle
meta-analisi: un reale passo avanti?" Rome November 30, 1996.
21. IVª Conferenza Nazionale della Società Italiana di Chemioterapia. Chemioterapia
antitumorale. Risultati attuali e prospettive future: "La chemioterapia nell'anziano."
Florence December 6-7, 1996.
22. Scuola Superiore di Oncologia e Scienze Biomediche. Nuovi orizzonti in Oncologia:
"Il trattamento del carcinoma polmonare nel paziente anziano." Naples January 29,
1997.
23. Attualità e prospettive in tema di chemio-immunoterapia antitumorale: il carcinoma
del polmone. "La chemioterapia del microcitoma: stato dell'arte." Naples February
21, 1997.
24. Mostra Interattiva e Multimediale. La prevenzione e la cura dei tumori: "Le cause del
cancro: alcune cattive abitudini." Naples April 17, 1997.
25. Nuove prospettive diagnostiche e terapeutiche nel microcitoma polmonare: "Il
trattamento: stato dell'arte." Naples June 10, 1997.
26. La terapia medica del tumore polmonare non microcitoma alle soglie del 2000: "Note
di epidemiologia e prevenzione, diagnostica e staging." Naples September 27, 1997.
27. La terapia medica del tumore polmonare non microcitoma alle soglie del 2000: "Il
trattamento del IV stadio." Trento October 31, 1997.
28. II Convegno Nazionale Tumori in età geriatria: “La chemioterapia del carcinoma
polmonare non a piccole cellule nel paziente anziano: stato dell’arte.” Rome
December 3-5, 1997.
29. IV° Simposio Nazionale GOIM (Gruppo Oncologico Italia Meridionale): “Nuovi
farmaci nel trattamento del NSCLC.” Palermo June 4-7, 1998.
30. 7° Congresso Nazionale FONICAP (Forza Operativa Nazionale Italiana Contro il
Cancro del Polmone). Simposio Satellite. Gemcitabina: un approccio alla terapia del
tumore polmonare non a piccole cellule: “La potenzialità nel paziente anziano.” Bari
June 11, 1998.
31. Congresso Nazionale FONICAP (Forza Operativa Nazionale Italiana Contro il
Cancro del Polmone): “Risultati dello studio ELVIS”. Bari June 11-13, 1998.
32. La chemioterapia del carcinoma polmonare non a piccole cellule nel paziente
anziano: “Chemioterapia o terapia di supporto? Risultati dello studio ELVIS”.
Ancona June 25-27, 1998.
24
33. XVII° Corso Nazionale AIOM (Associazione Italiana di Oncologia Medica). Meet
the professor: “La chemioterapia del carcinoma polmonare non a piccole cellule
avanzato nel paziente anziano: problematiche e prospettive.” Rende (Cs) June 25,
1998.
34. XVII° Corso Nazionale AIOM (Associazione Italiana di Oncologia Medica).
Simposium: Topotecan, attualità nel trattamento del microcitoma polmonare e del
carcinoma dell’ ovaio: “Topotecan nel trattamento del microcitoma del polmone:
dati preliminari e prospettive.” Rende (Cs) June 25, 1998.
35. Congresso Nazionale della Società Italiana di Medicina Respiratoria: “Gemcitabina:
famaco innovativo per il carcinoma polmonare non a piccole cellule?” Turin
November 4-7, 1998.
36. La chemioterapia nel paziente oncologico anziano: “Tumori del polmone.” Naples
March 23, 1999.
37. Incontro Oncologico Flegreo: “Discussione su i nuovi approcci terapeutici.” Pozzuoli
(Na) May 21, 1999.
38. Corso di Aggiornamento - Forza Operativa Nazionale Italiana Contro il Cancro del
Polmone (FONICAP). Toluse October 3-6, 1999.
39. 1° Congresso Nazionale di Oncologia Medica. Simposium “Terapia di combinazione
nel carcinoma polmonare non microcitoma avanzato: di più è sempre meglio?
Controversie nel trattamento del carcinoma polmonare non microcitoma.” Rome
October 24-28, 1999.
40. 1° Congresso Nazionale di Oncologia Medica. Simposium “Nuovi approcci
terapeutici in oncologia medica”. Rome October 24-28, 1999.
41. 1° Congresso Nazionale di Oncologia Medica. Simposium “Topotecan: nuove
acquisizioni e prospettive future.” Rome October 24-28, 1999.
42. 1° Congresso Nazionale di Oncologia Medica. “Vinorelbine: recenti conferme e
future prospettive.” Rome October 24-28, 1999.
43. Convegno nazionale GIOGer/GROG. “Neoplasie nel paziente in età avanzata.” Alba
November 4-5, 1999.
44. XXV Congresso Nazionale SIT (Società Italiana Tumori). “Il ruolo dell’amifostina
nel trattamento del carcinoma polmonare non a piccole cellule.” Sorrento (Na)
November 17-21, 1999.
45. XXV Congresso Nazionale SIT (Società Italiana Tumori). “Il ruolo della
chemioterapia senza cisplatino nel carcinoma polmonare non a piccole cellule
avanzato.” Sorrento (Na) November 17-21, 1999.
25
46. XXV Congresso Nazionale SIT (Società Italiana Tumori). “Il ruolo del topotecan nel
trattamento dei tumori del polmone: attualità e prospettive.” Sorrento (Na) November
17-21, 1999.
47. I Tumori della mammella e del polmone: scenari in movimento: “Il trattamento di I
linea del NSCLC: chemioterapia senza platino.” Boulogne November 27, 1999.
48. I Tumori della mammella e del polmone: scenari in movimento: “Il trattamento di I
linea del NSCLC: chemioterapia senza platino.” Naples December 18, 1999.
49. I° work-shop di telemedicina. “Telemedicina in oncologia - progetto MARILIN.”
Enna January 29-30, 2000.
50. Sopravvivenza e qualità della vita: end point a confronto in oncologia: “Neoplasie
polmonari.” Naples February 24-25, 2000.
51. IV Convegno Nazionale Collegio Primari Oncologi Medici Ospedalieri: “I
trattamenti combinati Chemio-Radioterapia nel NSCLC.” Maratea (Pz) April 28-29,
2000.
52. 5° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). Nuove vie
per la terapia del cancro: “Il trattamento combinato chemioradioterapico nel
NSCLC.” Bari June 7-10, 2000.
53. 5° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). Nuove vie
per la terapia del cancro: “Gem-Vin nel NSCLC: una alternativa ai regimi senza
platino?” Bari June 7-10, 2000.
54. Corso AIPO (Associazione Italiana Pneumologia Oncologica): “Trattamenti
adiuvanti.” Boulogne June 29, 2000.
55. Docetaxel nel NSCLC: un futuro presente: “Schemi di combinazione non contenenti
platino.” Boulogne July 1, 2000.
56. Nuove prospettive nella chemioterapia del carcinoma mammario e polmonare del
paziente anziano: “Problematiche e prospettive nel trattamento chemioterapico del
carcinoma polmonare non a piccole cellule.” Sassari September 30, 2000.
57. 2° Congresso Nazionale di Oncologia Medica. Anziani e cancro: qualità di vita e
qualità di cura: “Il trattamento del microcitoma polmonare nel paziente anziano.”
Genoa October 30, 2000.
58. 2° Congresso Nazionale di Oncologia Medica. Simposium “Il paziente anziano, la
fine di un pregiudizio? Studio MILES e G-STEP.” Genoa October 30, 2000.
59. 1° Convegno Nazionale di Farmacia Oncologica. Terapie Oncologiche: Aspetti
farmacuetici e farmacologici: “Protocolli terapeutici nel trattamento del tumore del
polmone.” Naples November 18, 2000.
26
60. Nuove prospettive nella chemioterapia del carcinoma mammario e polmonare del
paziente anziano: “Problematiche e prospettive nel trattamento chemioterapico del
carcinoma polmonare non a piccole cellule.” Vietri sul Mare (Sa) December 2, 2000.
61. Gestione del paziente affetto da neoplasia dell’apparato respiratorio e
sensibilizzazione alla sua prevenzione: “Il trattamento del non microcitoma nel
paziente anziano.” Naples December 15, 2000.
62. Carcinoma Polmonare non Microcitoma: il trattamento della malattia avanzatametastatica: “La terapia di seconda linea.” Milan January 27, 2001.
63. II° corso di aggiornamento in oncologia geriatria. La chemioterapia nel paziente
oncologico anziano: “Carcinoma polmonare non a piccole cellule.” Naples February
22, 2001.
64. II° corso di aggiornamento in oncologia geriatria. La chemioterapia nel paziente
oncologico anziano: “Microcitoma polmonare.” Naples February 22, 2001.
65. Ricerca clinica in Italia Meridionale e tumori del polmone: “La chemioterapia nella
malattia avanzata.” Padula (Sa) May 25-26, 2001.
66. Vinorelbina: stato dell’arte e prospettive future: “Chemioterapia del paziente
anziano.” Messina June 9, 2001.
67. 8 Congresso Nazionale della FONICAP (Forza Operativa Nazionale Italiana Contro
il Cancro del Polmone). Simposium: Docetaxel nel trattamento del NSCLC: ulteriori
sviluppi: “Docetaxel in 2 linea: la possibile evoluzione di uno standard.” Cagliari
June 2-5, 2001.
68. Congresso AIPO (Associazione Italiana Pneumologia Oncologica). Simposium:
Gemcitabina: soluzioni terapeutiche personalizzate per il paziente affetto da tumore
polmonare non microcitoma: “Il trattamento del non-microcitoma nel paziente
anziano.” Rimini June 19-22, 2001.
69. L’Oncologia nel Molise – Tumori in età geriatrica – Tumori polmonari: “Trattamento
medico nell’anziano.” Campobasso July 2-3, 2001.
70. 3° Congresso Nazionale di Oncologia Medica. “Il trattamento del CPNPC localmente
avanzato.” Naples November 5, 2001.
71. Approccio diagnostico, terapeutico e assistenziale nelle neoplasie del pancreas e del
retto: “Ruolo della chemioterapia.” Avellino January 11, 2002.
72. V Conferenza Nazionale AIOM (Associazione di Oncologia Medica Italiana). Round
Table: Approccio terapeutico nel carcinoma polmonare dopo i 70 anni: “Risultati
dello studio ELVIS e MILES nel carcinoma non microcitoma ed approccio
terapeutico suggerito.” Abano Terme (Pd) March 18-20, 2002.
27
73. V Conferenza Nazionale AIOM (Associazione di Oncologia Medica Italiana).
Simposium: Nuove prospettive terapeutiche: “Risultati clinici acquisiti.” Abano
Terme (Pd) March 18-20, 2002.
74. Eloxatin Meeting: “Razionale di impiego nel paziente anziano con NSCLC.” Milan
April 4-5, 2002.
75. Attualità nel trattamento dei tumori della mammella e del polmone: “La
chemioterapia.” Fasano (Br) April 13, 2002.
76. La palliazione in oncologia gastrointestinale: “Chemioterapia.” Naples April 15,
2002.
77. Seminario interattivo di psicologia-oncologica per una relazione molto speciale.
Quando il medico parla all’anima: “Progettare la qualità di vita.” Naples May 10-11,
2002.
78. Patologie ematologiche ed oncologiche: percorsi diagnostico-terapeutici. Nuove
acquisizioni nel trattamento medico dei tumori solidi: “Microcitoma
polmonare.”Avellino May 31, 2002.
79. Giornate Mediche della Magna Grecia. Oncologia Clinica: “Il trattamento medico del
carcinoma polmonare non a piccole cellule.” Siracusa June 7, 2002.
80. 6° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). Dalla
Biologia Molecolare all’Accreditamento di Eccellenza: “Le combinazioni con
farmaci non citotossici: una nuova sinergia.” Naples June 12, 2002.
81. 6° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). Dalla
Biologia Molecolare all’Accreditamento di Eccellenza: “Ruolo attuale dell’Iressa nel
trattamento delle neoplasie polmonari.” Naples June 13, 2002.
82. 6° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). Dalla
Biologia Molecolare all’Accreditamento di Eccellenza: “L’impatto della supportive
care sulla qualità di vita del paziente oncologico.” Naples June 14, 2002.
83. Carcinoma polmonare non a piccole cellule: gestione di pazienti in fase metastatica.
Incidenza, prevenzione e trattamento degli effetti collaterali: “Incidenza, prevenzione
e trattamento degli effetti collaterali.” Naples June 18, 2002.
84. Il carcinoma polmonare non a piccole cellule: “La chemioterapia non contenente
cisplatino.” Avellino September 11-12, 2002.
85. Il carcinoma polmonare non a piccole cellule: “Nuovi farmaci biologici.” Avellino
September 11-12, 2002.
86. Oncologia 2002, il futuro oggi: “Il carcinoma del polmone.” Naples September 1821, 2002.
28
87. Focus on vinorelbine: dieci anni di esperienza nel carcinoma polmonare non a piccole
cellule: “Ruolo dei trattamenti orali.” Florence September 21, 2002.
88. IV Congresso Nazionale di Oncologia Medica: “Progettare la qualità di vita.” Turin
September 28, 2002.
89. IV Congresso Nazionale di Oncologia Medica: “Gemcitabine-based chemotherapy as
platform for new biological treatments.” Turin September 28, 2002.
90. 12° Convegno multidisciplinare di oncologia. I tumori del polmone: “Il trattamento
del paziente anziano.” Catania November 7-8, 2002.
91. Postgenomica: la rivoluzione silenziosa della ricerca: “La ricerca nella pratica
clinica.” Avellino November 9, 2002.
92. Novità e prospettive sulle neoplasie del retto: “Il punto di vista dell’oncologo.”
Avellino November 14-16, 2002.
93. L’integrazione terapeutica nelle neoplasie del polmone: dalla ricerca clinica alla
pratica terapeutica: “I nuovi regimi induttivi per lo stadio III: un nuovo standard?”
Rome November 22, 2002.
94. XXVIII congresso nazionale della società italiana di chirurgia toracica: “Ruolo di
navelbine nel carcinoma polmonare non a piccole cellule.” Rome November 24-27,
2002.
95. Nuove prospettive nella diagnosi e trattamento dei tumori del polmone: “La
chemioterapia del NSCLC metastatico.” Naples November 25-26, 2002.
96. 1° corso avanzato di formazione in oncologia. Neoplasie dell’anziano: “Il trattamento
del carcinoma polmonare non a piccole cellule.” Bari February 10-12, 2003.
97. Il Carcinoma polmonare non microcitoma III stadio: quale standard?: “La
chemioterapia neoadiuvante nei IIIA-N2.” Rome February 28, 2003.
98. 15° convegno multidisciplinare di oncologia. Il cancro del polmone: “Farmaci
biologici.” Lecce April 4, 2003.
99. VII Conferenza Nazionale AIOM (Associazione di Oncologia Medica Italiana). Le
terapia integrate in Oncologia. Simposium: Tumori polmonari NSLC: luci ed ombre:
“Pro e Contro.” Taormina May 13, 2003.
100. I Farmaci a bersaglio molecolare in oncologia: primi bilanci e prospettive future:
“La ciclo-ossigenasi 2 come potenziale bersaglio terapeutico.” Naples September 1213, 2003.
101. Corso avanzato: Quando il medico parla all’anima: “Qualità di vita e obiettivi del
trattamento in oncologia.” Naples October 3-4, 2003.
29
102. Corso multidisciplinare di formazione assistenza domiciliare al malato terminale:
“La dimensione curativa ed assistenziale nella fase terminale della vita.” Naples
October 6, 2003.
103. V Congresso Nazionale di Oncologia Medica. Simposium: NSCLC: risposte che
contano: “Mono o polichemioterapia nel paziente anziano e/o PS2?” Rome October
21-24, 2003.
104. V Congresso Nazionale di Oncologia Medica. Chemioterapia dose density:
quando utilizzarla e come ottimizzarla: “La dose dense in chemioterapia nel tumore
del polmone.” Rome October 21-24, 2003.
105. Corso GIOGER. I Tumori dell’anziano: “Ca polmone: presentazione casi clinici.”
Naples October 30, 2003.
106.
“La gestione emotiva del paziente oncologico.” Avellino, November 6, 2003.
107. Attualità sulle neoplasie dello stomaco e del colon-retto: “I nuovi farmaci nelle
neoplasie del tubo digerente.” Avellino November 20-22, 2003.
108. 17° Convegno Multidisciplinare di Oncologia GOIM (Gruppo Oncologico Italia
Meridionale). Il percorso diagnostico e terapeutico in Oncologia. Lecture: “Le
prospettive nel trattamento dei tumori del polmone.” Campobasso November 22,
2003.
109. 18° Congresso Multidisciplinare di Oncologia GOIM (Gruppo Oncologico Italia
Meridionale). Il percorso diagnostico e terapeutico in Oncologia. II Session: Inibitori
della traduzione del messaggio: “Iressa.” Bari March 10-11, 2004.
110. La cultura dell’anemia: per guardare al futuro: “Anemia nel paziente oncologico
anziano.” Genoa April 2, 2004.
111. Corso AIOM/SIGG di Oncologia Geriatria: “Update su tumori del polmone.”
Florence April 3, 2004.
112. Le nuove vie della targeted-therapy nel carcinoma mammario: il ruolo
dell’HER2: “Inibizione PAN-ErbB ed anticorpo monoclonale 2c4.” Naples June 28,
2004.
113. Corso Nazionale di Formazione su Gestione dell’Emesi da Chemioterapia per
Oncologi Medici. Naples July 14, 2004.
114.
NSCLC: il paziente al centro della terapia. Naples September 10, 2004.
115. EGFR e target therapy: il ruolo sinergico tra oncologo e anatomo patologo:
“Prospettive terapeutiche dell’anticorpo monoclonale cetuximab nei tumori EGFR
positivi: NSCLC.” Naples September 14, 2004.
30
116. VI Congresso Nazionale di Oncologia Medica. Lecture: “Il trattamento del
carcinoma polmonare non a piccole cellule: il ruolo di Gefitinib, primo EGFR-KI.”
Boulogne September 21-24, 2004.
117. VI Congresso Nazionale di Oncologia Medica. Simposium: “Le opzioni
terapeutiche nel trattamento del paziente anziano con NSCLC avanzato.” Boulogne
September 21-24, 2004.
118. La gestione emotiva del paziente oncologico. La paziente con carcinoma
mammario: “Le fasi della malattia: i tempi della diagnosi, la diagnosi; l’intervento
chirurgico; la chemioterapia; i controlli periodici, la remissione/guarigione, la fase
terminale.” Avellino October 9, 2004.
119. Docetaxel nel trattamento dei tumori polmonari non a piccole cellule: il paziente
al centro della terapia: “Il trattamento del paziente anziano.” Genoa October 18,
2004.
120. Docetaxel nel NSCLC: il paziente al centro della terapia: “Il paziente con malattia
disseminata: il paziente anziano.” Mogliano Veneto (Ve) December 3, 2004.
121. Vecchi e nuovi farmaci: si è detto tutto?: “Qual è il trattamento standard dei
pazienti PS2 o anziani?” Rome February 24-25, 2005.
122. I trattamenti adiuvanti e neoadiuvanti in oncologia: “Carcinoma (NSCLC) del
polmone.” Naples April 11, 2005.
123. Recenti acquisizioni sul trattamento dellcarcinoma della mammella: “Chemioormonoterapia adiuvante: quale sequenza o combinazione.” Naples May 20, 2005.
124. Il carcinoma della mammella: un approccio integrato: “Dati clinici su
ibandronato.” Naples May 27, 2005.
125. 20° Congresso Nazionale GOIM (Gruppo Oncologico Italia Meridionale). VII
Session: Il carcinoma polmonare (NSCLC): “La ricerca italiana nel NSCLC.” Bari
June 13-16, 2005.
126. Programma X-B.R.T. Esperienze degli Oncologi Ospedalieri a Confronto:
“Capecitabina cronomodulata.” Naples June 27, 2005.
127. Novità terapeutiche nel trattamento dei tumori toracici: “Prospettive d’impiego
nel paziente anziano o con PS2.” Naples June 28, 2005.
128. Angiogenesi ed inibizioni del VEGF. Terapia antiangiogenica in oncologia:
attualità e prospettive future: “Inibizione dell’angiogenesi in altri tipi di tumore
(Polmone).” Naples November 29, 2005.
129. Intensità e tossicità dei trattamenti antineoplastici: il ruolo dei fattori di crescita
granulocitari e le linee guida NCCN: “La neutropenia quale marker di efficacia nel
NSCLC.” Naples December 1, 2005.
31
130. Up-date sui farmaci a bersaglio molecolare: “Farmaci anti-EGFR e NSCLC: uno
sguardo al futuro.” Naples March 10, 2006.
131. XII Conferenza Nazionale AIOM (Associazione di Oncologia Medica Italiana).
Tumori dell’apparato respiratorio: “Trattamento dei pazienti con NSCLC PS 2.”
Rome March 29-31, 2006.
132. Stato dell’arte del trattamento del microcitoma polmonare: focus su topotecan:
“Focus su qualità di vita e tollerabilità.” Verona April 12, 2006.
133. Attualità e prospettive sul trattamento delle neoplasie polmonari: “I farmaci a
bersaglio molecolare.” Naples April 21, 2006.
134. Tumori polmonari non microcitoma: “Il trattamento della fase avanzata.” Pavia
May 12, 2006.
135. Recenti acquisizioni in tema di management dell’anemia indotta da chemioterapia
e profilassi della neutropenia febbrile: “La neutropenia febbrile tra linee guida e
realtà.” Vietri sul Mare (Sa) May 26, 2006.
136. Recenti acquisizioni sul trattamento del carcinoma della mammella: “I fattori
prognostici e predittivi.” Naples May 30, 2006.
137. VIII Convegno Nazionale GOIM. “La ricerca oncologica in Italia oggi”. Messina
June 18-21, 2006.
138. VIII Convegno Nazionale GOIM. “Il percorso terapeutico nel NSCLC: come si
inserisce la ricerca clinica?”. Messina June 18-21, 2006.
139. XIII Conferenza Nazionale AIOM. Nuovi farmaci e nuove strategie terapeutiche.
“I Tumori del Polmone”. Naples September 14, 2006.
140. 3 Atelier. I Tumori del polmone.”Terapia della fase avanzata-metastatica. Monza
September 22, 2006.
141. Convegno SIFO “Terapie biologiche in Oncologia: risultati, criticità eruolo del
farmacista ospedaliero”. “Risultati clinici delle nuove molecole a bersaglio
molecolare nel carcinoma del polmone”. Naples October 23, 2006.
142. Carcinoma polmonare e terapie biologiche: progressi e prospettive. “Il
trattamento del paziente anziano con stadio IIIB/IV e del paziente con PS 2”. Genoa
October 20, 2006.
143. Secondo Corso Nazionale sui problemi metodologici e statistici delle
sperimentazioni cliniche in Oncologia. “Lo stato dell’arte del trattamento dei tumori
del polmone non a piccole cellule”. Naples October 26 2006.
144. VIII Congresso Nazionale di Oncologia Medica. Simposium Erlotinib e
carcinoma polmonare: dai trias clinici ai casi clinici. “Erlotinib: sviluppo clinico e
ongoing trias”. Milan November 18-21 2006.
32
145. La scomparsa del dolore da cancro: un sogno che diventa realtà. “L’Oncologia
italiana e le cure palliative: risultati indagine 2006”. Naples May 24 2007.
146. Il percorso terapeutico dei pazienti con tumore polmonare non microcitoma. “La
criticità di scelta in I linea” . Naples May 24 2007.
147. I tumori del polmone: tecnica radioterapica e moderne strategie terapeutiche. “La
chemioterapia adiuvante del NSCLC”. Naples, June 11, 2007.
148. XI Congresso Nazionale GOIM. Nuovi orientamenti in Oncologia Clinica.
“Certezze e prospettive nel trattamento di I linea del NSCLC”. Potenza June 18
2007.
149.
Terapie biologiche nel NSCLC. “Farmaci anti-EGFR”. Naples, June 22, 2007.
150. Terapie biologiche nel NSCLC. “Risultati dell’International Exerts Panel Sulla
terapia di II linea nel NSCLC”. Naples, June 22, 2007.
151. Percorso terapeutico nel carcinoma polmonare. “La chemioterapia adiuvante del
NSCLC”. Bari, July 10, 2007.
152. L’Oncologia oggi: scenari in movimento. “La terapia di II linea del NSCLC:
chemioterapia o targeted therapy?”. Avellino, September 28 2007.
153. Fumo: I care. Novità terapeutiche in tema di disassuefazione. “Attualità e
prospettive nel trattamento dei tumori del polmone”. Atripalda (AV), October 31
2007.
154. Percorso terapeutico nel carcinoma polmonare (NSCLC). “La terapia di I linea”.
Avellino, November 6, 2007.
155. Le neoplasie del torace. “La terapia di seconda linea del carcinoma polmonare
non a piccole cellule”. Naples, November 9, 2007.
156. L’Oncologia oggi: scenari in movimento. “La terapia di II linea del NSCLC:
chemioterapia o targeted therapy?”. Fiuggi (FR), November 16, 2007.
157. Terapie biologiche nel NSCLC. “Ruolo dei farmaci anti-EGFR”. Naples,
Novembre 22 2007.
158. Terapie biologiche nel NSCLC. “Risultati dell’International Expert Panel sulla
terapia di II linea del NSCLC”. Naples, Novembre 22, 2007.
159. Percorso terapeutico nel carcinoma polmonare (NSCLC) . “La chemioterapia
adiuvante”. Rome December 4, 2007.
160. Percorso terapeutico nel carcinoma polmonare (NSCLC) . “La chemioterapia
adiuvante”. Naples February 5, 2008.
33
161. Percorso terapeutico nel carcinoma polmonare (NSCLC) . “Il trattamento del
paziente anziano e dei PS 2”. Milan February 22, 2008.
162. Percorso terapeutico nel carcinoma polmonare (NSCLC) . “La terapia di I linea”.
Verona March 14, 2008
163.
Experts Forum. Oncotarget nel carcinoma polmonare.Parma, April 11, 2008.
164.
Experts Forum. Oncotarget nel carcinoma polmonare. Rome, April 29, 2008.
165. Attualità e prospettive nel trattamento delle metastasi osse. “Metastasi ossee e
bifosfonati nei tumori del polmone:quando, come e perché”. Naples, May 5 2008.
166. Associazione Italiana di Oncologia Toracica (AIOT). Il carcinoma polmonare.
“Combinazione di chemioterapia e targeted therapies nel trattamento del carcinoma
non a piccole cellule avanzato”. Sperlonga (LT) May 9 2008.
167. I Corso Educazionale AIOT Regione Lazio. Il carcinoma polmonare. “Quanti
farmaci biologici?”. Rome, May 16 2008.
168. I Corso Residenziale SIOT . Il carcinoma polmonare non a piccole cellule.
“L’importanza di una diagnosi certa e di un sample tissue”. Frascati (Rome) July 1011, 2008.
169. X Congresso Nazionale AIOM. “Terapia del NSCLC avanzato: stato dell’arte”.
Verona, October 11, 2008.
170. X Congresso Nazionale AIOM. “Simposio Eli Lilly. La chemioterapia di
mantenimento del NSCLC dopo la prima linea dell’avanzato”. Verona , October 12,
2008.
171. Angiogenesis in Lung Cancer. “Farmaci anti-angiogenetici: terapie attuali e
prospettive future”. Milano, October 16, 2008.
172. I Expert Forum Campano. Il carcinoma polmonare non a piccole cellule avanzato:
strategie terapeutiche. “Chemioterapia verso i farmaci a bersaglio molecolare in II
linea:quali scelte?. Avellino, November 11, 2008.
173. I Corso di aggiornamento Regione Calabria Associazione Italiana di Oncologia
Toracica. “I trattamenti di II linea:chemioterapia vs targeted therapies”. Catanzaro,
22 Novembre 2008.
174. I Corso Residenziale SIOT . Il carcinoma polmonare non a piccole cellule.
“NSCLC avanzato: terapia di I linea”. Frascati (Rome) November 28-29, 2008.
175. Percorso Terapeutico nel carcinoma polmonare. “Il trattamento del paziente
anziano e dei PS 2”. Bergamo, December 4 2008.
176. Angiogenesis in Lung Cancer. “Farmaci anti-angiogenetici: terapie attuali e
prospettive future”. Mogliano Veneto (TV), December 11, 2008.
34
177. Percorso Terapeutico nel carcinoma polmonare. “Problematiche di terapia
adiuvante nel paziente anziano”. Parma, 30 Gennaio 2009.
178. II Expert Forum Campano. La chemioterapia di I linea:up-date sui farmaci a
bersaglio molecolare.. Avellino, July 7, 2009.
179. III Expert Forum Campano. Ruolo dei farmaci antiangiogenetici nel trattamento
del NSCLC. Avellino, October 6, 2009.
180. XI Congresso Nazionale di Oncologia Medica (AIOM). “Le strategie terapeutiche
integrate nel NSCLC”. Milan, October 11, 2009.
181. I Corso Educazionale Friuli Venezia Giulia – AIOT. Innovazione nel trattamento
del tumore polmonare. “Fattori predittivi di risposta e sopravvivenza alle terapie
biologiche”. Udine, October 23, 2009.
182. Progetto LEAD. “Trattamento di I linea del NSCLC avanzato”. Frascati (Roma),
December 12, 2009.
183. LA PET/TAC in Oncologia.. “Le domande dell’Oncologo”. Acerra (NA),
December 19, 2009.
184. Corso ISF della Scuola Italiana di Oncologia Toracica. “La chemioterapia di II
linea nel NSCLC”. Frascati (Roma), January 12, 2010.
185. Le mutazioni di EGFR nel carcinoma polmonare : dalla ricerca all’applicazione
clinica. “Il posizionamento dei farmaci anti-EGFR nella strategia terapeutica del
NSCLC”. Istituto Nazionale Tumori, Naples, January 19, 2010.
186. Il carcinoma polmonare: dalla bilogia alla diagnosi differenziale. “Cosa chiede
l’oncologo al patologo”. Naples, Istituto Nazionale Tumori, March 1, 2010.
187. Il trattamento del NSCLC avanzato nell’era della mutazione di EGFR. “Il
trattamento del NSCLC avanzato nell’era della mutazione di EGFR”. Naples,
October 15, 2010.
188. AIOM XII Congresso Nazionale.”Targeted therapies in prima linea nel NSCLC:
pro”. Rome, November 7,2010.
189. L’innovazione al servizio della salute. “L’innovazione in Oncologia”. Avellino,
December 4, 2010.
190. I Congresso Congiunto AIMAR/ACCP. “Gefitinib nel trattamento di I linea del
NSCLC avanzato con mutazione di EGFR”. Stresa, March 17, 2011.
191. I Corso Campano Pneumo-Oncologico- “Terapia medica personalizzata nel
NSCLC avanzato”. Napoli, April 4, 2011.
35
192. Expert Meeting - Extra-Enhancing taxane treatment response with abraxane.
“Role of abraxane in NSCLC”. Napoli, June 10, 2011.
193. AIOM-SIAPEC. Determinazione delle mutazioni di EGFR nel NSCLC. “La
strategia terapeutica nel NSCLC avanzato”. Napoli, June 14, 2011.
194. 13 Congresso Nazionale GOIM. Nuovi paradigmi di trattamento del NSCLC.
“Ruolo ed implicazioni cliniche nella terapia di mantenimento”. Bari, June 20, 2011.
195. VI Expert Forum Campano. Up-date nella terapia del carcinoma polmonare non a
piccole cellule. Farmaci anti-VEGFnel NSCLC: conoscenze allo stato attuale e
possibili combinazioni con chemioterapia in I linea”. Avellino, June 30, 2011.
196. Progetto ERCOLE. Linee guida per l’Oncologia Toracica delle Terapie di
Supporto. “Tossicità gastrointestinali”. Parma, October 7, 2011.
197. Join Oncologists Italian Network: sfide cliniche e innovazione scientifica.
“Analisi critica dei principali studi esistenti nel NSCLC”. Rome, October 24, 2011.
198. XIII Congresso Nazionale di Oncologia Medica. NSCLC: il percorso terapeutico
ottimale nell’era delle terapie personalizzate. “Il nuovo paradigma della terapia di
mantenimento”. Bologna, November 6 2011.
199. Progetto INCRESAE: gestione pazienti con A-NSCLC. “Uno sgurado alle attuali
linee guida”. Naples, November 18, 2011.
200. A-NSCLC personalized treatment. “New antiangiogenetic drugs”. Naples,
November 24, 2011.
201. Progetto ERCOLE. Linee guida per l’Oncologia Toracica delle Terapie di
Supporto. “Tossicità gastrointestinali”. Avellino, November 25, 2011.
202. Prima giornata di Oncologia Toracica dell’Istituto Oncologico Europeo.
“Traslocazione ALK e nuovi target molecolari nel trattamento del tumore del
polmone non a piccole cellule”. Milan, December 16, 2011.
203. Progetto ERCOLE. Linee guida per l’Oncologia Toracica delle Terapie di
Supporto. “Tossicità gastrointestinali”. Rome, January 20 2012.
204. Nanotecnologie nella pratica clinica. “Nab-paclitaxel nel tumore del polmone”.
Naples, February 4 2012.
205. III Corso Formazione GOIM Regione Campania. Update in Oncologia.”Terapie
personalizzate biomolecolari oltre gli inibitori di EGFR nel NSCLC avanzato”.
Salerno, May 11 2012.
206. 14 Congresso Nazionale GOIM. La terapia medica del NSCLC. Rome, 19 June
2012.
36
207. VII Exper Forum Campano. Un-date nel trattamento del carcinoma polmonare
non a piccole cellule. “Farmaci anti-VEGF nel NSCLC: conoscenze allo stato attuale
e possibili combinazioni con chemioterapia in I linea. Avellino, July 12 2012.
208. Meet the Expert. “Opzioni terapeutiche nel NSCLC avanzato”. Ravenna, 17
September 2012.
209. Extrappeal Meeting. “Nab-paclitaxel nel NSCLC avanzato”. Naples, 25
September 2012.
210. JOIN: sfide cliniche e innovazione scientifica in Oncologia. “Analisi critica studi
clinici e percorso diagnostico-terapeutico nel NSCLC avanzato”. Rome, 16 October
2012.
211. Personalized algorythms of NSCLC therapy in Italy and around the
world.”L’algoritmo decisionale nella ptartica clinica”. Naples, 18 October 2012.
212. XIV Congresso AIOM. “Discussione con l’esperto: carcinoma del polmone
localmente avanzato”. Rome, 28 October 2012.
213. SIOT NET INSIGHT: tumori neuroendocrini toracici. “Nuovi farmaci biologici
nei pazienti affetti da NET”. Frascati (Rome), 23 November 2012.
214. Incontro annuale di Medicina Nucleare. “Metastasi osse: inquadramento clinico
oncologico”. Avellino, 29 Novembre 2012.
215. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. “Il trattamento guidato dai marcatori biomolecolari: focus sul
riarrangiamento di ALK”. Naples, 25 February 2013.
216. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. “Efficienza e rapidità nella diagnosi: il ruolo del team
multidisciplinare”. Naples, 25 February 2013.
217. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. “Il trattamento guidato dai marcatori biomolecolari: focus sul
riarrangiamento di ALK”. Bari, 14 March 2013.
218. ALKIMIST: gestione multidisciplinare del NSCLC avanzato nell’era delle terapie
personalizzate. “Efficienza e rapidità nella diagnosi: il ruolo del team
multidisciplinare”. Bari, 14 March 2013.
219. III National Course AIOM/SIAPEC. Marcatori biomolecolari nella terapia
personalizzata dei tumori: indicazioni cliniche e di laboratorio. “La personalizzazione
nella pratica clinica”. Naples, 22 March 2013.
220.
“I farmaci biologici cambiano l’algoritmo terapeutico?” Salerno, 18 May 2013.
221.
I tumori del pancreas. “La terapia medica”. Avellino, September 10, 2013.
37
222. Advanced EXTRA Expert Meeting. “Nuove evidenze scientifiche con Abraxane:
i tumori del polmone”. Napoli, 16 September , 2013.
223. POST-IASLC: la WCLC in Italia. “Novità nel trattamento di I linea”. Milano, 8
November ,2013.
224. “Dagli studi clinici alla pratica clinica: il carcinoma polmonare”. Salerno, 24 May
2014.
225. “EGFR nel tumore polmonare non a piccole cellule per la terapia target”.
Attualità sui test genetici e nuove applicazioni. Avellino, 12 June 2014.
38
INVITED LECTURES IN INTERNATIONAL CONFERENCE
1. II Andorrian Congress on Lung Cancer: "Treatment of unresectable non small cell
lung cancer in the elderly." Andorra February 6-7, 1997.
2. Lung cancer in the elderly: "Chemotherapy of non small cell lung cancer in elderly
patients." Naples June 6, 1997.
3. Il trattamento del cancro del polmone non microcitoma localmente avanzato e
metastatico: “La chemioterapia adiuvante.” Naples April 17, 1998.
4. 3rd International Congress on Cancer. Chemotherapy of non small-cell lung cancer:
new achievements: “Granulocyte growth factors.” Venice May 29-31, 1998.
5. Annual Meeting of British Oncological Association. Symposium: Treatment of Non
Small Cell Lung Cancer.Where do we go now?: “Treatment of the elderly.”
Nottingham July 5, 1998.
6. IV International Conference on Geriatric Oncology. Cancer in the Elderly: “Lung
cancer.” Rome October 4-7, 1998.
7. Convegno Internazionale di Chirurgia Toracica: “Il trattamento nell’anziano.”
Reggio Calabria January 22, 1999.
8. First World Conference on Clinical Cooperative Research for Lung Cancer:
“Originality, benefits and difficulties of clinical research performed by cooperative
groups.” Brussels March 4-6, 1999.
9. First World Conference on Clinical Cooperative Research for Lung Cancer: “Not
therapeutic clinical investigations for lung cancer.” Brussels March 4-6, 1999.
10. Navelbine Seminar: “Navelbine use in the elderly with NSCLC.” Singapore July 21,
1999.
11. Navelbine Symposium: “Navelbine in NSCLC.” Taichung (Taiwan) July 22, 1999.
12. NSCLC Conference: “Update on the treatment of non small cell lung cancer: the role
of Navelbine.” Osaka July 25, 1999.
13. Conferenza internazionale Il trattamento dei tumori dell’anziano (GROG/GIOGer):
“Lo studio MILES nel NSCLC dell’anziano.” Rome September 27-28, 1999.
14. Simposium on Non Small Cell Lung Cancer: “European Phase III trials in advanced
NSCLC and treatment of elderly patients.” Helsinki March 23, 2000.
15. Simposium on Non Small Cell Lung Cancer: “European Phase III trials in advanced
NSCLC and treatment of elderly patients.” Stokolm March 27, 2000.
16. Seminario di Aggiornamento. La qualità della Vita in Oncologia: “La gestione
dell’emesi.” Paris May 13, 2000.
39
16.III International Meeting on Recent Progress in Oncology: “La terapia medica
antineoplastica nel paziente anziano.” Santa Margherita di Pula (Ca) September 1-3,
2000.
17. 9th World Conference on Lung Cancer: “Chemotherapy with new drugs (NSCLC):
not cisplatin-based chemotherapy.” Tokyo September 13, 2000.
18. 9th World Conference on Lung Cancer: “ELVIS study in the Elderly (NSCLC).”
Tokyo September 13, 2000.
19.9th World Conference on Lung Cancer: “New combination chemotherapy in advanced
non small cell lung cancer.” Tokyo September 15, 2000.
20.Workshop: “Tratamento dos estadios precoces do cancro pulmao de nao pequenas
celulas.” Coimbra January 20, 2001
21.4th Annual Lung Cancer Symposium: “Treatment of advanced NSCLC in the elderly.”
Miami March 10, 2001.
22.ESO-Lilly Medical Oncology Course: “Non platinum doublets in the treatment of the
NSCLC “unfit” or elderly patient.” Milan March 19-20, 2001.
23.Non Small Cell Lung Cancer Treatment No Standards, Many Options: “How can we
treat elderly patients?” Venice April 2, 2001.
24.Concurrent perspectives on biomolecular indicators and clinical management of
bladder, breast, colorectal and lung cancer: “Chemotherapy in the elderly:
pharmacologic and clinical issues in NSCLC.” Erice (Pa) April 18-22, 2001.
25.Caring for Cancer Patients in the new Millennium: a clinical update of GEMZAR
(gemcitabine) and ALIMTA (pemetrexed disodium): “MILES phase III randomized
trial of gemzar + vinorelbine vs gemzar vs vinorelbine in advanced NSCLC elderly
patients.” Indianapolis May 11, 2001.
26.American Society of Clinical Oncology (ASCO) 2001 Annual Meeting. Meet the
Professor Session: “Approaches to the treatment of lung cancer in elderly patients”.
San Francisco May 13, 2001.
27. New approaches in the treatment of NSCLC: “Meeting the needs of special patients
(elderly/PS2).” Rome June 16, 2001.
28.Second Meeting of SIOG (International Society of Geriatric Oncology). “Cancer in
the Elderly.” Lyon, September 14-15, 2001.
29.Second World Congress of World Federation of Surgical Oncology Society:
“Indication to venous ports in Oncology: the Italian experience”. Naples September
19-22, 2001.
40
30.European Organization for Research and Treatment of Cancer (EORTC) - Lung
Cancer Group Meeting: “New non-DDP-based doublet in NSCLC: the GEMVIN
experience.” Genoa September 29, 2001.
31.The European Cancer Conference Gemzar and Premetrexed in thoracic cancers:
present and future perspectives: “Gemvin phase III randomized trial in advanced
NSCLC: gemzar + vinorelbine vs gemzar + cisplatin vs vinorelbine + cisplatin.”
Lisboa October 21-25, 2001.
32.Workshop on Lung Cancer: ”Chemotherapy for elderly and unfit patients.”
Heidelberg December 13-15, 2001.
33.European School of Oncology: Advances in solid tumour treatment: “Chemotherapy
of SCLC.” Rome February 25, 2002.
34.IASLC International workshop. Early invasive Lung Cancer: “Single Agent
Chemotherapy.” Turin March 14-15, 2002.
35.IASLC International workshop. Early invasive Lung Cancer. Satellite Simposium:
The future of chemotherapy in Lung Cancer: “How to combine cytotoxic & cytostatic
agents.” Turin March 14-15, 2002.
36.IASLC International workshop. Early invasive Lung Cancer. Session: Combined
modality treatments in early lung cancer: “The management of early lung cancer in
the elderly.” Turin March 14-15, 2002.
37.Thoracic cancer from bench to beside: “Chemotherapy for elderly and unfit patients.”
Rome April 12-13, 2002.
38.Italian-German Cooperative Educational Symposium on Diagnosis and Treatment of
non-small cell lung cancer: “Chemotherapy for elderly and unfit patients.” Heidelberg
April 18-20, 2002.
39.Cancer Initiative 21st Century: “Non Small Cell Lung Cancer (NSCLC).” Educational
Program of MD Anderson Cancer Center.Houston (USA) May 23, 2002.
40.European Conference Navelbine oral: a major advance in oral chemotherapy:
“Treatment of advanced NSCLC: how to treat our patients adequately.” Siviglia
November 30, 2002.
41.ESO Course. Advances in solid tumour treatment: “SCLC: have we moved forward?”
Rome February 24-25, 2003.
42.European Institute of Healthcare. Oncology Symposium Thoracic Malignancies:
“Management of NSCLC in the elderly.” Barcelona March 8, 2003.
43.MASCC/ISOO 15th International Symposium on supportive care in cancer: “Antiemetic care in the elderly: complex considerations.” Berlin June 19, 2003.
41
44.10th World Conference on Lung Cancer: “Chemotherapy for NSCLC in the elderly.”
Vancouver August 11-15, 2003.
45.Fourth Meeting of SIOG. Geriatric Oncology: Cancer in the elderly: “Methods in
clinical trials: medical challenges encountered in a clinical trial.” Rome November 20,
2003.
46.Workshop on Molecular profiling by Mass Spectrometry: “Clinical research for solid
tumors at S.G. Moscati Hospital.” Avellino January 30, 2004.
47.Investigators’ Meeting. Targeted therapies for the treatment of lung cancer:
“Supportive care.” San Diego February 19-21, 2004.
48.Advances in solid tumor treatment: “SCLC: current treatments opinions.” Sorrento
(Na) February 25–26, 2004
49.VIII International State of the Art: Interdisciplinary review course on thoracic
medicine: “Oral Navelbine Pharmacokinetics & Toxicological Profile.” Athen May 7,
2004.
50.1st Milan Lung Cancer Conference: “How to treat elderly patients.” Milan September
17-18, 2004.
51.Italian-Spanish cooperative educational course on the diagnosis and treatment of lung
cancer: “Management of eldelry and PS2 patients.” Barcelona September 30-October
2, 2004.
52.2nd Mediterranean Conference on Oncology. Management of lung cancer and
mesothelioma: “Anti-angiogenetic agents.” Alexandria (Egypt) December 8-10, 2004.
53. Introducing the IACT congress: Europe and US discuss about the leading edge in
anti-cancer treatment: “Update on chemotherapy of advanced NSCLC.” Paris January
31–February 1, 2005.
54. Winter Lung Cancer Conference: “Treatment of special patient populations.” Florida
March 18-20, 2005.
55.American Society of Clinical Oncology 41st Annual Meeting: “Chemotherapy of stage
I to III Non-Small Cell Lung Cancer in the Elderly Patients.” Orlando May 13-17,
2005.
56.Italian-Dutch cooperative educational course on the diagnosis and treatment of
thoracic tumors: “Treatment of late stage NSCLC.” Amsterdam June 9-11, 2005.
57.International conference on non small cell lung cancer and brain tumors: “Italian
research in elderly patients with advanced NSCLC.” Palermo September 16, 2005.
58.Sixth Congress on Lung Cancer: “Novel cytotoxic agents.” Barcelona December 1-2,
2005.
42
59.Advance in Thoracic Oncology. “NSCLC in the elderly”. Perugia June 30, 2006.
60. 1st Mediterranean Forum of Neuro-Oncology.”New prospective in clinical research
and treatment of brain metastases”. Naples, October 31 2006.
61. 7 Meeting of the International Society of Geriatric Oncology. “Targeted therapies and
chemotherapy: new challenge for the treatment of advanced NSCLC elderly patients. ;
The Hague (Netherland), November 2-4 2006.
62. ESMO International Symposium on Chest Tumors. “First-line therapy for advanced
NSCLC”. Geneve , March 31, 2007.
63. ESMO International Symposium on Chest Tumors. “Patient case discussion:
advanced NSCLC”. Geneve, April 1, 2007.
64. AROME (Association of Radiotherapy and Oncology of the Mediterranean area)
Meeting. “Epidemiology of cancer, registers and inventory of technical plates for
management of cancer in the Mediterranean area”. Naples, April 28, 2007.
65. 12 World Conference on Lung Cancer. Meet the Professor: “Treatment of elderly and
poor performance status patients”. Seoul (Korea), September 5, 2007.
66. Highlights in Oncology: “ Second and third-line in NSCLC: what’s new?”. Naples,
November 23, 2007.
67. Perspectives in lung cancer. Symposium “Metastatic NSCLC: is there a standard
chemotherapy?”. Turin, March 15, 2008.
68. I ESMO-IASLC Lung Cancer Conference “New avenues for second-line tratment of
NSCLC”. Geneve, April 23-26, 2008.
69. 33 ESMO Congress “Challenges treating older lung cancer patients”. Stockolm,
September 14, 2008.
70.33 ESMO Congress. Merck Seroo Satellite Simposium “Where are we now in the
treatment of NSCLC”. Stockolm, September 16, 2008.
71. 4 IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung
Cancer. “First-line treatment of advanced NSCLC with EGFR-inhibitors: the TORCH
study”. St Paul de Vence (France), April 2, 2009.
72. European Multidisciplinary Conference on Thoracic Oncology. Systemic treatment
of elderly and PS 2 patients with advanced NSCLC. Lugano, May 3 , 2009.
73. 45 Annual Meeting of American Society of Clinical Oncology (ASCO).
Chemotherapy and targeted therapies in the older patients with NSCLC . Orlando, 31
Maggio 2009.
43
74.13 World Lung Cancer Conference. Roche Lung Cancer Investigators Meeting
Breaking new ground in NSCLC therapy. “The expanding role of erlotinib as secondline therapy”. San Francisco (USA), July 31, 2009.
75.13 World Conference on Lung Cancer. Meet the professor session. Special
population: elderly. San Francisco (USA), August 3,2009.
76. ECCO 15- ESMO 34 Congress. Which is the best treatment for non small cell lung
cancer patients with PS 2? Berlin, September 22 2009.
77. ECCO 15- ESMO 34 Congress. Debate: this house believes that targeted treatment
should be used in all cases with lung cancer. Berlin, 23 Settembre 2009.
78.VIII Congress on Lung Cancer of Spanish Lung Cancer Group (SLCG). “EGFR: the
TORCH trial”. Barcelona (Spain), November 26, 2009.
79. II European Conference on Lung Cancer (IASLC/ESMO). “The role of first-line
targeted therapies in advanced NSCLC”. Geneve (Switzerland), April 30, 2010.
80. 46 American Society of Medical Oncology (ASCO) Congress. Oral presentation
Session : Metastatic Lung Cancer. “International multicenter randomized phase III
study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine
(CG) versus first-line CG followed by second-line E in advanced non small cell lung
cancer (NSCLC). Chicago (USA), June 8, 2010.
81.ESMO Congress. “New molecular targets in NSCLC: the next generation of drugs”.
Milan, October 10, 2010.
82. Anti-Angiogenesis Clinical Experience Exchange Meeting. “Maximising outcomes in
adenocarcinoma patients: putting clinical data into perspective”. Copenaghen
(Denmark), November 5, 2010.
83.European Multidisciplinary Conference on Thoracic Oncology.
recommendation in metastatic NSCLC”. Lugano, February 25, 2011.
“ESMO
84.European Multidisciplinary Conference on Thoracic Oncology. “Maintenance
treatment by targeted therapies in advanced NSCLC”. Lugano, February 26, 2011.
85. 47 American Society of Clinical Oncology (ASCO) Annual Meeting . Therapy of
elderly patients with NSCLC”. Chicago, June 4 2011.
86.14 World Lung Cancer Conference (WLCC). Discussant session Lung Cancer.
Amsterdam, July 4. 2011.
87.ECCO 16/ ESMO 36 European Multidisciplinary Cancer Congress. “2010 ESMO
Consensus on lung cancer: new recommendation and current status of biomarker
assessment”. Stockolm, September 27 2011.
44
88.3° European Lung Cancer Conference. “State of the art: suggested treatment
algorithms for stage IV NSCLC”. Geneve, April 20 2012.
89. III International Conference on Thoracic Oncology (CIOT). “Advanced NSCLC:
pemetrexed as standard “. Naples, June 29 2012.
90.III International Conference on Thoracic Oncology (CIOT). “ PI3K “. Naples, June
30 2012.
91.III International Thoracic Oncology Congress. “ Individualization of anti-neoplastic
therapy in the elderly patients in suffering from advanced NSCLC” , Dresden
(Germany), 14 September 2012.
92. ESMO Congress. “Clinical Practice Guidelines: advanced NSCLC”. Vienna
(Austria), 30 September 2012.
93.6th International Conference on Molecular Targeted Therapy in Lung Cancer. “PI3K
inhibitors”. Sorrento, 19 April 2013.
94. IV International Conference on Thoracic Oncology. “PI3K and buparlisib”.
Roma,26-28 June 2014.
45
ORGANIZATION OF NATIONAL CONFERENCES AND MEETINGS
1. Attualità in tema di carcinoma polmonare non microcitoma. Naples April 5, 1989.
1. Attualità in tema di carcinoma polmonare a piccole cellule aspetti
implicazioni diagnostiche-terapeutiche. Naples March 16, 1990.
biologici e
3. Seminario di Aggiornamento in Oncologia Medica. La chemioterapia nel paziente
oncologico anziano. Naples March 22-23, 1999.
4. II° Corso di Aggiornamento in Oncologia Geriatrica. La chemioterapia nel paziente
oncologico anziano. Naples February 21-22, 2001.
5. Corso di Aggiornamento GOIM (Gruppo Oncologico Italia Meridionale). I Tumori
Uro-genitali. Avellino January 22, 2002.
6. Corso Nazionale di Perfezionamento in Oncologia Polmonare. Il carcinoma
polmonare non a piccole cellule. Avellino September 11-12, 2002.
7. Terapia Medico-Nucleare del dolore Oncologico Scheletrico. Avellino September 20,
2002.
8. Il trattamento del carcinoma polmonare non a piccole cellule: stato dell’arte e
prospettive future. Avellino , Novembre 15 2002.
9. Attualità e prospettive nel trattamento del carcinoma mammario: nuovi farmaci orali.
Avellino October 7, 2002.
10. Quando la psicologia incontra l’oncologia. Avellino April 8, 2003.
11. Il carcinoma polmonare non microcitoma III stadio: quale standard? Avellino May
23, 2003.
12. Convegno di aggiornamento. Diagnosi e trattamento dei tumori stromali gastrointestinali (GIST). Avellino June 26, 2003.
13. Focus Group on Anemia. Avellino September 9, 2003.
14. La scomparsa del dolore da cancro. Avellino, March 1 2006.
15. Nuovi farmaci e nuove strategie terapeutiche in Oncologia. Avellino, May 18-19
2007.
16. I Corso di aggiornamento in Oncologia Geriatrica. Avellino, Novembrer 10 2007.
46
17. La scomparsa del dolore da cancro. Naples, May 24 2007.
18. Seminari in Oncologia. Il carcinoma della mammella. Naples, June 26 2007.
19. L’Oncologia oggi: scenari in movimento. Avellino, September 28 2007.
20. Seminari in Oncologia. I tumori del colon-retto. Naples, October 5 2007.
21. Seminari in Oncologia. Le neoplasie del distretto testa-collo. Naples,October 19
2007.
22. Aggiornamento in Oncologia. Il carcinoma della mammlla. Ravello (SA), October
19-20 2007.
23. Neoplasie del polmone e della mammella: nuove prospettive terapeutiche. Avellino,
October 30, 2007.
24. Il percorso terapeutico nel carcinoma polmonare (NSCLC). Avellino, November 5-6
2007.
25. Seminari in Oncologia. Le neoplasie del torace. Napoli, November 9 2007.
26. Corso Interregionale. Terapie biologiche nel NSCLC. Naples, November 22 2007.
27. La scomparsa del dolore da cancro: un sogno che diventa realtà. Naples , December
6, 2007.
28. Seminari di Oncologia. Le neoplasie dello stomaco Naples, May 14 2008.
29. Seminari di Oncologia. L’epatocarcinoma. Naples, May 23 2008.
30. I Conferenza Italiana di Oncologia Toracica (CIOT). Naples , June 26-28, 2008.
31. Seminari di Oncologia. Le neoplasie dell’apparato urinario e genitale. Avellino,
September 23 2008.
32. Seminari di Oncologia. Le neoplasie del sistema nervoso centrale. October 7 2008.
33. Hot Topics in NSCLC. Incontro con l’ esperto. Naples, July 3 2008.
34. I Expert Forum Campano. Il carcinoma polmonare non a piccole cellule avanzato:
strategie terapeutiche. Avellino, November 11, 2008.
35. II Expert Forum Campano. Il carcinoma del polmone non a piccole cellule avanzato:
strategie terapeutiche. Avellino, July 7, 2009.
36. III Expert Forum Campano. “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, October 6, 2009.
47
37. IV Expert Forum Campano. “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, July 8, 2010.
38. V Expert Forum Campano. “Ruolo della targeted therapy nel trattamento del
carcinoma polmonare non a piccole cellule”. Avellino, September 27, 2010.
39. II Conferenza Italiana di Oncologia Toracica (CIOT). Rome, June 24-26, 2010.
40. VI Expert Forum Campano. Up-date nella terapia del carcinoma polmonare non a
piccole cellule. Avellino, June 30, 2011.
41. III International Conference on Thoracic Oncology (CIOT). Naples, June 28-30,
2012.
42. VII Expert Forum Campano. Up-date nel trattamento del carcinoma polmonare non a
piccole cellule. Avellino July 12, 2012.
48
ORGANIZATION OF INTERNATIONAL CONFERENCES
1. EORTC - Lung Cancer Cooperative Group Meeting. New trends in lung cancer.
Naples May 11, 1996.
2. EORTC and ESO Meeting. Lung cancer in the elderly. Naples June 6, 1997.
3. Survival and quality of life: comparing end points in oncology. Two years later.
Naples December 13-14, 2002.
4. European consensus panel on treatment of advanced NSCLC patients with
performance status 2. Avellino April 14, 2003.
6. International Naples conference. Results of an international experts panel on treatment
of advanced NSCLC in the elderly. Naples April 9, 2004.
7. Hematopoietic Growth Factors in solid tumors: experts panel meeting and conference.
Avellino April 11, 2006.
8. International Experts Panel Conference. “Second-line treatment of advanced NSCLC”
Naples April 17, 2007.
9. International Experts Panel Conference. “First-line treatment of advanced NSCLC”.
Sperlonga (Italy), May 8, 2009.
10. International Experts Panel Conference. “Role of maintenance treatment in advanced
NSCLC “. Sperlonga (Italy), May 6, 2011.
11. Internationa Conference on Thoracic Oncology (CIOT). Naples, 28-30 June, 2013.
12. International Experts Panel Conference. “ Treatment of advanced NSCLC with
EGFR mutation or ALK genetic alterations”. Sperlonga (Italy), May 3, 2013.
49
PROJECT LEADERSHIP
1. MARILIN (Multicenter Audio-video Regional Interactive Linkage INvestigation)
Regional project on interactive audio-video comunication between patient and
oncologic center after chemotherapy at high risk of toxicity. The project developed the
clinical trial: “Interactive audio-video comunication versus usual comunication in
oncologic patients treated with chemotherapy at high risk of toxicity”. The project
involved the nine principal Institutions of Regione Campania.
2. Survival and quality of life: comparing end points in Oncology. Project started on
October 1999 with expert boards (lung, gastrointestinal, gynecological, urogenital,
head – neech, cancer in the elderly) and ended on Febraury 2000 with a national
conference. The proceedings have been published on a supplement of Annals of
Oncology.
50
ACTING AS REVIEWER
1. DRUGS
2. EUROPEAN JOURNAL OF CANCER
3. INTERNATIONAL JOURNAL OF CANCER
4. LUNG CANCER
5. EXPERT OPINION ON PHARMACOTHERAPY
6. EXPERT OPINION IN BIOLOGICAL THERAPY
7. ONCOLOGY
8. EXPERT REVIEW OF ANTICANCER THERAPY
9. TUMORI
10.ANNALS OF ONCOLOGY
11.CANCER
12. CLINICAL CANCER RESEARCH
13.DRUGS AGING
14. JOURNAL OF MEDICAL ECONOMICS
15. CANCER THERAPY
16. DRUG DESIGN, DEVELOPMENT AND THERAPY
17.THE ONCOLOGIST
18.BRITISH JOURNAL OF CANCER
19. PHARMACOECONOMICS
20. DRUG SAFETY
21. FUTURE ONCOLOGY
22. DRUGS OF TODAY
23. CHEST
24. CLINICAL LUNG CANCER
51
25. ANTICANCER DRUGS
26. CANCER CHEMOTHERAPY AND PHARMACOLOGY
27. RESPIRATION
28. JOURNAL OF THORACIC ONCOLOGY
29. CURRENT MEDICAL LITERATURE- LUNG CANCER
30.JOURNAL OF POSTGRADUATE MEDICINE
31. QUALITY OF LIFE RESEARCH
32. VASCULAR HEALTH AND RISK MANAGEMENT
33. ONKOLOGIE
34. EUROPEAN RESPIRATORY JOURNAL
35. JOURNAL OF THE PANCREAS
36. JOURNAL OF PATHOLOGY
37. JOURNAL OF GERONTOLOGY:MEDICAL SCIENCES
38. THERAPEUTICS AND CLINICAL RISK MANAGEMENT
39. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY
40. JOURNAL OF GERIATRIC ONCOLOGY
41. JOURNAL OF THE NATIONAL CANCER INSTITUTE
42. LANCET ONCOLOGY
43. JOURNAL OF CLINICAL ONCOLOGY
ASSOCIATE EDITOR ACTIVITY
1) CANCER REPORT, from 1993 to 2000.
52
2) CANCER, Italian Edition, from 1999 to 2002.
3) CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, since 2000.
4) RASSEGNA DI ONCOLOGIA TORACICA - SUPPLEMENTO ALLA RASSEGNA
DI PATOLOGIA DELL’APPARATO RESPIRATORIO, from 2001 to 2004.
5) CANCER AGING, since 2003.
6) THE ONCOLOGIST, since 2003 (Section Editors “Lung Cancer”).
7) SUPPORTIVE AND PALLIATIVE CANCER CARE, since 2004.
8) LANCET ONCOLOGY, from 2006 to 2009.
9) CANCER, since 2006.
10) CURRENT MEDICAL LITERAURE- LUNG CANCER since 2007
11) LUNG CANCER since 2007
12) THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY since 2008
13) EXPERT OPINION ON EMERGING DRUGS since 2009
14) EUROPEAN JOURNAL OF CLINICAL AND MEDICAL ONCOLOGY since 2010
15) CLINICAL INVESTIGATION since 2010
16) JOURNAL OF GERIATRIC ONCOLOGY since 2010
17) JOURNAL OF THORACIC DISEASE since 2010
18) WORLD JOURNAL OF RESPIROLOGY since 2011
19) TRANSLATIONAL MEDICINE since 2014
20) JOURNAL OF TUMOR since 2014
53
ABSTRACTS AT NATIONAL MEETINGS
1. Palmieri G, Zilembo N, Gridelli C, Montesarchio V. "Descrizione di un caso
clinico di cancro-cirrosi." IV Convegno Internazionale "La chirurgia digestiva
distrettuale." Naples December 10-13, 1986.
2. Lauria R, Gridelli C, Calderopoli R, Contegiacomo A. "Localizzazione
leptomeningea secondaria a microcitoma polmonare: descrizione di un caso clinico."
IV Convegno Internazionale "La chirurgia digestiva distrettuale." Naples December
10-13, 1986.
3. Palmieri G, Aconito P, Gridelli C, Marinelli A. Pepe R. "Metastasi cerebrale come
prima manifestazione di neoplasia: esperienza clinico-terapeutica." IV Convegno
Internazionale "La chirurgia digestiva distrettuale." Naples December 10-13, 1986.
4. Lauria R, Gridelli C, Zilembo N, Contegiacomo A. "Nefrotossicità reversibile da
cisplatino." IV Convegno Internazionale "La chirurgia digestiva distrettuale." Naples
December 10-13, 1986.
5. Palmieri G, Aconito P, Gridelli C, De Placido S, Pagliarulo C. "Neoplasie a sede
primitiva ignota: esperienze clinico-terapeutiche". IV Convegno Internazionale "La
chirurgia digestiva distrettuale." Naples December 10-13, 1986.
6. Palmieri G, Gridelli C, Montesarchio V, Bianco AR. "Dati preliminari sulla
chemioterapia sistemica con methotrexate (MTX) ad alte dosi e 5-Fluorouracile (5Fu) nei pazienti con ca. del colon-retto avanzato." IV Convegno Internazionale "La
chirurgia digestiva distrettuale." Naples December 10-13, 1986.
7. Palmieri G, Gridelli C, Montesarchio V, De Placido S, Argenzio V. "Melanoma
metastatico in una paziente anziana: successo terapeutico con tamoxifene (TMX)."
IV Convegno Internazionale "La chirurgia digestiva distrettuale." Naples December
10-13, 1986.
8. Palmieri G, De Placido S, Gridelli C, Marinelli A, Argenzio V. "Sindrome da
compressione midollare (SLM) secondaria a ca. mammario avanzato: successo
terapeutico con 4-Epidoxorubicina." IV Convegno Internazionale "La chirurgia
digestiva distrettuale." Naples December 10-13, 1986.
9. Palmieri G, Gridelli C, Torino G, Montesarchio V, Marinelli A, Bianco AR. "Elevata
incidenza di varicocele in pazienti affetti da linfoma." TUMORI, 72:721 (abstr.),
1986.
10. Palmieri G, Lauria R, Aconito P, Gridelli C, Bianco AR."Esperienza terapeutica con
interferon (ß-IFN) nell'adenocarcinoma renale (RCC) in fase avanzata." TUMORI,
72:722 (abstr.), 1986.
11. Palmieri G, Montesarchio V, Gridelli C, Zampino MG, Bianco AR. "Linfomi cutanei
a cellule T: esperienza clinica e terapeutica." TUMORI, 72:722 (abstr.), 1986.
54
12. Stefani S, Palmieri, Iaffaioli RV, Gridelli C, Caponigro F, Bianco AR. "Istiocitosi X:
nuove prospettive terapeutiche con irradiazione ipofisaria a dosi non convenzionali."
TUMORI, 72:733 (abstr.), 1986.
13. Palmieri G, Montesarchio V, Pagliarulo C, Gridelli C, De Placido S, Bianco AR.
"Dati preliminari sull'impiego del methotrexate ad alte dosi (HDMTX) e 5Fluorouracile (5-Fu) nel carcinoma del colon-retto avanzato." TUMORI, 73
(suppl.):54 (abstr.), 1987.
14. Gridelli C, Palmieri G, Pepe R, Bianco AR. "Mitoxantrone: nuove prospettive
terapeutiche nel carcinoma midollare della tiroide." TUMORI, 73 (suppl.):189
(abstr.), 1987.
15. Palmieri G, Gridelli C, Pepe R. "Carcinoma polmonare a piccole cellule sincrono a
cistoadenocarcinoma del pancreas." I Congresso Nazionale Società Italiana di
Chirurgia Geriatrica. Naples December 9-12, 1987.
16. Palmieri G, Gridelli C, Airoma G. "Sindrome femminilizzante in paziente maschio
affetto da carcinoma surrenalico." I Congresso Nazionale Società Italiana di
Chirurgia Geriatrica. Naples December 9-12, 1987.
17. Palmieri G, Montesarchio V, Pagliarulo C, Gridelli C, De Placido S, Bianco AR.
"Dati preliminari sull'impiego del methotrexate ad alte dosi (HDMTX) e 5Fluorouracile nel carcinoma del colon-retto avanzato." I Congresso Nazionale
Società Italiana di Chirurgia Geriatrica. Naples December 9-12, 1987.
18. Gridelli C, Palmieri G, Pepe R. "Mitoxantrone nuove prospettive terapeutiche nel
carcinoma midollare della tiroide." I Congresso Nazionale Società Italiana di
Chirurgia Geriatrica. Naples December 9-12, 1987.
19. Palmieri G, Gridelli C, Zilembo N, Pepe R. "Esperienza con timostimolina in un caso
di cancro-cirrosi." III Workshop TP-1, Nairobi March, 1988.
20. Palmieri G, Gridelli C, Tagliaferri P, Airoma G, Bianco AR. "Beta-Interferone e 5Fluorouracile nel trattamento del carcinoma del colon-retto avanzato". TUMORI, 74
(suppl.):242 (abstr.), 1988.
21. Gridelli C, Pepe R, Incoronato P, Palmieri G. "Il mitoxantrone nel trattamento del
carcinoma della colecisti avanzato: esperienza clinico-terapeutica." TUMORI, 74
(suppl.):240 (abstr.), 1988.
22. Palmieri G, Gridelli C, Montesarchio V, Incoronato P, Bianco AR. "Trattamento dei
tumori germinali del testicolo non seminomatosi in fase avanzata a cattiva prognosi."
TUMORI, 74 (suppl.):306 (abstr.), 1988.
23. Lauria R, Gridelli C, Contegiacomo A, Gentile M, Conte A, Giampaglia F, Stefani
S, Ferrante G, Bianco AR. "Carcinoma polmonare a piccole cellule in fase limitata:
risultati di un protocollo di terapia combinata." TUMORI, 74 (suppl.):279 (abstr.),
1988.
55
24. Iaffaioli RV, Palmieri G, Contegiacomo A, Frasci G, Lauria R, Gridelli C, Perone V,
Aconito P, Bianco AR. "Valutazione dell'efficacia del ß-Interferone (IFN) da solo o
in associazione a chemio o radioterapia nel trattamento dei tumori refrattari."
TUMORI, 74 (suppl.):168 (abstr.), 1988.
25. Palmieri G, De Sena G, Cimino L, Gridelli C, Incoronato P, Topa M, Caponigro F,
Budillon G, Bianco AR. "Il mitoxantrone nel trattamento dell'epatocarcinoma
inoperabile." TUMORI, 75 (suppl.):93 (abstr.), 1989.
26. Palmieri G, Gridelli C, Airoma G, Balestrino M, Bisogno A, Bianco AR.
"Methotrexate ad alte dosi (HDMTX) e 5-Fluorouracile (5-Fu) nel carcinoma del
colon-retto in fase avanzata." TUMORI, 75 (suppl.):14 (abstr.), 1989.
27. Gridelli C, Pepe R, Gentile M, Giampaglia F, Palmieri G, Ferrante G, Bianco AR.
"Mitomicina C, etoposide e vindesina nel trattamento del carcinoma polmonare non a
piccole cellule stadio IV.” TUMORI, 75 (suppl.):273 (abstr.), 1989.
28. Caponigro F, Iaffaioli RV, Pagliarulo C, De Placido S, Palmieri G, Frasci G, Gridelli
C, Bianco AR. "CEA, TPA, CA 15.3 nel follow-up del carcinoma mammario: studio
su 238 pazienti." TUMORI, 75 (suppl.):91 (abstr.), 1989.
29. Gridelli C, Pepe R, Gentile M, Palmeri S, Palmieri G, Gebbia V, Airoma G, Russo A,
Ferrante G, Bianco AR. "Dati preliminari sullo schema polichemioterapico MEV
(Mitomicina C, Etoposide e Vindesina) nel carcinoma polmonare non a piccole
cellule in fase metastatica (stadio IV)." III Congresso Nazionale FONICAP, Florence
December 7-9, 1989.
30. Gridelli C, Pepe R, Palmeri S, Iacobelli S, Palmieri G, Gebbia V, Airoma G, Garufi
C, Russo A, Bianco AR. "Schema polichemioterapico MEV (Mitomicina C,
Etoposide, Vindesina): una possibile valida alternativa nel carcinoma polmonare non
a piccole cellule stadio IV." TUMORI, 76 (suppl.):127 (abstr.), 1990.
31. Gridelli C, Maiorino A, Curcio C, D'Aprile M, Ianniello G, Brancaccio L, Palmeri S,
Gentile M, Comella G, Pedicini T, Airoma G, Incoronato P, Gebbia V, Russo A, De
Placido S, Ferrante G, Iacobelli S, Rausa L, Bianco AR. "Carboplatino + epirubicina
+ VP-16, radioterapia concomitante “split course" e chirurgia adiuvante nel
carcinoma polmonare a piccole cellule." TUMORI, 77 (suppl.):86 (abstr.), 1991.
32. Gridelli C, D'Aprile M, Curcio C, Veltri E, Brancaccio L, Palmeri S, Gentile M,
Comella G, Casaretti R, Airoma G, De Placido S, Gebbia V, Ferrante G, Rausa L,
Bianco AR. "Carboplatin + epirubicin + VP-16, radioterapia concomitante e chirurgia
adiuvante nel carcinoma a piccole cellule in fase di malattia limitata." TUMORI, 79
(suppl.):39 (abstr.), 1993.
33. Bianco AR, Gridelli C, D'Aprile M, Veltri E, Palmeri S, Gentile M, Curcio C, Russo
A, Gebbia V, Ianniello G, De Placido S, Pepe R, Incoronato P, Lorusso V, De Lena
M. "Studio di fase I con carboplatino + epirubicina + VP-16 e G-CSF nel carcinoma
polmonare a piccole cellule (CPPC) in fase di malattia estesa." TUMORI, 79
(suppl.):36 (abstr.), 1993.
56
34. Bruni GS, Posca T, Gridelli C, Celiento G, Rinaldi L, Scoppa GF, Pergola M. "La
chemioterapia concomitante nel carcinoma polmonare non a piccole cellule (CPNPC)
stadio IIIA-IIIB: dati preliminari di uno studio di fase II non randomizzato."
TUMORI, 80 (suppl.):103 (abstr.), 1994.
35. Rossi A, Gridelli C, D'Aprile M, Palmeri S, Curcio C, Gebbia V, Veltri E, Ianniello
G, Lorusso V, Palmieri G, De Placido S, De Lena M, Pepe R, Incoronato P, Leonardi
V, Airoma G, Bianco AR. "Studio di fase I-II con carboplatino, epirubicina e VP-16
più G-CSF nel carcinoma polmonare a piccole cellule (CPPC) in fase di malattia
estesa." TUMORI, 80 (suppl.):105 (abstr.), 1994.
36. Gridelli C, D'Aprile M, Palmeri S, Cognetti F, Gebbia V, Perrone F, Veltri E,
Leonardi V, Scinto AF, Bruni GS, De Placido S, Bianco AR. "Mitomicina C +
vindesina + etoposide (MEV) vs mitomicina C + vindesina + cisplatino (MVP) nel
carcinoma polmonare non a piccole cellule (CPNPC) stadio IV: studio multicentrico
randomizzato di fase III." TUMORI, 80 (suppl.):73 (abstr.), 1994.
37. Silvestro P, Caparrotti G, Bruni GS, Apice G, Gridelli C, Pignata S, Pergola M.
"Epirubicina e lonidamina nel trattamento del carcinoma della mammella avanzato."
TUMORI, 80 (suppl.):115 (abstr.), 1994.
38. Gridelli C, Rossi A, Incoronato P, Airoma G, Pepe R, Palazzolo G, Bruni GS, Rinaldi
L, Bianco AR. "Phase I study of ifosfamide plus high dose epirubicin in advanced
non small cell lung cancer." TUMORI, 81 (suppl.):107 (abstr.), 1995.
39. Gridelli C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile
M, Rossi A, Perrone F, Migliorino R, Pergola M, Bianco AR."Studio di fase II con
vinorelbina in pazienti anziani affetti da carcinoma polmonare non a piccole cellule
(CPNPC) stadio IIIB-IV." Congresso Nazionale "Tumori in età geriatrica" Lucca
June 28-29, 1996.
40. Gridelli C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F,
D'Aprile M, Rossi A, Perrone F, Migliorino R, Pergola M, Bianco AR. "Phase II
study of vinorelbine in elderly patients with stage IIIB-IV non small cell lung
cancer." TUMORI, 82:69, 1996.
41. Rossi A, Gridelli C, De Marinis F, Tucci E, D'Aprile M, Cioffi R, Cortesi E,
Migliorino R, Pisano A, Guida C, Scognamiglio F, Bianco AR. "Combination of
VM-26 with lonidamine (LND) in pretreated small cell lung cancer (SCLC): a phase
II study." TUMORI, 82:94, 1996.
42. Ianniello G, Gridelli C, Brancaccio L, Iaffaioli RV, Curcio C, Lorusso V, D'Aprile
M, Cioffi R, Rossi A, Scognamiglio F, Guida C, Fiore F, Pepe R, Palazzolo G,
Bianco AR, Pergola M. "A phase II study on carboplatin plus vinorelbine in
extensive small cell lung cancer (SCLC)." TUMORI, 82:94, 1996.
43. Lorusso V, Amadori D, Antimi M, Gridelli C, Luporini G, Pollera C, Pacini M, De
Lena M. "A phase II study of gemcitabine (GEM) in bladder cancer." TUMORI,
82:77, 1996.
57
44. Gridelli C. "La chemioterapia nell'anziano."J CHEMOTHER, 8 (suppl. 3):31, 1996.
45. De Lena M, Lorusso V, Amadori D, Antimi M, Gridelli C, Luporini G, Pollera C,
Ditonno P, Battaglia M, Selvaggi FP, Oliva C, Pacini M. "Gemcitabina nel carcinoma
vescicale in stadio avanzato studio di fase II." J CHEMOTHER, 8 (suppl. 3):39-41,
1996.
46. Gridelli C, Ianniello G, Brancaccio L, Perrone F, Iaffaioli RV, Curcio C, D'Aprile M,
Cioffi R, Cigolari S, Rossi A, Rinaldi L, Veltri E, Palazzolo G, Bianco AR, Pergola
M, Monfardini S. "Carboplatin plus vinorelbine: a new active regimen in extensive
small cell lung cancer. Results of a multicenter phase II study." TUMORI, 83:21,
1997.
47. Rossi A, Cigolari S, Maiorino A, Ianniello G, De Cataldis G, Pedicini T, Brancaccio
L, Maiorino L, Guida C, Pisano A, Barletta E, Gridelli C. “Cisplatin plus vinorelbine
plus amifostine in the treatment of advanced non small cell lung cancer (NSCLC): a
multicenter phase II study”. TUMORI, 84 (suppl 1):92, 1998.
48. Gridelli C, Ianniello GP, Maiorino L, Piantedosi V, Cigolari S, Manzione L, Failla G,
Zuccarino L, Pedicini T, Vinante O, Castiglione F, Clerici M, Bearz A, Piazza E,
Tonato M, Rossi A, Monfardini S, Frontini L, Gallo C, Perrone F. “Vinorelbine
(VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced nonsmall cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III
randomized trial.” TUMORI, 84 (suppl 1):54, 1998.
49. Frontini L, Perrone F, Gulisano M, Robbiati SF, Farris A, Clerici M, Castiglione F,
Piazza E, Ianniello GP, Gasparini GP, Rossi A, Gallo C, Gridelli C. “Gemcitabine +
Vinorelbine (GEMVIN) in the treatment of advanced non-small cell lung cancer
(NSCLC). Sequential phase I and phase II trials.“ TUMORI, 84 (suppl 1):65, 1998.
50. Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Biglietto M, Verderame F,
Pandolfo G, Valdesi M, Gebbia N, Colucci G. “Studio prospettico di fase III del
Gruppo Oncologico Italia Meridionale (GOIM) nei carcinomi polmonari non a
piccole cellule (NSCLC) avanzati con Mitomicina + Vindesina + Cisplatino (MVP)
versus Vinorelbina + Cisplatino (PN).” Congresso Nazionale FONICAP, Bari June
11-13, 1998.
51. Bilancia D, Gridelli C, Ianniello GP, Maiorino L, Piantedosi V, Cigolari S, Manzione
L , Aiello R , Zuccarino L, Pedicini T, Frontini L, Pappagallo GL, Gallo C, Perrone
F. “Vinorelbina (VNR) più Terapia di Supporto (TS) vs TS nel trattamento del
carcinoma polmonare non a piccole cellule (CPNPC) in pazienti anziani. Risultati di
uno studio randomizzato di fase III.” Congresso Nazionale FONICAP, Bari June 1113, 1998.
52. Gridelli C. “Associazione di gemcitabina con farmaci non-platino derivati”.
Congresso Nazionale della Società Italiana di Medicina Respiratoria:Gemcitabina:
farmaco innovativo per il carcinoma polmonare non a piccole cellule? Turin
November 4-7, 1998.
58
53. De Marinis F, Crinò L, Conte PF, Rinaldi M, Gridelli C, Ceribelli A, Matano E,
Marangolo M, Bartolucci R, Oliva C, Tonato M. “A randomised trial of gemcitabine
cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced NonSmall Cell Lung Cancer (NSCLC). A multicenter phase III study.” TUMORI, 84
(suppl 1):53, 1998.
54. Rinaldi M, Crinò L, Scagliotti G, De Marinis F, Gridelli C, Mosconi AM, Della
Giulia M, Poggi P, Selvaggi G, Darwish S, Bartolucci R, Calandri C, Tonato M.
“Phase II randomized study in advanced NSCLC with gemcitabine (GEM) ant two
different cisplatin (DDP) doses in a three weeks schedule.” TUMORI, 84 (suppl
1):65, 1998.
55. Scagliotti GV, Crinò L, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A,
Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V,
Portalone L, Cruciani G, Masoni A, Ferrara G, Gozzelino F, Tonato M. Gemcitabinecisplatin versus mitomycin C-ifosfamide-cisplatin in advanced non-small cell lung
cancer. A randomized phase II study of the Italian Lung Cancer Project. Atti I°
Congresso Nazionale di Oncologia Medica, Rome October 24-28, 1999.
56. Gulisano M, Gridelli C, Frontini L, Cigolari S, Castiglione F, Robbiati SF, Gasparini
GP, Ianniello GP, Farris A, Clerici M, Felletti R, Piazza E, Gallo C, Perrone F.
“Phase I-II study of Gemcitabine + Vinorelbine (GemVin) in the treatment of
advanced non-small cell lung cancer (NSCLC).” Atti I° Congresso Nazionale di
Oncologia Medica, Rome October 24-28, 1999.
57. Gridelli C, Cigolari S, Manzione L, Ianniello GP, Frontini L, Failla G, Robbiati SF,
Adamo V, Gasparini G, Novello S, Piazza E, De Marinis F, Corradini G, Raucci C,
Gallo C, Perrone F. “Activity and toxicity of gemcitabine (GEM) and
gemcitabine+vinorelbine (GEMVIN) in advanced nsclc elderly patients (Pts). Initial
phase II. Data from the MILES (multicenter italian lung cancer in the elderly study)
randomised trial.” Atti I° Congresso Nazionale di Oncologia Medica, Rome October
24-28, 1999.
58. Gridelli C, Barzelloni ML, Barletta E, Gatani T, Fiore F, Guida C, Scognamiglio F.
“Il Ruolo dell’amifostina nel trattamento del carcinoma polmonare non a piccole
cellule (CPNPC) avanzato.” Atti XXV Congresso Nazionale SIT, Sorrento (Na)
November 17-21, 1999.
59. Gridelli C, Barzelloni ML, Barletta E, Gatani T, Fiore F, Guida C, Scognamiglio F.
“Il Ruolo della chemioterapia senza cisplatino nel carcinoma polmonare non a
piccole cellule (CPNPC) avanzato.” Atti XXV Congresso Nazionale SIT, Sorrento
(Na) November 17-21, 1999.
60. Gridelli C, Barzelloni ML, Barletta E, Gatani T, Fiore F, Guida C, Scognamiglio F.
“Il ruolo del topotecan nel trattamento dei tumori del polmone: attualità e
prospettive.” Atti XXV Congresso Nazionale SIT, Sorrento (Na) November 17-21,
1999.
61. Guida C, Elmo M, Russo Spena F,Ravo V, Pecori B, Frezza P, Silvestro G, Verga E,
Barletta E, Barzelloni ML, Gridelli C. “Radioterapia toracica e vinorelbina
59
giornaliera come radiosensibilizzante nel trattamento del carcinoma polmonare non
small cell (CPNPC) localmente avanzati, più o meno amifostine: studio di fase I.”
RAYS, 24 (suppl 2):27, 1999.
62. Barzelloni ML, Guida C, Barletta E, Scognamiglio F, Gatani T, Tambaro R, Gridelli
C. “Radioterapia (RT) + vinorelbina (VNR) giornaliera a scopo radiosensibilizzante
nel carcinoma polmonare non a piccole cellule (NSCLC) localmente avanzato: studio
di fase I.” ATTI 5° Congresso Nazionale: Nuove vie per la terapia del cancro. Bari
June 7-10, 2000.
63. Cigolari S, Pignata S, Ianniello GP, Pontillo V, Daniele B, De Lucia L, Iaffaioli RV,
Pedicini T, Maiorino L, Perrone F, Gridelli C. “Comunicazione audiovisiva vs
comunicazione telefonica tra centro oncologico e pazienti sottoposti a chemioterapia.
Studio randomizzato MARILIN (Multicenter Audio-video Regional Interactive
Linkage Investigation).” ATTI 5° Congresso Nazionale: Nuove vie per la terapia del
cancro. Bari June 7-10, 2000.
64. Barletta E, Manzione L, D’Aprile M, Cioffi R, Ianniello GP, Frontini L, Barzelloni
ML, Perrone F, Gridelli C. “Carboplatino + paclitaxel nel carcinoma polmonare a
piccole cellule (SCLC) in fase estesa. Studio multicentrico di fase II.” ATTI 5°
Congresso Nazionale: Nuove vie per la terapia del cancro. Bari June 7-10, 2000.
65. Cigolari S, Bilancia D, Piantedosi FV, Barbera S, Piazza E, Frontini L, Vinante O,
De Marinis F, Robbiati SF, Bertetto O, Sacco C, Perrone F, Gridelli C. “Studio di
fase II con gemcitabina (GEM) e gemcitabina + vinorelbina (GEMVIN) nel
carcinoma polmonare non a piccole cellule (NSCLC) avanzato nell’anziano. Dati
dallo studio di fase II MILES (Multicenter Italian Lung cancer in the Elderly Study).”
ATTI 5° Congresso Nazionale: Nuove vie per la terapia del cancro. Bari June 7-10,
2000.
66. Illiano A, Barletta E, De Marino V, Barzelloni ML, Rossi A, Zampa G, Rossi N,
Gridelli C. “Carboplatino + paclitaxel + gemcitabina con supporto di amifostina nel
carcinoma polmonare non a piccole cellule (NSCLC) avanzato.” ATTI 5° Congresso
Nazionale: Nuove vie per la terapia del cancro. Bari June 7-10, 2000.
67. Barletta E, Manzione L, Bilancia D, Rossi A, Frontini L, Zonato S, Barzelloni ML,
Gridelli C. “Docetaxel + profilassi primaria con lenograstim nel carcinoma
polmonare non a piccole cellule (NSCLC) pretrattato: studio multicentrico di fase II.”
ATTI 5° Congresso Nazionale: Nuove vie per la terapia del cancro. Bari June 7-10,
2000.
68. Brancaccio L, Curcio C, Iaffaioli RV, Veltri E, Cigolari S, Gebbia V, Palazzolo G,
Tambaro R, Rossi A, Perrone F, Gridelli C. “Carboplatino + epirubicina + VP-16 +
lenograstim (CEV-L) seguito da radioterapia sul torace + carboplatino giornaliero
(RT-C) radiosensibilizzante nel carcinoma polmonare a piccole cellule (SCLC)
limitato. Studio multicentrico di fase II.” ATTI 5° Congresso Nazionale: Nuove vie
per la terapia del cancro. Bari June 7-10, 2000.
60
69. Gridelli C. “Trattamento integrato chemioradioeterapico nel carcinoma polmonare
non a piccole cellule (CPNPC).” ATTI 5° Congresso Nazionale: Nuove vie per la
terapia del cancro. Bari June 7-10, 2000.
70. Gridelli C. “GEM-VIN nel NSCLC: una alternativa ai regimi senza platino?” ATTI
5° Congresso Nazionale: Nuove vie per la terapia del cancro. Bari June 7-10, 2000.
71. Gridelli C. “Il ruolo del docetaxel in schemi di combinazione non contenenti
cisplatino nel carcinoma polmonare non a piccole cellule avanzato.” ATTI
Convegno: Docetaxel nel NSCLC, un futuro presente. Boulogne July 1, 2000.
72. Normanno N, De Luca A, Maiello M, Barzelloni ML, Casamassimi A, Pignata S,
Gridelli C. “Detection of tumor cells in the peripheral blood carcinoma patients by an
EGF-Receptor reverse transcriptase-PCR assay.” TUMORI 86 (suppl 1):86-87, 2000.
73. Gridelli C, Maione P. “Il trattamento del carcinoma polmonare a piccole cellule
nell’anziano.” ATTI Seminari di Aggiornamento: Anziani e cancro: qualità di vita e
qualità di cura. Genoa October 28-30, 2000.
74. Gridelli C. “Il paziente anziano la fine di un pregiudizio? Studio MILES e G-STEP.”
ATTI Simposio Satellite Eli Lilly, 2° Congresso Nazionale di Oncologia Medica,
Genoa October 30, 2000.
75. Gridelli C, Maione P, Barletta E. “Protocolli terapeutici nel trattamento del tumore
del polmone.” 1° Convegno Nazionale di Farmacia Oncologica, Naples November
16-18, 2000.
76. Gridelli C, Maione P, Barletta E. “Il trattamento del non-microcitoma nel paziente
anziano.” Rassegna di Patologia dell’Apparato Respiratorio, 16/S5: 145-146, 2001.
77. De Marinis F, Scagliotti GV, Rinaldi M, Crinò L, Gridelli C, Ricci S, Bianco AR,
Boni C, Marangolo M, Failla G, Adamo V, Altavilla G, Ceribelli A, Clerici M, Di
Costanzo F, Frontini L, Tonato M. “Phase II randomized trial comparing three
platinum-based doublets in advanced non-small cell lung cancer.” ANNALS OF
ONCOLOGY 12 (suppl 4):1, 2001.
78. Gridelli C, Maione P, Barletta P. “Il trattamento del carcinoma polmonare non a
piccole cellule localmente avanzato.” Atti 3° Congresso Nazionale di Oncologia
Medica, Naples November 4-7, 2001.
79. Gridelli C, Maione P, Barletta E. “Chemotherapy of advanced NSCLC in the
elderly.” Atti XXVII Congrsso Nazionale di Oncologia, Rome November 21-23,
2001.
80. Gridelli C, Maione P, Nicolella D. “La chemioterapia”. Atti Corso educazionale: La
pallazione in Oncologia, Naples April 14-16, 2002.
81. Gridelli C, Rossi A, Maione P, Colantuoni G, Airoma G, Ferrara C, Guerriero C, Del
Gaizo F, Nicolella D. “Le combinazioni con farmaci non citotossici: una nuova
sinergia.” Atti 6° Congresso Nazionale GOIM pag. 127-129. Naples June 11-15,
2002.
61
82. Gridelli C, Rossi A, Maione P, Colantuoni G, Airoma G, Nicolella D, Guerriero C,
Ferrara C, Del Gaizo F. “Ruolo attuale di Iressa nel trattamento delle neoplasie
polmonari.” Atti 6° Congresso Nazionale GOIM pag. 165-167. Naples June 11-15,
2002.
83. Gridelli C, Rossi A, Maione P, Colantuoni G, Airoma G, Ferrara C, Del Gaizo F,
Nicolella D, Guerriero C. “Impatto della terapia di supporto sulla qualità di vita del
paziente oncologico.” Atti 6° Congresso Nazionale GOIM pag. 351-353. Naples June
11-15, 2002.
84. Maione P, Romano G, Panico L, Ferrara C, Del Gaizo F, Esposito P, Ferbo U,
Gridelli C. “Leiomiomatosi peritoneale disseminata: rara neoplasia benigna che
simula la carcinosi peritoneale. Un caso clinico.” Atti 6° Congresso Nazionale GOIM
pag. 439. Naples June 11-15, 2002.
85. Colantuoni G, Rossi A, Guerriero C, Nicolella D, Ferrara C, Del Gaizo F, Maione P,
Gridelli C. “Nuova schedala di somministrazione del trastuzumab nel trattamento del
carcinoma mammario metastatico: esperienza clinica.” Atti 6° Congresso Nazionale
GOIM pag. 440. Naples June 11-15, 2002.
86. Rossi A, Guerriero C, Nicolella D, Colantuoni G, Ferrara C, Del Gaizo F, Airoma G,
Gridelli C. “Recidiva di cancro della mammella dopo 25 anni con presentazione
atipica di neoplasia polmonare primitiva: caso clinico.” Atti 6° Congresso Nazionale
GOIM pag. 494. Naples June11-15, 2002.
87. Rossi A, Colantuoni G, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Airoma G,
Maione P, Gridelli C. “La monochemioterapia nel paziente anziano affetto da
carcinoma del polmone non a piccole cellule avanzato.” Atti 6° Congresso Nazionale
GOIM pag. 345. Naples June 11-15, 2002.
88. Gridelli C. “Razionale di impiego nel paziente anziano con NSCLC.” Eloxatin
Meeting Italy, Milan April 4-5, 2002.
89. Gridelli C. “Gemcitabine-based chemotherapy as platform for new biological
treatments.” IV Congresso Nazionale di Oncologia Medica, Turin September 28,
2002.
90. Rossi E, Perrone F, Amabile G, Labonia V, Landi G, Nuzzo F, Gridelli C, Di Maio
M, de Matteis A. “Gemcitabine plus vinorelbine as second-line chemotherapy of
metastatic breast cancer. A single center phase 2 study.” ANNALS OF
ONCOLOGY, 13 (suppl 3):17, 2002.
91. De Marinis F, Nelli F, Migliorino R, Portalone L, Cortesi E, Brancaccio L, Crispino
C, Martelli O, Di Molfetta M, Gridelli C. “Gemcitabine-paclitaxel-cisplatin (GTP) as
induction chemotherapy for stage IIIA(N2) non small cell lung cancer (NSCLC)
patients: preliminary results of a multicenter phase II study.” ANNALS OF
ONCOLOGY, 13 (suppl 3):32, 2002.
92. Di Maio M, Gridelli C, Gallo C, Barletta E, Piantedosi FV, Rossi A, Cigolari S,
Esposito M, Robbiati SF, Esani G, Frontini L, Castiglione F, Veltri E, De Maio E,
62
Maoine P, Perrone F. “Supportive care (SC) in patients with advanced non small cell
lung cancer (NSCLC).” ANNALS OF ONCOLOGY, 13 (suppl 3):51, 2002.
93. Maione P, Perrone F, Di Maio M, Iaffaioli RV, Brancaccio L, Manzione L, Cioffi A,
Illiano A, Barbera S, Piazza E, Cabiddu M, Porcile G, Rosetti F, De Maio E, Gallo C,
Gridelli C. “Use of analgesic in patients with advanced non small cell lung cancer
(NSCLC).” ANNALS OF ONCOLOGY, 13 (suppl 3):66, 2002.
94. Nicolella D, Airoma G, Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Maione
P, Rossi A, Gridelli C. “Valutazione della qualità di vita negli anziani con tumori
gastro-intestinali.” GIORNALE DI GERENTOLOGIA, L(S-5):274, 2002.
95. Rossi A. Del Gaizo F, Nicolella D, Ferrara C, Colantuoni G, Guerriero C, Airoma G,
Barzelloni ML, Maione P, Gridelli C. “Carcinoma del polmone: terapia della fase
metastatica – Vinorelbina settimanale.” ATTI CONGRESSUALI LE TERAPIE
SETTIMANALI TRE ANNI DOPO, Rome June 23-24, 2003.
96. Nicolella D, Gridelli C. “Dermatite acuta da vinorelbina. Terapia con emulsione a
base di olio di avocado”. 78° Congresso Nazionale della Società Italiana di
Dermatologia e Venereologia, Rome June 25-28, 2003.
97. Iandoli R, Maione P, Rossi A, Gridelli C. “Controllo degli effetti collaterali cutanei
secondari a terapia con Gefinitib: tre casi clinici.” XI riunione Giornate di Terapia in
Dermovenerologia, Catania January 17-18, 2004.
98. Gridelli C, Rossi A. “Quali limiti al trattamento nel paziente geriatrico.” 4° Attualità
in Oncologia, Foggia May 13-14, 2004.
99. Gridelli C, Maione P, Rossi A, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D,
Balzelloni ML, Colantuoni G. “Il trattamento del carcinoma polmonare non a piccole
cellule in fase avanzata: la chemioterapia nel paziente anziano.” 5° Giornata
Veronese di Oncopneumologia. Verona December 10-11, 2004.
100. Ferrara C, Rossi A, Colantuoni G, Del Gaizo F, Guerriero C, Nicolella D, Maione
P, Gridelli C. “Contemporaneous bilateral retinal metastases from lung
adenocarcinoma.” ANNALS OF ONCOLOGY, 16 (suppl 4):161 (abstr F6), 2005.
101. Gridelli C, Reck M, Gregorc V, Migliorino M, Muller TR, Manegold C,
Favaretto A, Crucitta E, Munoz M, Cirri L, Marini L, Rossi A, Koschel G. “Singleagent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line
chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients
or patients inelegible for platinum-based chemotherapy: preliminary results of a
phase II randomized trial.” ANNALS OF ONCOLOGY, 16 (suppl 4):162 (abstr F7),
2005.
102. Rossi A, Maione P, Guerriero C, Colantuoni G, Del Gaizo F, Nicolella D, Ferrara
C, Gridelli C. “Single-agent gefitinib in advanced non-small cell lung cancer elderly
patients unsuitable for chemotherapy: experience in two patients with chronic renal
failure.” ANNALS OF ONCOLOGY, 16 (suppl 4):164 (abstr F14), 2005.
63
103. Gridelli C, Reck M, Gregorc V, Migliorino M, Muller TR, Manegold C,
Favaretto A, Crucitta E, Munoz M, Cirri L, Marini L, Rossi A, Koschel G. “Phase II
randomized trial of pemetrexed or sequentially-administered pemetrexed/gemcitabine
for untreated advanced non-small cell lung cancer (NSCLC) in elderly or PS2
patients.” ANNALS OF ONCOLOGY, 16 (suppl 7):vii28 (abstr B40), 2005.
104. Maione P, Mencoboni M, Carrozza F, Vigano MG, Gebbia V, Verusio C, Gallo
C, Morabito A, Piccirillo MC, Gridelli C, Ciardiello F, Perrone F. “ Additino of
cetuximab to gemcitabine in elderly or performance status 2 patients with advanced
non small cell lung cancer: the CALC-1 randomized phase 2 trials. ANNALS OF
ONCOLOGY, 19 (suppl 9):ix24, 2008.
105. Gridelli C, Zilembo N, De Marinis F, Crinò L, Barni S, Ardizzoni A, Piazza E,
Lorusso V, Barbera S, Caprioli A. “Patient management of over 1000 patient cohort
affected by stage IIIB-IV NSCLC: vaseline results from the SUN study. ANNALS
OF ONCOLOGY, 19 (suppl 9):ix24, 2008.
106. Gebbia V, Verusio C, Frontini L, Pisanelli B, Barletta E, Gamucci T, Mancuso G,
Di Maio M, Piccirillo MC, Gridelli C, Gallo C, Perrone F. “Weekly docetaxel vs
docetaxel based combination chemotherapy as second-line treatment of advanced non
small cel lung cancer patients. The DISTAL 2 randomized trial. ANNALS OF
ONCOLOGY, 19 (suppl 9):ix25, 2008.
107.
Police MA, Ventruto M, Mosca L, De Stefano N, Ferbo U, Gridelli C.
Ricerca delle mutazioni del gene K-ras nei tumori del colon come biomarcatore.
XII Congresso SIGU, Turin, November 8-10, 2009.
108. Gridelli C, Ciardiello F, Feld R, Butts CA, Gebbia V, Genestreti G, Favaretto
AG, Wierzbicki R, Gallo C, Perrone F.“International multicenter randomized phase
III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine
(CG) versus first-line CG followed by second-line E in advanced non small cell lung
cancer”. ANNALS OF ONCOLOGY, 20 (suppl 10), 2010.
109. Gridelli C, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O,
Laack E, Reck M, Chella A, Amoruso D, Fasola G, bearz A, Boni C, Grossi F,
Maione P, Ricciardi S, Corinovis D, Corral J, Melemed S, John W, Chouaki N,
Zimmermann A, Visseren-Grul Carla, Paz-Ares L. “PARAMOUNT: phase III study
of maintenance pemetrexed plus best supportive care versus placebo plus best
supportive care following induction treatment with pemetrexed plus cisplatin for
advanced non squamous non small cell cancer (NSCLC)”. TUMORI, 11 (suppl), S1,
2011.
110. Di Maio M, Leinghl N, Signoriello G, Rossi A, Gebbia V, Morgillo F, Wierzbicki
R, Favaretto R, Alam Y, Cinieri S, Siena S, Marciano R, Cartenì G, Spatafora M,
Ravaioli A, Maione P, Butts C, Ciardiello F, Field R, Gallo C, Perrone F, Gridelli C.
“Quality of life results of the TORCH randomized phase III trial: first-line erlotinib
follone by second-line cisplatin + gemcitabine versus reverse sequence in advanced
non small cell lung cancer”. TUMORI, 11(suppl), S59, 2011.
64
ABSTRACTS AT INTERNATIONAL MEETINGS
1. Ferrante G, Stefani S, Gentile M, Contegiacomo A, Lauria R, Conte A, Giampaglia
F, Gridelli C, Elia S, Bianco AR. "Intensive chemo-radiotherapy for small cell
carcinoma of the lung." 6th European Congress on disease of the chest. Tel Aviv
June 15-19, 1986.
2. Bianco AR, Stefani S, Contegiacomo A, Gentile M, Conte A, Lauria R, Giampaglia
F, Gridelli C, Ferrante G. "Intensive alternating chemotherapy and radiation therapy
for small cell lung cancer." International Conference on Small Cell Lung Cancer.
Ravenna March 27-28, 1987.
3. Iaffaioli RV, Palmieri G, Contegiacomo A, Lauria R, Frasci G, Castiglione F,
Aconito P, Gridelli C, Bianco AR. "Beta-Interferon alone or as reinducer of
chemosensitivity in refractary neoplasms." Third International Conference on
Progress in Cancer Research. Sanremo May 4-6, 1987.
4. Iaffaioli RV, Palmieri G, Frasci G, Gridelli C, Perone V, Aconito P, Castiglione F,
Bianco AR. "Beta-Interferon (IFN) alone or in combination with chemotherapy or
radiotherapy, in human refractary tumors." 13th Congress of the European Society
for Medical Oncology (ESMO). Lugano October 30-November 1, 1988
65
5. Palmieri G, Caponigro F, Nuzzo F, Contegiacomo A, Iaffaioli RV, Montesarchio V,
Gridelli C, Bianco AR. "Salvage chemotherapy for non Hodgkin's lymphoma with a
combination of CCNU and vinblastine." European School of Oncology. Postgraduate
Course on Malignant Lymphomas. Orta San Giulio May 2-5, 1989.
6. Gridelli C, Pepe R, Gentile M, Palmeri S, Palmieri G, Airoma G, Gebbia V, Russo A,
Bianco AR. "Mitomicina C, etoposide e vindesina nel trattamento del carcinoma
polmonare non a piccole cellule in fase metastatica (stadio IV)." Medical Treatment
of Lung Cancer. Ancona September 15-16, 1989.
7. Contegiacomo A, Lauria R, Gentile M, Conte A, Giampaglia F, Gridelli C, Stefani
S, Ferrante G, Bianco AR."Carcinoma polmonare a piccole cellule (CPPC): risultati
di uno studio di terapia combinata." Medical Treatment of Lung Cancer. Ancona
September 15-16, 1989.
8. Bianco AR, Gridelli C, Pepe R, Gentile M, Palmeri S, Gebbia V, Airoma G, Russo
A, Palmieri G. "Phase II Study of mitomycin C, etoposide and vindesine in stage IV
non small cell lung cancer (NSCLC)."PROC AM SOC CLIN ONCOL, 9:899 (abstr.),
1990.
9. Gridelli C, Lauria R, Gentile M, Ferrante G, Contegiacomo A, Bianco AR. "CCNU
and methotrexate as second-line chemotherapy in small cell lung cancer." Second
International Conference on Small Cell Lung Cancer. Milano Marittima May 11-12,
1990.
10. Gridelli C, Incoronato P, Airoma, Pepe R, Rossi A, Palazzolo G, Arpinelli F, Bianco
AR. "Il controllo della nausea e del vomito in oncologia: Ondansetron nella profilassi
della nausea e vomito nei pazienti trattati con carboplatino." Convegno
Internazionale: "Il trattamento della nausea e del vomito da chemioterapia
antineoplastica: nuove acquisizioni sul ruolo dei 5HT3 antagonisti." Verona June 18,
1991.
11. Gridelli C, Incoronato P, Airoma G, Arpinelli F, Bianco AR. "Efficacy and safety of
ondansetron in the prophilaxis of emesis in patients treated with carboplatin." EUR J
CANCER, 2 (suppl):S298 (abstr), 1991.
12. Gridelli C, Incoronato P, Airoma G, Pepe R, Bianco AR. "Mitomycin plus vindesine
or cisplatin plus epirubicin as second-line chemotherapy in symptomatic advanced
non small cell lung cancer (NSCLC)." EUR J CANCER, 2 (suppl):S170 (abstr),
1991.
13. Gridelli C, Maiorino A, Curcio C, D'Aprile M, Ianniello G, Brancaccio L, Palmeri S,
Gentile M, Comella G, Pedicini T, Incoronato P, Iacobelli S, Rausa L, Veltri E, De
Placido S, Ferrante G, Bianco AR. "Carboplatin, epirubicin and VP-16 in the
treatment of extensive small cell lung cancer (SCLC)." EUR J CANCER, 2
(suppl):S185 (abstr), 1991.
14. Gridelli C, Maiorino A, Curcio C, D’Aprile M, Ianniello G, Brancaccio L, Palmeri S,
Gentile M, Comella G, Pedicini T, Airoma G, De Placido S, Ferrante G, Bianco AR.
66
"Carboplatin plus epirubicin plus VP-16, concurrent radiotherapy and adjuvant
surgery for limited SCLC." EUR J CANCER, 2 (suppl):S186 (abstr), 1991.
15. Gridelli C, Pepe R, Palmeri S, Airoma G, Gebbia V, Russo A, Iacobelli S, Palmieri
G, De Placido S, Perrone F, Garufi C, Rausa L, Bianco AR. "Mitomycin C, etoposide
and vindesine in stage IV non small cell lung cancer." EUR J CANCER, 2
(suppl):S170 (abstr), 1991.
16. Gridelli C, Pepe R, Palmeri S, Gentile M, Airoma G, Gebbia V, Russo A, Iacobelli S,
Palmieri G, De Placido S, Perrone F, Garufi C, Rausa L, Ferrante G, Bianco AR.
"Phase II study of Mitomycin C, etoposide and vindesine in stage IV non small cell
lung cancer (NSCLC)." LUNG CANCER, 7 (suppl):104 (abstr), 1991.
17. Gridelli C, Maiorino A, Curcio C, D’Aprile M, Ianniello G, Brancaccio L, Palmeri S,
Gentile M, Comella G, Pedicini T, Airoma G, De Placido S, Giampaglia F, Ferrante
G, Iacobelli S, Rausa L, Bianco AR. "Carboplatin plus epirubicin plus VP-16,
concurrent radiotherapy and adjuvant surgery for limited small cell lung cancer
(SCLC)." LUNG CANCER, 7 (suppl):104 (abstr), 1991.
18. Gridelli C, Ianniello G, Maiorino A, Curcio C, D’Aprile M, Veltri E, Palmeri S,
Gebbia V, Brancaccio L, Gentile M, Comella G, Pedicini T, Airoma G, Ferrante G,
Incoronato P, De Placido S, Bianco AR. "Carboplatin, epirubicin and VP-16
chemotherapy in the treatment of small cell lung cancer (SCLC)." PROC AM SOC
CLIN ONCOL, 11:301 (abstr), 1992.
19. Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G,
Bianco AR. "Phase I study of epirubicin (EDX) plus vinorelbine (VNR) with or
without G-CSF in advanced non small cell lung cancer (NSCLC)." PROC AM SOC
CLIN ONCOL, 12:342 (abstr), 1993.
20. Gridelli C, D’Aprile M, Curcio C, Veltri E, Brancaccio L, Palmeri S, Gentile M,
Comella G, Casaretti R, Airoma G, De Placido S, Gebbia V, Ferrante G, Rausa L,
Bianco AR. "Carboplatin plus epirubicin plus VP-16, concurrent radiotherapy and
'adjuvant' surgery for limited small cell lung cancer (SCLC)." Third International
Conference on small cell lung cancer. Ravenna May 6-7, 1993.
21. Gridelli C, D’Aprile M, Veltri E, Palmeri S, Gentile M, Curcio C, Russo A, Gebbia
V, Ianniello G, De Placido S, Pepe R, Incoronato P, Lorusso V, De Lena M, Bianco
AR. "Phase I study of carboplatin, epirubicin and VP-16 chemotherapy plus G-CSF
in extensive small cell lung cancer (SCLC)." Third International Conference on small
cell lung cancer. Ravenna May 6-7, 1993.
22. Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G,
Bianco AR. "Phase I study of epirubicin (EDX) plus vinorelbine (VNR) with or
without G-CSF in advanced non small cell lung cancer (NSCLC)." Chemotherapy of
non small cell lung cancer: five years later. Perugia June 18-19, 1993.
23. Gridelli C, D’Aprile M, Palmeri S, Curcio C, Gebbia V, Veltri E, Ianniello G, Russo
A, Lorusso V, Gentile M, De Placido S, De Lena M, Bianco AR. "Phase I study of
67
carboplatin, epirubicin and VP-16 plus G-CSF in extensive small cell lung cancer
(SCLC)." EUR J CANCER, 6 (suppl):S156 (abstr), 1993.
24. Gridelli C, D’Aprile M, Curcio C, Brancaccio L, Palmeri S, Comella G, Veltri E,
Ferrante G, Gentile M, Rossi A, De Placido S, Bianco AR. "Carboplatin plus
epirubicin plus VP-16, concurrent radiotherapy and adjuvant surgery for limited
small cell lung cancer (SCLC)." EUR J CANCER, 6 (suppl):S156 (abstr), 1993.
25. Gridelli C, D’Aprile M, Palmeri S, Curcio C, Gebbia V, Veltri E, Ianniello G,
Lorusso V, Gentile M, De Placido S, Rossi A, Bianco AR. "Phase I-II study of
carboplatin, epirubicin and VP-16 plus G-CSF in extensive small cell lung cancer
(SCLC)." LUNG CANCER, 11 (suppl 1):374 (abstr), 1994.
26. Bruni GS, Posca T, Gridelli C, Daniele B, Rinaldi L, Celiento G, Scoppa GF, Guida
C, Scognamiglio F, Ruffolo P, Di Giacomo R, Pergola M. "Combined carboplatin
and radiation therapy for stage IIIA-IIIB non small cell lung cancer (NSCLC):
preliminary results." Fourth International Symposium on Combination Therapies.
Chia Laguna (Ca) June 14-17, 1994.
27. Bruni GS, Posca T, Gridelli C, Daniele B, Rinaldi L, Celiento G, Scoppa GF, Guida
C, Scognamiglio F, Ruffolo P, Di Giacomo R, Pergola M. "Combined carboplatin
and radiation therapy for stage IIIA-IIIB non small cell lung cancer (NSCLC):
preliminary results." ANN ONCOL, 5 (suppl 8):151 (abstr), 1994.
28. Rosti G, Zumaglini F, Meacci M, Gridelli C, Bianco AR, Bruni GS, Scagliotti GV,
De Marinis F, Clerici M, M. Turolla, M. Marangolo. "Carboplatin and oral VP-16 in
advanced lung cancer patients aged > 70 years. A phase II trial." Cancer in the
elderly. Genoa September 19-21, p. 225, 1994.
29. Gridelli C, D’Aprile M, Palmeri S, F. Cognetti, Rossi A, Gebbia V, Perrone F, Pepe
R, Veltri E, Airoma G, Russo A, Scinto AF, Bruni GS, Palazzolo G, De Placido S,
Gallo C, Bianco AR. "Mitomycin C + vindesine + etoposide (MEV) vs mitomycin C
+ vindesine + cisplatin (MVP) in stage IV non small cell lung cancer (NSCLC): a
phase III randomized trial." PROC AM SOC CLIN ONCOL, 14:361 (abstr), 1995.
30. De Lena M, Lorusso V, Amadori D, Antimi M, Gridelli C, Luporini G, Pollera C,
Oliva C. "Gemcitabine in resistant stage IV bladder cancer: a phase II study." EUR J
CANCER, 31A (suppl 5):S240 (abstr), 1995.
31. Gridelli C, Ianniello G, Ambrosini G, Mustacchi G, Pedicini T, Farris A, Iacobelli S,
Rossi G, Boni C, D’Aprile M, De Lena M, Di Carlo A, Bonsignori M, Silingardi V,
Catalano G, Mosconi M, Olivieri A, Bianco AR. "Ondansetron vs ondansetron plus
dexamethasone in the prophylaxis of delayed emesis over three courses of cisplatin
chemotherapy: results of a double blind randomised study." PROC AM SOC CLIN
ONCOL, 15:545, 1996.
32. Gridelli C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D’Aprile
M, Rossi A, Migliorino R, Napoli D, Bartolucci R, Pergola M, Bianco AR. "Phase II
study of vinorelbine in elderly patients with stage IIIB-IV non small cell lung cancer
68
(NSCLC): activity, symptom's relief and optimal schedule." PROC AM SOC CLIN
ONCOL, 15:392, 1996.
33. De Lena M, Gridelli C, Lorusso V, Amadori D, Antimi M, Luporini G, Pollera C,
Oliva C. "Gemcitabine activity, objective responses and symptom improvement in
resistant stage IV bladder cancer." PROC AM SOC CLIN ONCOL, 15:246, 1996.
34. Gridelli C, Ianniello G, Brancaccio L, Iaffaioli RV, Curcio C, Lorusso V, D’Aprile
M, Cioffi R, Rossi A, Fiore F, Scognamiglio F, Pepe R, Palazzolo G, Bianco AR. "A
phase II study on carboplatin plus vinorelbine in extensive small cell lung cancer
(SCLC)." Fourth International Conference on Small Cell Lung Cancer. Ravenna
April 25-26, 1996.
35. Gridelli C, De Marinis F, Tucci E, D’Aprile M, Cioffi R, Cortesi E, Rossi A, Pisano
A, Bianco AR. "Combination of VM-26 with lonidamine (LND) in pretreated small
cell lung cancer (SCLC): a phase II study." Fourth International Conference on Small
Cell Lung Cancer.Ravenna April 25-26, 1996.
36. Van Meerbeeck JP, Debruyne C, Postmus PE, Groen HJM, Manegold C, Baas P, van
Zandwijk N, Pennucci AMC, Gridelli C, Galdermans AD, Lentz M, Giaccone G.
"Sequential phase 2 studies with paclitaxel and gemcitabine in malignant pleural
mesothelioma." EUR RESP J, 9 (suppl 23):4005, 1996.
37. Gridelli C, Perrone F, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo
F, D’Aprile M, Rossi A, Pergola M, Bianco AR. "Phase II study of vinorelbine in
elderly patients with stage IIIB-IV non small cell lung cancer." ANN ONCOL, 7
(suppl 5):200 (abstr), 1996.
38. Gridelli C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D’Aprile
M, Rossi A, Perrone F, Migliorino R, Pergola M, Bianco AR. "Phase II study of
vinorelbine in elderly patients with stage IIIB-IV non small cell lung cancer." Cancer
in the Elderly Conference. Tampa November 13-15, 1996
39. Gridelli C, Ianniello G, Brancaccio L, Perrone F, Iaffaioli RV, Curcio C, D’Aprile M,
Cioffi R, Cigolari S, Rossi A, Rinaldi L, Veltri E, Palazzolo G, Leo L , Bianco AR,
Pergola M, Monfardini S. "Carboplatin plus vinorelbine: a new active regimen in
extensive small cell lung cancer. Results of a multicenter phase II study." PROC AM
SOC CLIN ONCOL, 16:1620 (abstr), 1997.
40. Gridelli C, Perrone F, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo
F, D’Aprile M, Rossi A, Pergola M, Bianco AR. "Phase II study of vinorelbine in
elderly patients with stage IIIB-IV non small cell lung cancer." LUNG CANCER, 18
(suppl 1): 56, 1997.
41. Gridelli C, Ianniello G, Brancaccio L, Perrone F, Iaffaioli RV, Curcio C, D’Aprile M,
Cioffi R, Cigolari S, Rossi A, Rinaldi L, Veltri E, Palazzolo G, Leo L, Bianco AR,
Pergola M, Monfardini S. "Carboplatin plus vinorelbine: a new active regimen in
extensive small cell lung cancer. Results of a multicenter phase II study." LUNG
CANCER, 18 (suppl 1): 55, 1997.
69
42. Van Meerbeeck JP, Baas P, Debruyne C, Groen HJM, Manegold C, Ardizzoni A,
Gridelli C, Galdermans D, Lentz MA, Giaccone G. "Gemcitabine in malignant
pleural mesothelioma: a phase II study." LUNG CANCER, 18 (suppl 1): 17, 1997.
43. Gebbia V, Galetta D, Riccardi F, Gridelli C, Testa A, Durini D, Gebbia N, Colucci G.
“Randomized phase III trial of mitomycin plus vindesine and cisplatin versus
vinorelbine and cisplatin in stage III - IV non small cell lung cancer: A Southern Italy
Oncology Group (G.O.I.M.).” LUNG CANCER, 18 (suppl 1):25, 1997.
44. Gridelli C, Ianniello G, Brancaccio L, Perrone F, Iaffaioli RV, Curcio C, D’Aprile M,
Cioffi R, Cigolari S, Rossi A, Rinaldi L, Palazzolo G, Garcia M, Guida C, Bianco
AR, Pergola M, Monfardini S."Carboplatin plus vinorelbine: a new active regimen in
extensive small cell lung cancer. Results of a multicenter phase II study." EUR J
CANCER, 33 (suppl 8):S231, 1997.
45. Gebbia V, Galetta D, Riccardi F, Gridelli C, Testa A, Durini E, Gebbia N, Colucci G.
“Randomized phase III trial of mitomycin plus vindesine and cisplatin versus
vinorelbine and cisplatin in stage III - IV non small cell lung cancer: A Southern Italy
Oncology Group Study (G.O.I.M.).” Eight International Congress on Anti-Cancer
Treatment. Paris February 3-6, 1998.
46. Perrone F, Rossi A, Ianniello G, Maiorino L, Piantedosi FV, Cigolari S, Manzione L,
Failla G, F. Figoli F, Pedicini T, Frontini L, Vinante O, Monfardini S, Gallo C,
Gridelli C. “Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the
treatment of advanced non small cell lung cancer elderly patients. Results a phase III
randomized trial.” PROC AM SOC CLIN ONCOL 17:1752 (abstr), 1998.
47. Crinò L, Conte P, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Matano E,
Marangolo M, Bartolucci R, Oliva C, Tonato M. “A randomised trial of gemcitabine
cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced nonsmall cell lung cancer (NSCLC). A multicenter phase III study.” PROC AM SOC
CLIN ONCOL 17:1750 (abstr), 1998.
48. Rinaldi M, Crinò L, Scagliotti G, Mosconi AM, De Marinis F, Gridelli C, Selvaggi
G, Darwish S, Bartolucci R, Calandri C, Sassi S, Tonato M. “A new schedule of
gemcitabine-cisplatin in advanced non small cell lung cancer (NSCLC) with two
different cisplatin dose levels: a phase II randomized trial.” PROC AM SOC CLIN
ONCOL 17:1807 (abstr), 1998.
49. Gebbia V, Galetta D, Riccardi F, Gridelli C, Testa A, Durini E, Gebbia N, Colucci G.
“Mitomycin C plus Vindesine and cisplatin (MVP) versus vinorelbine and cisplatin
(PV) in stage III-IV non small cell lung cancer: a randomized phase III trial of the
Southern Italy Oncology Group Study (G.O.I.M.).” PROC AM SOC CLIN ONCOL
17:1788 (abstr), 1998.
50. Gridelli C, Ianniello G, Maiorino L, Brancaccio L, Cigolari S, Bilancia D, Aiello G,
Zuccarino L, Pedicini T, Zonato S, Pappagallo GL, Monfardini S, Rossi A, Gallo C,
Perrone F. “Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the
treatment of advanced non - small cell lung cancer (NSCLC) elderly patients (PTS).
Results of a phase III randomized trial.” BR J CANCER, 78 (suppl 2):3, 1998.
70
51. Gridelli C, Ianniello G, Maiorino L, Brancaccio L, Cigolari S, Bilancia D, Aiello R,
Zuccarino L, Pedicini T, Zonato S, Pappagallo GL, Monfardini S, Rossi A, Gallo C
and Perrone F. “Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the
treatment of advanced non - small cell lung cancer (NSCLC) elderly patients (PTS).
Results of a phase III randomized trial.” LUNG CANCER, 21(suppl 1):33-34, 1998.
52. Clerici M, Frontini L, Ianniello G, Maiorino L, Piantedosi FV, Cigolari S, Manzione
L, Failla G, Zuccarino L, Pedicini T, Vinante O, Castiglione F, Bearz A, Tonato M,
Rossi A, Monfardini S, Gallo C, Perrone F, Gridelli C. “Vinorelbine plus best
supportive care (BSC) vs BSC in the treatment of advanced non small cell lung
cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial.”
ANNALS OF ONCOLOGY, 9 (suppl 3):62, 1998
53. Gridelli C, Ianniello G, Maiorino L, Piantedosi V, Cigolari S, Manzione L, Failla G,
Zuccarino L, Pedicini T, Vinante O, Castiglione F, Clerici M, Bearz A, Darwish S,
Rossi A, Monfardini S, Gallo C, Perrone F, Frontini L. “Vinorelbine (VNR) plus best
supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung
cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial”.
ANNALS OF ONCOLOGY, 9 (suppl 4):85, 1998.
54. Cigolari S, Gridelli C, Frontini L, Gulisano M, Robbiati SF, Farris A, Clerici M,
Castiglione F, Piazza E, Ianniello G, Perrone F. “Gemcitabine + Vinorelbine
(GEMVIN) in the treatment of advanced non-small cell lung cancer (NSCLC).
Sequential phase I and phase II trials”. ANNALS OF ONCOLOGY, 9:408 (abstr),
1998.
55. Scagliotti G, Crinò L, Rinaldi M, De Marinis F, Gridelli C. “Randomized phase III
study of gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced
non-small cell lung cancer (NSCLC)”. ANNALS OF ONCOLOGY, 9:408 (abstr),
1998.
56. Clerici M, Frontini L, Ianniello G, Maiorino L, Piantedosi FV, Cigolari S, Manzione
L, Failla G, Zuccarino L, Pedicini T, Vinante O, Castiglione F, Bearz A, Tonato M,
Rossi A, Monfardini S, Gallo C, Perrone F, Gridelli C. “Vinorelbine plus best
supportive care (BSC) vs BSC in the treatment of advanced non small cell lung
cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial.”
ANNALS OF ONCOLOGY, 9 (suppl 3):62, 1998
57. M. De Bellis, Perrone F, Gridelli C, Marone P, Petrulio F, Rossi GB, Tempesta A.
“Fiberoptic bronchoscopy for the diagnosis of lung cancer in the elderly.” ANNALS
OF ONCOLOGY, 9 (suppl 3):70, 1998
58. Gridelli C, Ianniello G, Maiorino L, Piantedosi FV, Cigolari S, Manzione L, Failla G,
Zuccarino L, Pedicini T, Vinante O, Castiglione F, Clerici M, Bearz A, Piazza E,
Darwish S, Rossi A, Monfardini S, Frontini L, Gallo C, Perrone F. “Vinorelbine plus
best supportive care (BSC) vs BSC in the treatment of advanced non small cell lung
cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial.”
LUNG CANCER, 24:205, 1999.
71
59. Piazza E, Frontini L, Perrone F, Gulisano M, Robbiati SF, Farris A, Clerici M,
Castiglione F, Ianniello G, Gasparini GP, Barletta E, Rossi A, Gallo C, Gridelli C.
“Gemcitabine + Vinorelbine (GemVin) in the treatment of advanced non-small cell
lung cancer (NSCLC). Sequential phase I and phase II trials.” Perugia International
Cancer Conference VI. Chemotherapy of non small cell lung cancer: ten years later.
Perugia October 11-13, 1998.
60. Gridelli C . “Treatment of advanced non small cell lung cancer in the elderly: an
update”. ANNALS OF ONCOLOGY 9 (suppl 3):36, 1998.
61. Gridelli C. “The GOCSI programme on lung cancer treatment”. First World
Conference on Clinical Cooperative Research for Lung Cancer. Brussels March 4-6,
1999.
62. Gridelli C. “Originality, benefits and difficulties of clinical research performed by
cooperative groups”. First World Conference on Clinical Cooperative Research for
Lung Cancer. Brussels March 4-6, 1999.
63. Gridelli C. “Non therapeutic clinical investigation for lung cancer”. First World
Conference on Clinical Cooperative Research for Lung Cancer. Brussels March 4-6,
1999.
64. Gridelli C. “Vinorelbine (VNR) vs Gemcitabine (GEM) vs Gemcitabine +
Vinorelbine (GEM + VNR) in advanced NSCLC elderly patients: the MILES phase
III randomized trial (Multicenter Italian Lung cancer in the Elderly Study).” The First
International Lilly Oncology Young Investigators’ Meeting. Indianapolis June 24-25,
1999.
65. Gridelli C. “Optimal doses of Gemcitabine + Vinorelbine (GEMVIN) in the
treatment of advanced non-small-cell lung cancer (NSCLC). A “keep-the -winner”
phase 2 study”. The First International Lilly Oncology Young Investigators’ Meeting.
Indianapolis June 24-25, 1999.
66. Rossi A, Perrone F, Barletta E, Tambaro R, Barzelloni ML, Scognamiglio F, Gatani
T, Bilancia D, Maiorino L, Gridelli C. “Activity of gemcitabine (GEM) in cisplatinpretreated patients with advanced non small cell lung cancer (NSCLC): a phase II
trial”. PROC AM SOC CLIN ONCOL, 18:484a, 1999.
67. Manzione L, Cigolari S, Maiorino A, Ianniello G, Brancaccio L, De Cataldis G,
Pedicini T, Maiorino L, Rossi A, Barletta E, Di Lanno M, Gridelli C. “Cisplatin
(CDDP) plus vinorelbine (VNR) plus amifostine (AMF) in the treatment of advanced
non small cell lung cancer (NSCLC): a multicenter phase II study.” PROC AM SOC
CLIN ONCOL, 18:499a, 1999.
68. Gridelli, Frontini L, Gulisano M, Cigolari S, Castiglione F, Robbiati SF, Farris A,
Ianniello G, Clerici M, Felletti R, Piazza E, Rossi A, Gallo C, Perrone F. “Optimal
doses of gemcitabine plus vinorelbine (GEMVIN) in the treatment of advanced non
small cell lung cancer (NSCLC). A “keep-the-winner” phase II study.” PROC AM
SOC CLIN ONCOL, 18:477a, 1999.
72
69. Guida C, Barletta E, Scognamiglio F, Gatani T, Gebbia V, Elmo M, Gridelli C.
“Thoracic radiotherapy (RT) and daily vinorelbine as radiosensitizer in locally
advanced non small cell lung cancer (NSCLC): a phase I study.” PROC AM SOC
CLIN ONCOL, 19:2074, 2000.
70. Gridelli C, Cigolari S, Bilancia D, Piantedosi FV, Barbera S, Piazza E, Frontini L,
Vinante O, De Marinis F, Robbiati SF, Bertetto O, Sacco C, Novello S, Failla G,
Gallo C, Perrone F. “Phase II study of gemcitabine (Gem) and gemcitabine +
vinorelbine (GemVin) in advanced NSCLC elderly patients within the phase III
MILES (Multicenter Italian Lung cancer in the Elderly Study) randomised trial.”
PROC AM SOC CLIN ONCOL, 19:2092, 2000.
71. Illiano A, Barletta E, Di Marino V, Barzelloni ML, Santoro A, Zampa G, Rossi N,
Gridelli C. “Triplet chemotherapy combination with carboplatin (CBDCA), paclitaxel
(TAX) and gemcitabine (GEM) plus amifostine (AMF) support in advanced
NSCLC.” PROC AM SOC CLIN ONCOL, 19:2075, 2000.
72. Cigolari S, Pignata S, Ianniello GP, Pontillo V, Daniele B, De Lucia L, Iaffaioli RV,
Pedicini T, Maiorino L, Perrone F, Gallo C, Gridelli C . “Interactive audiovisual vs
standard telephone communication between oncologists and home of patients
undergoing out-patient chemotherapy. The MARILIN (Multicenter Audio-video
Regional Interactive Linkage Investigation) randomized trial.” PROC AM SOC
CLIN ONCOL, 19:2507, 2000.
73. Barletta E, Manzione L, Frontini L, Bilancia D, Rossi A, Barzelloni ML, Zonato S,
Gridelli C. “Single agent docetaxel and primary prophylactic lenograstim in
pretreated patients with advanced non small cell lung cancer (NSCLC): a multicenter
phase II study.” PROC AM SOC CLIN ONCOL, 19:2137, 2000.
74. Brancaccio L, Curcio C, Iaffaioli RV, Veltri E, Cigolari S, Gebbia V, Palazzolo G,
Tambaro R, Rossi A, Perrone F, Gridelli C. “Carboplatin + Epirubicin + VP-16 +
lenograstim (CEV-L) followed by thoracic radiotherapy + daily Carboplatin (RT-C)
as radiosensitizer in limited small cell lung cancer (SCLC). A multicenter phase II
study”. PROC AM SOC CLIN ONCOL, 19:2133, 2000.
75. Manzione L, D’Aprile M, Cioffi R, Ianniello GP, Frontini L, Barzelloni ML, Perrone
F, Gridelli C. “Carboplatin + Paclitaxel in the treatment of extensive small cell lung
cancer (SCLC). A multicenter phase II study”. PROC AM SOC CLIN ONCOL,
19:1928, 2000.
76. Gridelli C. “La terapia medica antineoplastica nel paziente anziano”. Proc III
International Meeting on recent Progress in Oncology, September 1-3, 2000.
77. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S,
Gatani T, Fiore F, Guida C, Scognamiglio F. “ELVIS trial: single-agent navelbine as
first-line treatment in elderly patients with advanced NSCLC: a phase II study. The
Elderly Lung Cancer Vinorelbine Italian Study Group.” LUNG CANCER 29 (suppl
2):81, 2000.
73
78. Gridelli C. “Not cisplatin-based chemotherapy in advanced non small cell lung
cancer.” LUNG CANCER 29 (suppl 2):110-111, 2000.
79. Galetta D, Gebbia V, Riccardi F, Borsellino N, Gridelli C, Testa A, Durini E, Gebbia
N, Colucci G. “A randomized phase III trial of the Southern Italy Oncology Group
(G.O.I.M.) of mitomycin C plus vindesine and cisplatin (MVP regimen) verus
vinorelbine plus cisplatin (PV regimen) in stage III-IV non small cell lung cancer.”
LUNG CANCER 29 (suppl 1):21, 2000.
80. Gridelli C. “Chemotherapy of advanced non small cell lung cancer in the elderly.”
Lung Cancer Symposium, Miami March 10, 2001.
81. Gridelli C, Maione P, Barletta E. “How can we treat elderly patients?” “Non Small
Cell Lung Cancer Treatment. No standards, Many options”. Venice April 2, 2001.
82. Gridelli C. “Chemotherapy of advanced NSCLC in the elderly.” Proceedings of the
63rd Course Advances in Oncology - Current perspectives on biomolecular indicators
and clinical management of bladder, breast, colorectal and lung cancers. Erice (Pa)
April 18-22, 2001.
83. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Bianco A, Boni
C, Marangolo M, Failla G, Adamo V, Altavilla G, Ceribelli A, Clerici M, Di
Costanzo F, Frontini L, Tonato M. “Phase III randomized trial comparing three
platinum-based doublets in advanced non small cell lung cancer.” PROC AM SOC
CLIN ONCOL, 20:1227, 2001.
84. Gridelli C, Perrone F, Cigolari S, Manzione L, Piantedosi F, Barbera S, Piazza E,
Vinante O, Clerici M, Robbiati F, Bertetto O, Frontini L, Sacco C, Iaffaioli R, Gallo
C. “The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial:
gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced
NSCLC patients.” PROC AM SOC CLIN ONCOL, 20:1230, 2001.
85. Rossi A, Gridelli C, Manzione L, Gebbia V, Maione P, Tortoriello A, Borsellino N,
Frattolillo A, Rossi N, Pisani A, Iaffaioli RV. “Single agent vinorelbine in elderly
patients with advanced breast cancer: a multicenter phase II study.” PROC AM SOC
CLIN ONCOL, 20:1993, 2001.
86. Illiano A, Tortoriello A, Turitto G, Battiloro C, Frattolillo A, Varriale E, Iodice P, De
Marino V, Libutti M, Perone V, Griffo S, Elia S, Gentile M, Gridelli C, Iaffaioli RV.
“Epidoxorubicin and gemcitabine in stage IV NSCLC. A preliminary report of a
phase I-II study.” PROC AM SOC CLIN ONCOL, 20:2745, 2001.
87. Gridelli C. “MILES phase III randomized trial of gemzar + vinorelbine vs gemzar vs
vinorelbine in advanced NSCLC elderly patients.” Caring for Cancer Patients in the
New Millennium: A Clinical Update of GEMZAR (gemcitabine) and ALIMTA
(pemetrexed disodium), Indianapolis May 11, 2001.
88. Eldman M, Socinski M, Vokes E, Maters G, Lilenbaum R, Gridelli C, Le Chevalier
T. “New possibilities in the treatment of Non-Small Cell Lung Cancer.” Paris May
29, 2001.
74
89. Gridelli C. “Meeting the needs of special patients (elderly/PS2).” New Approaches
in the Treatment of NSCLC, Rome June 16, 2001.
90. Gridelli C. “Gemvin phase III randomized trial in advanced NSCLC: gemzar +
vinorelbine vs gemzar + cisplatin vs vinorelbine + cisplatin.” ECCO 11, Lisboa
October 21-25, 2001.
91. Gridelli C, Gebbia V, Galetta D, Colucci G. “Organization and lung cancer program
of the Gruppo Oncologico Italia Meridionale (GOIM).” Second World Conference on
Clinical Cooperative Research for Lung Cancer, Brussels March 7, 2002.
92. Gridelli C, Gebbia V, Galetta D, Colucci G. “The GOIM program on small cell lung
cancer.” Second World Conference on Clinical Cooperative Research for Lung
Cancer, Brussels March 7, 2002.
93. Gridelli C, Gebbia V, Galetta D, Colucci D. “The GOIM program on non small cell
lung cancer.” Second World Conference on Clinical Cooperative Research for Lung
Cancer, Brussels March 7, 2002.
94. Tonato M, Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S,
Matano A, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A,
Clerici M, Di Costanzo F, Frontini L. “Phase III randomized trial comparing three
platinum-based doublets in advanced non small cell lung cancer.” Second World
Conference on Clinical Cooperative Research for Lung Cancer, Brussels March 7,
2002.
95. Gridelli C. “How to combine cytotoxic and cytostatic agent.” IASLC International
Workshop – Early Invasive Lung Cancer. Turin March 14-15, 2002.
96. Gridelli C. “Single agent chemotherapy.” IASLC International Workshop – Early
Invasive Lung Cancer. Turin March 14-15, 2002.
97. Gridelli C, Maione P, Rossi A. “The management of early lung cancer in the elderly.”
IASLC International Workshop – Early Invasive Lung Cancer. Turin March 14-15,
2002.
98. Rinaldi M, Selvaggi G, Martelli O, Maestri A, Gridelli C, Ricci S, Matano E, Banzi
M, Zumaglini F, Adamo V, Gozzelino F, Pacini M, Hayden AM, Liepa S, Sorbolini
S. “Quality of life (QOL) analysis of an ILCP trial comparino three platinum-based
doublets for advanced non-small cell lung cancer (NSCLC).” PROC AM SOC CLIN
ONCOL, 21:1229, 2002.
99. Crinò L, Novello S, Migliorino MR, Foggi P, Gridelli C, Galli C, Matano E, Paletta
V, Giovanis P, Altavilla G, Marini L, Hayden AM, Miller MA, Tonato M. “A phase
III randomized trial comparing three platinum-based doublets in advanced non-small
cell lung cancer (NSCLC): impact of PS=2 vs 0 or 1 and age > 70 vs < 70 on
chemotherapy outcome.” PROC AM SOC CLIN ONCOL, 21:1258, 2002.
100. Gridelli C, Shepherd F, Perrone F, Illiano A, Piantedosi FV, Robbiati SF, L.
Manzione L, Barbera S, Frontini L, Veltri E, Cigolari S, Findlay BP, Hirsh V,
75
Seymour L, Bezjak A, Gallo C. “Gemvin III: a phase III study of gemcitabine plus
vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine
chemotherapy (PCT) for stage IIIb or IV non-small cell lung cancer (NSCLC): an
Italo-Canadian study.” PROC AM SOC CLIN ONCOL, 21: 1165, 2002.
101. De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferraù F, Barbera S, Berretto
O, Barni S, Michetti M, La Bianca R, Recchia F, Mattioli M, Martelli O, Rizzotto V.
“A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG)
versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell
lung cancer (SCLC): preliminary results.” PROC AM SOC CLIN ONCOL, 21:1219,
2002.
102. Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni
M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F. “Prolonged
gemcitabine infusion in NSCLC: randomized phase II study of two different
schedules in combination with cisplatin.” PROC AM SOC CLIN ONCOL, 21:1311,
2002.
103. Perrone F, Gridelli C, Cigolari S, Bilancia D, Piantedosi FV, Barbera S, Piazza E,
Vinante O, Clerici M, Robbiati SF, Bertetto O, Cabiddu M, Sacco C, Iaffaioli RV,
Gallo C. “Baseline assessment of qualità of life (QOL) is a strong prognostic factor
for survival of elderly patients with advanced non-small cell lung cancer (NSCLC).
A secondary analysis of the MILES study.” PROC AM SOC CLIN ONCOL,
21:1346, 2002.
104. Rossi E, Perrone F, Amabile G, Labonia V, Landi G, Nuzzo F, Gridelli C, Di
Maio M, de Matteis A. “Gemcitabine plus vinorelbine as second line chemotherapy
of metastatic breast cancer. A single-center phase 2 study.” ANNALS OF
ONCOLOGY, 13 (supp 5):69, 2002.
105. De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferrau F, Barbera S, Bertetto
O, Barni S, Michetti S, La Bianca R. “A multicenter randomised phase II study of
cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first
line treatment in patients with small cell lung cancer (SCLC): preliminary results.”
ANNALS OF ONCOLOGY, 13 (suppl 5):133, 2002.
106. Nelli F, De Marinis F, Migliorino MR, Martelli O, Di Molfetta M, Portalone L,
Cortesi E, Brancaccio L, Crispino C, Gridelli C. “Combination of gemcitabinepaclitaxel-cisplatin (GTP) as induction chemotherapy for unresectable stage IIIA
(N2) non small cell lung cancer (NSCLC) patients: preliminary results of a
multicenter phase II study.” ANNALS OF ONCOLOGY, 13 (suppl 5):139, 2002.
107. Di Maio M, Perrone F, Gridelli C, Gallo C, Frontini L, Barletta E, Piantedosi FV,
Robbiati SF, Cigolari S, Castiglione F. “Supportive care (SC) in patients with
advanced non small cell lung cancer (NSCLC).” ANNALS OF ONCOLOGY, 13
(suppl 5):180, 2002.
108. De Maio E, Gridelli C, Perrone F, Gallo C, Di Maio M, Piazza E, Manzione L,
Illiano A, Barbera S, Rosetti F. “Use of analgesics in patients with advanced non
76
small cell lung cancer (NSCLC).” ANNALS OF ONCOLOGY, 13 (suppl 5):181,
2002.
109. Gridelli C, Rossi A, Maione P. “Polypharmacy in the elderly cancer patient – is
there a risk?” The 7th International Conference on Cancer in the Elderly, Boston
September 27-28, 2002.
110. Gridelli C, Illiano A, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Tibaldi C,
Ceribelli A, Iaffaioli RV, Perrone F. “Effect on quality of life (QoL) of weekly vs 3weekly docetaxel (D) in second line treatment of advanced non small cell lung
cancer. The DISTAL randomized phase 3 study.” PROC AM SOC CLIN ONCOL,
22:625, 2003.
111. Gridelli C. “Anti-emetic care in the elderly: complex considerations.”
MASCC/ISOO 15th International Symposium on supportive Care in Cancer. Berlin
June 19, 2003.
112. Gridelli C, Maione P, Rossi A, Nicolella D, Del Gaizo F, Ferrara C, Guerriero C,
Salerno V, Colantuoni G. “Chemotherapy for non small cell lung cancer in the
elderly.” LUNG CANCER, 41 (suppl 3):S43-S44, 2003.
113. De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferraù F, Barbera S, Bertetto
O, Barni S, La Bianca R, Nelli F. “A multicenter randomised phase II study of
cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first
line treatment in patients with small cell lung cancer (SCLC): preliminary results.”
LUNG CANCER, 41 (suppl 2):S81, 2003.
114. Gridelli C, De Marinis F, Manegold C, Mali P, Portalone L, Castelnau O, Stahel
R, Betticher D, Hermann R, Pons JT, Aubert D, Burillon JP, Gatzmeier U. “Results
of a phase II study conducted in elderly patients with unresectable localised or
metastatic non small cell lung cancer (NSCLC) with oral vinorelbine given as weekly
monotherapy.” LUNG CANCER, 41 (suppl 2):S44, 2003.
115. Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, Robbiati
SF, Ianniello GP, Ferraù F, Piazza E, Frontini L, Rosetti F, Iaffaioli RV, Perrone F.
“Prevalence and management of pain in patients with advanced non small cell lung
cancer.” ANNALS OF ONCOLOGY, 14 (suppl 4):iv61, 2003.
116. Gridelli C, Parlier Y, Brandely M, Aubert D, Nguyen L, Jassem J. “Oral
chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea
and vomiting in non small cell lung cancer (NSCLC) patients (pts) treated with oral
navelbine (NVB) and standard antiemetic prophylaxis.” ECCO, The European
Cancer Conference, Copenhagen September 21-25, 2003.
117. Gatzemeier U, De Marinis F, Manegold C, Mali P, Portalone L, Castelnau O,
Stahel R, Betticher D, Pons Terrassa Pons, Gridelli C. “Elderly patients (pts) with
unresectable localised or metastatic non small cell lung cancer (NSCLC): a results of
a phase II study wiyh oral navelbine (NVB) given as weekly monotherapy and first
line treatment.” ECCO, The European Cancer Conference, Copenhagen September
21-25, 2003.
77
118. Gridelli C. “Methods in clinical trials: medical challenges encountered in clinical
trials.” Fourth Meeting of SIOG Geriatric Oncology: Cancer in the elderly. Rome
November 21-22, 2003.
119. Gridelli C, Maione P, Rossi A, Guerriero C, Barzelloni ML, Ferrara C. “Gefitinib
(Iressa ZD1839) in special patient population (elderly > 70 years or perfomance
status > 2) with advanced non small cell lung cancer: a case series report from the
“Iressa expanded access programme.” BRITISH JOURNAL OF CANCER, 89 (suppl
2):S25-S35, 2004.
120. Gridelli C, Rossi A, Maione P, Musto L, Del Gaizo F, Airoma G. “Gefitinib
(Iressa ZD1839) in heavily pretreated non small cell lung cancer patients: a case
seriea report from the Iressa expanded access programme.” BRITISH JOURNAL OF
CANCER, 89 (suppl 2):S25-S35, 2004.
121. Maione P, Musto L, Rossi A, Nicolella D, Lombardi C, Gridelli C. “Complete
response of brain metastases from lung adenocarcinoma with gefitinib (Iressa
ZD1839).” BRITISH JOURNAL OF CANCER, 89 (suppl 2):S25-S35, 2004.
122. Gridelli C, Rossi A, Maione P, Guerriero C, Colantuoni G, Del Gaizo F, Ferrara
C. “Chemotherapy in the elderly.” Oncology Symposium, Concepts and Principles of
Chemotherapy. Barcelona March 6, 2004.
123. Scagliotti G, Rossi A, Novello S, De Marinis F, Dogliotti L, Crinò L, Lorusso V,
Martoni A, Paccagnella A, Gridelli C. “Gefitinib (ZD1839) combined with
gemcitabine or vinorelbine as single agent in elderly patients with advanced non
small cell lung cancer (NSCLC).” PROC AM SOC CLIN ONCOL, 23:633, 2004.
124. Mali P, De Marinis F, Manegold C, Castelnau O, Pless M, Pouget JC, Aubert D,
Burillon JP, Gridelli C. “Single agent vinorelbine (NVB) in advanced non small cell
lung cancer (NSCLC) in the elderly: patient benefit improvement by weekly
schedale.” PROC AM SOC CLIN ONCOL, 23:643, 2004
125. Gridelli C, Reck M, Gregorc V, Migliorino MR, Muller T, Manegold C,
Favaretto A, Crucitta E, Rossi A, Koschel G. “Single-agent premetrexed or
sequentially administered premetrexed/gemcitabine as first-line chemotherapy for
advanced non-small cell lung cancer (NSCLC) in elderly patients or patients
inelegible for platinum-based chemotherapy:Preliminary results of a phase II
randomized trial”. JOURNAL OF CLINICAL ONCOLOGY, 23 (suppl 1):659s,
2005.
126. Iandoli R, Maione P, Rossi A, Gridelli C. “Traitment des effets collatéraux
cutanés du Gefitinib: 3 cas cliniques.” 25 Congrès Iinternational de l’Association des
Dermatologistes Francophones. Aosta June 22-25, 2005.
128. Gridelli C. “Antiemetic decision in elderly lung cancer patients.” LUNG
CANCER, 49 (suppl 2):s39, 2005.
78
129. Gridelli C, Reck M, Gregorc V, Migliorino M, Muller T, Manegold C, Favaretto
A, Schmittel A, Caffo O, Blatter J, Mmunoz M, Crucitta E, Rossi A, Koschel G.
“Single-agent premetrexed or sequentially administered premetrexed/gemcitabine as
first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly
patients or patients inelegible for platinum-based chemotherapy: Preliminary results
of a phase II randomized trial”. LUNG CANCER, 49 (suppl 2):s245, 2005.
130. Perrone F, Illiano A, Piantedosi FV, Bearz A, Favaretto A, Lorusso V, Manzione
L, Iaffaioli RV, Valerio MR, Gridelli C. “Two consecutive phase 1-2 studies of
cisplatin (P)-based 1st-line chemotherapy (CT) in elderly patients (pts) with advanced
non-small cell lung cancer (NSCLC). The MILES-2P studies.” JOURNAL OF
CLINICAL ONCOLOGY, 24:373s (abstr 7037), 2006.
131. Gridelli C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carrozza F, Favaretto
A, Daniele B, Galetta D, Morabito A. “A factorial phase III randomized trial of
rofecoxib and prolonged constant infusion of gemcitabine at 10 mg/m²/min (PCI-G)
in first-line treatment of adult patients (pts) with advanced non-small cell lung cancer
(NSCLC): The GECO study. JOURNAL OF CLINICAL ONCOLOGY, 24:381s
(abstr 7069), 2006.
132. Di Maio M, Gallo C, Barbera S, Ceribelli A, Gamucci T, Isa L, Piazza E,
Borsellino N, Zagonel V, Gridelli C. “Two-drug gemcitabine-based first-line
treatment of elderly patients (pts) with small-cell lung cancer (SCLC): The G-STEP
program.” JOURNAL OF CLINICAL ONCOLOGY, 24:386s (abstr 7089), 2006.
133. De Maio E, Morabito A, Barbera S, Robbiati SF, Piazza E, Brancaccio L, Rosetti
F, Foa P, Verusio C, Gridelli C. “A prospective phase II study of single-agent
gemcitabine at prolonged constant infusion of 10 mg/m²/min rate (PCI-G) in the firstline treatment of elderly patients (pts) with advanced non-small cell lung cancer
(NSCLC): The MILES-2G study.” JOURNAL OF CLINICAL ONCOLOGY,
24:395s (abstr 7125), 2006.
134. Gridelli C. “Targeted therapies and chemotherapy:new challenge for the treatment
of advanced NSCLC elderly patients”. CRITICAL REVIEW IN ONCOLOGY
HEMATOLOGY, 60:S7, 2006.
135. Verrengia A, Bruno R, Ruggiero G , Gridelli C. “Suggestion of a new clinical
interventation: the restructuring psychotherapy groups for breast cancer patients with
psychological-relational problems being before falling. 8 World Congress of PsychoOncology.Psycho-Oncology 15:S1-S478, 2006.
136. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Watchers FM,
Gebbia V, Morabito A, Perrone F, Gridelli C. “Single agents vs combination
chemotherapy as second-line treatment of advanced non small cell lung cancer:
individual patients data meta-analysis of five randomized trials”. JOURNAL OF
CLINICAL ONCOLOGY, 26 (suppl):436s, 2008.
137. Gridelli C, Mencoboni M, Carrozza F, Viganò MG, Gebbia V, Verusio C,
Maione P, Gallo C, Perrone F, Ciardiello F. “Cetuximab and gemcitabine in elderly
79
or adult PS2 advanced non small cell lung cancer patients: the CALC-1 randomized
phase II trials”. JOURNAL OF CLINICAL ONCOLOGY, 26 (suppl): 453s, 2008.
138. De Marinis F, Raftopulos H, Bria E, Gridelli C, Rossi A, Grossi F, Gralla R J.
“Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of
advanced non small cell lung cancer ? Meta-analysis of 7 randomized clinical trials
with 3WD comparators arm. JOURNAL OF CLINICAL ONCOLOGY. 26 (suppl)
445s, 2008.
139. Gebbia V, Morena R, Frontini L, Aitini E, Daniele B, Gamucci T, Di Maio M,
Morabito A, Gallo C, Gridelli C. “The DISTAL-2 phase III randomized trial of single
agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD
plus capecitabine (X) as second-line treatment of advanced non samll cell lung
cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(suppl):710s, 2008.
140. Cortesi E, Barni S, Massidda B, Aitini E, Colucci G, Gridelli C, Iacono C,
Lorusso V, Maltoni M, Pronzato P. “How Italian oncologist cope with end-of-life
care: a pilot study”. JOURNAL OF CLINICAL ONCOLOGY, 26(suppl): 729s,2008.
141. Rossi A, Garassino M, Cinquini M, Sburlati P, Borgonovo K, La Verde N,
Hollander L, farina G, Gridelli C, Torri V. “Maintenance or consolidation therapy in
small cell lung cancer with non chemotherapic agents: a systematic review”.
ANNALS OF ONCOLOGY, 19 (suppl):v139, 2008.
142. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Watchers FM,
Gebbia V, Morabito A, Perrone F, Gridelli C. “Single agents vs combination
chemotherapy as second-line treatment of advanced non small cell lung cancer:
individual patients data meta-analysis of five randomized trials” ANNALS OF
ONCOLOGY, 19 (suppl): v 139, 2008.
143. Krzakowski MJ, Gridelli C, Paccagnella A, Aslanis V, Perraud K, Lucas C. “Oral
vinorelbine at trhee weekly flat-dose intakes concomitantly with thoracic
radiotherapy in loally advanced or inoperable stage III non small cell lung cancer:
results of a phase I dose escalation trial. ANNALS OF ONCOLOGY, 19 (suppl 8) v
94, 2008.
144. Gridelli C, Mencoboni M, Carrozza F, Viganò MG, Gebbia V, Verusio C,
Maione P, Gallo C, Piccirillo MC, Ciardiello F. “Addition of cetuximab to
gemcitabine in elderly or performance status 2 patients with advanced non small cell
lung cancer: the CALC-1 randomized phase II trial. ANNALS OF ONCOLOGY, 19
(suppl 8) v 96, 2008.
145. Rossi A, Garassino MC, Sburlati P, Cinquini M, Gridelli C, Farina G, Torri V.
“Maintenance or consolidation therapy in small cell lung cancer: a systematic review
and meta-analysis. ANNALS OF ONCOLOGY, 19 (suppl 8) v 118, 2008.
146. Di Maio M, Camps C, Smit F, Schuette W, Georgoulia V, Takeda K, Quoix E,
Wachters FM, Gebbia V, Gridelli C. “Prognostic factors in patients enrolled in
clinical trials of second-line chemotherapy for advanced non small cell lung cancer
80
(aNSCLC): a pooled analysis of 11 randomized trials. JOURNAL OF CLINICAL
ONCOLOGY, 27:427s, 2009.
147. Gridelli C. Elderly and co-morbid patients with NSCLC: systemic treatment.
LUNG CANCER, 64 (suppl 1): S18-19, 2009.
148. Gridelli C.”The role of first-line targeted terapie in advanced NSCLC”. II
European Conference on Lung Cancer. Geneve (Switzerland), April 28-May 1, 2010.
149. Gridelli C, Ciardiello F, Feld R, Butts CA, Gebbia V, Genestreti G, Favaretto
AG, Wierzbicki R, Gallo C, Perrone F.“International multicenter randomized phase
III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine
(CG) versus first-line CG followed by second-line E in advanced non small cell lung
cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY,28(18S):540s, 2010.
150. Di Maio M, Morabito A, Barbera S, Gebbia V, Daniele B, Ceribelli A, Carrozza
F, Rossi A, Signoriello G, Gridelli C. “Education level as prognostic factor of
patients with advanced non small cell lung cancer enrolled in clinical trials. J Clin
Oncol, 28(18s):478s, 2010.
151. De Marinis F, Atmaca A, Tiseo M, Ciuffreda L, Gridelli C, Gebbia V, Wolf M,
Dal Zotto S, Marsoni S. “Deacetylase inhibitor panobinostat in relapsed small cell
lung cancer patients: results of a multi center phase II trial. J Clin Oncol, 28 (18S),
abstr e17521), 2010.
152. Ciuleanu T, Gridelli C, Hirsch FR, Jassem J, Krzakowski MJ, Manegold C, Pirker
R, Pujol R, Stahel R, Zielinski C. “Third CECOG Consensus on the systemic
treatment of non small cell lung cancer”. Ann Oncol,21 (suppl.8),viii126,2010.
153. Groen HJM, Socinski M, Grossi F, Juhasz E, Gridelli C, Baas P. “Randomised
phase II study of sunitinib plus erlotinib vs placebo plus erlotinib for the treatment of
metastatic no small cell lung cancer. Ann Oncol,21 (suppl.8),viii139,2010.
154. Gridelli C. “New molecular targets in NSCLC- The next generation of drugs. Ann
Oncol,21(suppl.8),viii125,2010
155. Gridelli C, Ardizzoni A, Bajetta E, Barni S, Crino’ L, Caprioli A, Filipazzi V,
Lorusso V, De Marinis F. “Medical treatment choices of patients affected by
advanced NSCLC in routine clinical practice:results from the Italian Observational
“SUN”
(Survey on the Lung Cancer Management) study. Ann
Oncol,21(suppl.8),viii151,2010.
156. Gridelli C, Morgillo F, Favaretto A, De Marinis F, Chella A, Siena S, Mattioli R,
Tortora G, Di Maio M, Ciardiello F.”Gemcotabine or erlotinib in combination with
sorafenib in elderly patients with advanced non small cell lung cancer (GEST): a
randomized phase II study”. Ann Oncol,21(suppl.8),viii141,2010.
157. De Marinis F, Atmaca A, Al-Batran S, Tiseo M, Ciuffreda L, Gridelli C, Gebbia
V, Wolf M, Dal Zotto L, Marsoni S. “Results of a multi center phase II trial with the
81
deacetylase inhibitor panobinostat in relapsed small cell lung cancer patients”. Ann
Oncol,21(suppl.8),viii148,2010.
158. Gridelli C, Besse B, de Marinis F, Gandara D, Paz-Ares L, Pirker R, Reck M,
Smit E, van Meerbeeck J, Stahel R, Felip E. “ESMO recommendation 2011:
advanced NSCLC”. Lung Cancer,71 (suppl 2):S3, 2011.
159. Gridelli C. “Advanced NSCLC: maintenance with targeted therapies”. Lung
Cancer, 71 (suppl 2):S3, 2011.
160. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O,
Sahaoo TP, Laack E, Reck M, Corral J, Melemed SA, John WJ, Zimmerman A,
Visseren Grul CM, Gridelli C. “PARAMOUNT: phase III study of maintenance
pemetrexed plus best supportive care versus placebo plus best supportive care
immediately following induction treatment with pemetrexed plus cisplatin for
advanced nonsquamous non small cell lung cancer. Proc Am Soc Clin Oncol,
CRA7510, 2011.
161. Krzakowski MJ, Di Maio M, Perraud K, Kowalski M, Gridelli C. “Prognostic
score for second-line chemotherapy of advanced non small cell lung cancer: external
validation in a phase III trial comparing vinflunine with docetaxel”. Proc Am Soc
Clin Oncol, 7556, 2011.
162. Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D, Frueh M, Qian
W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee
SM.“COCIS individual patient data meta-analysis: carboplatin or cisplatin-based
chemotherapy as first-line treatment of small cell lung cancer”. Proc Am Soc Clin
Oncol, 7022, 2011.
163. Gridelli C, De Marinis F, Pujol J-L, Reck M, Ramlau R, Parente B, Pieters T,
Middleton G, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki
N, Visseren-Grul C, Paz-Ares L G. “Safety, resource and quality of life results from
PARAMOUNT”. Journal of Thoracic Oncology, 6 (suppl.6):S323, 2011.
164. Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol JL; Bidoli P, Molinier O,
Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N,
Zimmermann AH, Visseren-Grul C, Gridelli C. “PARAMOUNT: phase III trials
results of maintenance pemetrexed plus best supportive care (BSC) versus placebo
plus BSC immediately following induction treatment with pemetrexed plus cisplatin
for advanced nonsquamous non small cell lung cancer (NSCLC)”. Journal of
Thoracic Oncology, 6 (suppl.6):S275, 2011.
165. Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos DV, Frueh M,
Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli
O, Lee SM. “Carboplatin- or cisplatin-based chemotherapy as first-line chemotherapy
as first-line treatment of small cell lung cancer (SCLC): the COCIS individual
patients data meta-analysis”. Journal of Thoracic Oncology, 6 (suppl.6):S312, 2011.
82
166. Krzakowski M, Di Maio M, Perraud K, Kowalski M, Gridelli C. “Prognostic
score for second-line chemotherapy of advanced non small cell lung cancer: external
validation in a phase III trial comparing vinflunine with docetaxel”. Journal of
Thoracic Oncology, 6 (suppl.6):S1208, 2011.
167. Scagliotti GV, Gridelli C, De Marinis F, Thomas M, Dedui M, Pujol JL,
Manegold C, Melemed S, John W, Zimmermann AH, Chouaki N, Melemed A,
Visseren-Grul C, Paz-Ares L. “First-line chemotherapy with pemetrexed plus
cisplatin in advanced nonsquamous non small cell lung cancer (NSCLC): a
comparison of two phase III trials. Journal of Thoracic Oncology, 6 (suppl.6):S1160,
2011.
168. Gridelli C, Thomas M, Prabhash K, El Koun C, Blackhall F, Melemed S,
Zimmermann A, Chouaki N, Visseren-Grul C, Paz-Ares LG. “Pemetrexed (Pem)
maintenance therapy in elderly patients (pts) with good performance status- Analysis
of PARAMOUNT phase III study of Pem versus placebo in advanced non-squamous
non small cell lung cancer (NSCLC). European Journal of Cancer,9:S613, 2011.
169. Tsao MS, Gallo C, Saieg M, Santos GD, Gebbia V, Perrone F, Feld R, Gridelli C.
“Biomarkers of TORCH trial on first-line erlotinib followed by second-line
chemotherapy in advanced non small cell lung cancer”. III European Lung Cancer
Conference, Geneve, abstrc 1630 PR, April 18-21, 2012.
170. Gridelli C. Treatment algorithms for stage IV non small cell lung cancer. III
European Lung Cancer Conference, Ginevra, abstr. 37IN,18-21 April 2012.
171. Gridelli C, Bennonua J, De Castro J, Dingemans AM, Griesinger F, Grossi F,
Thatcher N, Ohe Y, Perez-Moreno PD, Langer C. “AvaALL: open-label randomized
phase IIIb trial evaluating the efficacy and safety of standard of care +/- continous
bevacizumab (BV) treatment beyond disease progression in patients (pts) with
advanced non-squamous non small cell lung cancer (NSCLC) after first-line
treatment with BV plus platinum-doublet chemotherapy”. Proc Am Soc Clin Oncol,
abstr. 94861, 2012.
172. Gridelli C, Novello S, Zilembo N, Foa P, Favaretto AG, De Marinis F, Genestreti
G, Crinò L, Grossi F, Caffo O, Ferraù F, Cruciani G, Brandes AA, Galetta D, Barni
S, Fasola G, Siena S, Mari E, Iannaccone C, Ciardiello F. “Final results of a
randomised , double-blind, phase II study of gemcitabine plus vandetanib or plus
placebo in the treatment of advanced (stage IIIB/IV) non small cell lung cancer
(NSCLC) elderly patients (ZELIG study NCT00753714). Proc Am Soc Clin Oncol,
abstr. 96537, 2012.
173. Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O,
Sahoo TP, Laack E, Reck M, Jaime JC, Melemed S, John WJ, Chouaki N,
Zimmermann A, Vissere-Grul C, Gridelli C. “Overall survival of maintenance
pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC
immediately following induction treatment with pem plus cisplatin for advanced non83
squamous non small cell lung cancer: final results of a phase III study
(PARAMOUNT). Proc Am Soc Clin Oncol, abstr. 94836, 2012.
174. Reck M, Paz-Ares L, de marinis F, Molinier O, Sahoo PT, Laack E, Jhon W,
Zimmermann A, Visserel-Grul CM, Gridelli C. “PARAMOUNT: descriptive
subgroup analyses of final overall survival of the phase III study of maintenance
pemetrexed versus placebo following induction treatment with pemetrexed plus
cisplatin for advanced non-squamous non small cell lung cancer”. 37 ESMO
Congress , abstr.1235PD, 2012.
175. Pujol J, Paz-Ares L, Dediu M, Thomas M, Bidoli P, Corral J, Chouaki N,
Visseren-Grul CM, Zimmermann C, Gridelli C. “Update safety and quality of life
results of PARAMOUNT study: maintenance pemetrexed plus best supportive care
versus placebo plus best supportive care immediately following induction treatment
with pemetrexed plus cisplatin for advanced non-squamous non small cell lung
cancer”. 37 ESMO Congress, abstr.1275P, 2012.
176. Gridelli C, Thomas M, Prabhash KP, El Kouri C, Blackhall F, Bustin F, San
Antonio B, Zimmermann A, Chouaki N, Visseren-Grul C, Paz-Ares L. “ Final
efficacy and safety results of pemetrexed continuation therapy in the elderly from the
PARAMOUNT phase III study”. Proc Am Soc Clin Oncol, abstr 8068, 2013.
177. Morabito A, Gebbia V, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L,
de Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso
G, Nacci A, Giordano P, Daniele G, Gridelli C, Rocco G, Gallo C, Di Maio M.
“Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in
advanced non samll cell lung cancer and performance status Cappa-2 study”. Proc
Am Clin Oncol, abstr 8066, 2013.
178. Chung C, Isaranuwatchai W, Di Maio M; Jiang H, Lau A, Hoch JS, Feld R, Tsao
S, Gridelli C, Ciardiello F, Butts CA, Gallo C, Perrone F, Leighl NB. “Economic
analysis of TORCH: erlotinib versus cisplatin and gemcitabine as first-line therapy
for advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2013.
179. Dy GK, Vansteenkiste J, Thomas M, De Pas T, Grossi F, De Greve J, Felip E,
Canon JL, Gray J, de Braud F, Reck M, Thongaprasert S, Planchard D, Grideli C,
Roussou P, Gurnani M, Atalla G, Sternberg D, Engelman JA. “Epidemiology of
PI3K pathway alterations in patients with metastatic non small cell lung cancer
(NSCLC): findings from the international BASALT-1 study”. World Lung Cancer
Conference, Sydney 27-30 October 2013.
84
BOOK CHAPTERS
1. Palmieri G, Gridelli C, Zilembo N, Bianco AR. "La chemioterapia sistemica del
carcinoma epatocellulare." In: "Diagnosi e terapia dei tumori del fegato e delle vie
biliari", pp.161-166. Eds. F Mazzeo, F Rendano. CIC Edizioni Internazionali, 1986.
2. Lombardi G, Torino G, Palmieri G, Gridelli C, Nuzzo F, Montesarchio V, Bianco
AR. "Elevata incidenza di varicocele in pazienti affetti da linfoma." In: “Progressi in
Andrologia Chirurgica.” Ed. ACTA MEDICA. Rome 1987.
3. Palmieri G, Gridelli C, Zilembo N, Pepe R, Bianco AR. "La chemioterapia del
carcinoma gastrico." In: "I tumori dello stomaco", pp. 277-282. Eds. F Mazzeo, P
Forestieri. Edizioni SES, 1989.
4. Bianco AR, Palmieri G, Gridelli C, Pepe R. "La terapia loco-regionale delle metastasi
epatiche". In: "Il carcinoma del colon-retto", pp.345-355. Eds. G Colucci, F Prete.
Edizioni Cacucci, Bari, 1989.
5. Bianco AR, Gridelli C. "Carcinoma polmonare inoperabile." In: "Casi clinici in
oncologia", pp. 99-101. Eds. E Bonmassar, Alberto Costa. Masson, 1995.
6. Gridelli C. “Tumori del tessuto neuroepiteliale. Gliomi ad alto grado. Trattamento
combinato (radioterapia stereotassica e farmaci radiosensibilizzanti).” In:
“Compendio di radioterapia stereotassica”, pp.60-63. Eds. F Smaltino, R Ruggiero, F
Fortunato. Ed. Medisarte, Naples, 1995.
7. Gridelli C. “Studi di fase I”, pp. 91-101. Docetaxel - Farmacologia e Clinica, 1998.
8. Gridelli C. “Tollerabilità e gestione effetti tossici”, pp. 131-146. Docetaxel Farmacologia e Clinica, 1998.
85
9. Gridelli C, Rossi A. “Tumori del polmone.” In: “Oncologia medica pratica”, pp. 479506. Eds. M Lopez. Ed. Scietà Editrice Universo, pp. 479-506, Rome, 2000.
10. Rossi A, Guerriero C, Ferrara C, Del Gaizo F, Nicolella D, Airoma G, Maione P,
Colantuoni G, Barzelloni ML, Salerno V, Gridelli C. “Nuovi farmaci biologici.” In:
“Il cancro del polmone, verso una diagnosi precoce”. Pp. 109-113, Ed Giuseppe De
Nicola, 2003.
11. Gridelli C, Rossi A. “Il carcinoma del polmone non microcitoma.” In: V Lorusso, D
Cova, G Colucci , L Balducci (eds.) ”Neoplasie dell’anziano”, Bari, Ragusa Grafica
Moderna, Vol. I, pp 305-312, 2003.
12. Rossi A, Gridelli C. “Il microcitoma polmonare.” In: V Lorusso, D Cova, G Colucci ,
L Balducci (eds.) ”Neoplasie dell’anziano”, Bari, Ragusa Grafica Moderna, Vol. 1,
pp. 331-336, 2003.
13. Gridelli C. “Il trattamento dei malati con carcinoma polmonare.” In “Oncologia
Geriatria 3 – I trattamenti integrati”, pp 67-79, Il Pensiero Scientifico Editore, 2004.
14. Gridelli C, Rossi A. “Tumori del polmone.” In: Lopez M. (eds. 2): Oncologia medica
pratica. Rome, Società Editrice Universo, pp. 1015-1053, 2005.
15. Gridelli C, Maione P. “Integration of chemotherapy in the management of locally
advanced non small cell lung cancer”. In Syrigos KN, Nutting CM, Roussos C:
Tumors of the chest. New York, Springer,pp 249-257, 2006.
16. Spatafora M, Maione P, Perrone F, Gridelli C. Lung Cancer: does age affect
treatment strategy? Eropean Respiratory Monograph. Latimer Trend and co.
Plymouth (UK),306-326, 2009.
17. Gridelli C, Rossi A. Lung Cancer. In P. Manga and L. Repetto. Textbook of Geriatric
Oncology. Grupo Aula Medica 2010.
18. Horn L, Gridelli C, Langer C, Johnson DH. Chemotherapy and Lung Cancer. In :
Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti G, turrisi AT. Principles
and Practice of Lung Cancer.Wolters Kluwer/Lippincott Williams and Wilkins.
Philadelphia, 2010.
19. Gridelli C, Rossi A.Clinical results with EGFR inhibitors in NSCLC and their use in
the treatment of metastatic disease.In Ciardiello F. “EGFR inhibitors in cancer
treatment” . Future Medicine, London 2012.
20. Gridelli C, Rossi A. First-line therapy of advanced non small cell lung cancer not
harboring an activating EGFR mutation. In Stahel R . “Lung Cancer Therapy Annual
7. Informa Healthcare, London 2012.
86
87
BOOKS
1. Monfardini S, Gridelli C. "La chemioterapia nel paziente oncologico anziano." Il
Pensiero Scientifico Editore, Rome, 1997.
2. Barni S, Frontini L, Tamburrini M, Zonato S, Gridelli C et al. "Terapia medica
oncologica. Guida per il paziente." Ed. Studio Giovanni Origgi, Milan October 1997.
3. Gridelli C. “Focus on: L’epirubicina nel trattamento del carcinoma polmonare non a
piccole cellule.” Medica-Editoria e Diffusione Scientifica, Milan, 1999.
4. Gridelli C, Daniele B, Pignata S. “Quadri sinottici in oncologia.” Edizioni Momento
Medico, Salerno, 2000.
5. Gridelli C, Repetto L. “La chemioterapia nel paziente oncologico anziano.” Pacini
Editore Medicina, March 2001.
6. Gridelli C. “Trattamento del carcinoma del polmone non a piccole cellule. Stato
dell’arte e prospettive future.” Accademia Nazionale di Medicina, Genoa, July 2003.
7. Gridelli C, Cuomo A. “La terapia del dolore oncologico.” Edizioni Momento
Medico, Salerno, 2005.
8. Colucci G, Crinò L, de Marinis F, Gridelli C, Grossi F, Marangolo M. “Percorso
terapeutico nel carcinoma polmonare (NSCLC)”. Gruppo Oncologico Italia
Meridionale, Bari 2009.
9. Gridelli C. ”Fattori prognostici e predittivi nel carcinoma polmonare non a piccole
cellule”. Edizioni Editree srl, Monza, 2010.
10. Gridelli C, M. Rapellino. “Il rischio clinico nella gestione del carcinoma polmonare”.
Edizioni SEEd, Torino, 2010.
11. Ciardiello F, Gridelli C. “ EGFR TKIs nel carcinoma polmonare non a piccole
cellule: similitudini e differenze. Edizioni Elsevier, Milano, 2010.
12. Gridelli C. “Appropriatezza terapeutica nel trattamento di II linea del NSCLC
nell’era dei farmaci a bersaglio molecolare”. Edizioni Editree, Monza, 2012.
13. Gridelli C, Audisio R. Management of lung cancer in older patients. Springer,
London 2013.
88
BOOKS AND MANUALS ON ELECTRONIC VERSION
1. Gridelli C. “Combination Chemotherapy Programs.” Medica, Editoria e Diffusione
Scientifica, Milan, 1999.
2. Gridelli C. “2nd Combination Chemotherapy Programs.” Medica, Editoria e
Diffusione Scientifica, Milan, 2001.
3. Gridelli C. “3rd Combination Chemotherapy Programs.” Medica, Editoria e
Diffusione Scientifica, Milan, 2001.
89
ARTICLES ON NATIONAL JOURNALS
1. Palmieri G, Gridelli C, Lauria R, Pepe R, Nuzzo F. "Il prurito nelle neoplasie
maligne." IDEA MEDICA, 1:5-11, 1984.
2. Iaffaioli RV, Iervoglini A, Frasci G, Ullucci V, Gridelli C, Zampino MG. "Recettori
ormonali e carcinoma mammario: valutazioni critiche e metodologie." SYNTHESIS
MEDICA, 1:1-8,1985.
3. Palmieri G, Gridelli C, Lauria R, Pepe R, Nuzzo F. "La linfoadenopatia
angioimmunoblastica." AGGIORNAMENTI DI MEDICINA E CHIRURGIA, 4:1-8,
1985.
4. Palmieri G, Lauria R, Gridelli C. "Presentazione di un caso di adenocarcinoma
epatico." Atti III Convegno Internazionale "Le Complicanze in Chirurgia: Aspetti
Medico-Chirurgici." Naples November 27-30, 1985.
5. Palmieri G, Lauria R, Gridelli C, Nuzzo F. "La cachessia neoplastica." Atti III
Convegno Internazionale "Le Complicanze in Chirurgia: Aspetti Medico-Chirurgici."
Naples November 27-30, 1985.
6. Iaffaioli, Frasci G, Iervoglini A, Gridelli C, Cerrotta A, Pezzullo A. "Fattori
prognostici e terapia adiuvante del carcinoma della mammella." RASSEGNA
MEDICA, 12:1-12, 1985.
7. Vitale A, Cozzolino M, Palmieri G, Gridelli C. "La terapia del carcinoma
spinocellulare del pene." RASSEGNA MEDICA, 5:1-7, 1986.
8. Bianco AR, Palmieri G, Gridelli C, Lauria R, Contegiacomo A. "La terapia medica
dei tumori surrenalici." MEDICINA OGGI, 4:421-425, 1987.
9. Palmieri G, Pepe R, Gridelli C, Bianco AR. "L'oncologo nella riabilitazione del
paziente neoplastico." Atti I Congresso Nazionale Società Italiana di Riabilitazione
Medico-Chirurgica. Copanello (Cz) June 11-13, 1987.
10. Palmieri G, Montesarchio V, Gridelli C, Bianco AR. "Treatment of poor prognosis
non seminomatous testicular cancer." Atti Convegno Internazionale sui Tumori delle
Gonadi. Jesi (An) September 23-26, 1987.
11. Contegiacomo A, Lauria R, Gridelli C, Bianco AR. "Il trattamento del microcitoma
polmonare." AGGIORNAMENTO DEL MEDICO, 11, 3:163-168, 1987.
12. Pagliarulo C, Marinelli A, Gridelli C, Palmieri G. "La terapia adiuvante del
carcinoma del colon retto." AGGIORNAMENTO DEL MEDICO, 11, 10:678-684,
1987.
13. Palmieri G, Gridelli C, Torino G, Montesarchio V, Marinelli A, Bianco AR. "Elevata
incidenza di varicocele in pazienti affetti da linfoma." FOLIA ONCOLOGICA, 10
(suppl A):124-126, 1987.
90
14. Palmieri G, Gridelli C, Aconito P, Lauria R, Bianco AR. "Esperienza terapeutica con
interferon (ß-IFN) nell'adenocarcinoma renale (RCC) in fase avanzata." FOLIA
ONCOLOGICA, 10 (suppl A):179-182, 1987.
15. Palmieri G, Montesarchio V, Gridelli C, Zampino MG, Bianco AR. "Linfomi cutanei
a cellule T: esperienza clinico-terapeutica." FOLIA ONCOLOGICA, 10 (suppl
A):99-102, 1987.
16. Giampaglia F, Ferrante G, Griffo S, Di Prisco B, Rotondo A, Lauria R, Marino G,
Elia S, Scotto Di Santolo G, Muto P, Vetrani A, Gridelli C. "Diagnostica invasiva e
programmazione terapeutica dei noduli solitari del polmone." ARCHIVIO
MONALDI, 5:445-457, 1987.
17. Giampaglia F, Cecere C, Vetrani A, Di Prisco B, Rotondo A, Elia S, Cirillo LS,
Gridelli C, Franco F. "Tecniche attuali di biopsia del mediastino: 1) La
Mediastinoscopia." ARCHIVIO MONALDI, 5:459-476, 1987.
18. Gridelli C. "La chemioterapia neo-adiuvante nel tattamento del carcinoma polmonare
non microcitoma al III stadio." BOLLETTINO SOCIETA’ ITALIANA DI
ENDOSCOPIA TORACICA, 0:6,1988.
19. Gridelli C, Airoma G, Aconito P, Palmieri G. "La Timostimolina nella prevenzione
delle infezioni in oncologia." PROGRESSI IN ONCOLGIA CLINICA, 2 (suppl
1):339-341, 1988.
20. Gridelli C, Palmieri G, Pepe R, Bianco AR. "Il mitoxantrone nel trattamento del
carcinoma midollare della tiroide." FOLIA ONCOLOGICA, 11:210-213, 1988.
21. Palmieri G, Gridelli C, Montesarchio V, Pagliarulo C, De Placido S, Pepe R, Bianco
AR. "Dati preliminari sull'impiego del methotrexate ad alte dosi e 5-Fluorouracile nel
carcinoma del colon-retto avanzato." FOLIA ONCOLOGICA, 11:196-199, 1988.
22. Gridelli C, Pepe R, Incoronato P, Airoma G, Palmieri G. "Il mitoxantrone nel
trattamento del carcinoma della colecisti avanzato: esperienza clinico-terapeutica."
FOLIA ONCOLOGICA, 12:142-144, 1989.
23. Palmieri G, Gridelli C, Pepe R, Airoma G, Incoronato P, Bianco AR. "Le emergenze
in oncologia." AGGIORNAMENTO DEL MEDICO, 13:754-763, 1989.
24. Bianco AR, Palmieri G, Gridelli C, Pepe R, Giampaglia F, Vetrani A. "Il nodulo
polmonare: iter diagnostico." AGGIORNAMENTO DEL MEDICO, 14:350-358,
1990.
25. Gridelli C, Pepe R, Gentile M, Palmeri S, Palmieri G, Gebbia V, Russo A, Bianco
AR. "Dati preliminari sull'impiego di mitomicina C, etoposide e vindesina (MEV) nel
carcinoma polmonare non a piccole cellule stadio IV." FOLIA ONCOLOGICA,
13:129-131, 1990.
91
26. Gridelli C, Airoma G, Bianco AR. "La chemioterapia nel carcinoma polmonare a
piccole cellule." FOLIA ONCOLOGICA, 14:269-273, 1991.
27. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinelli F, Bianco AR. "Ondansetron
nella profilassi della nausea e vomito nei pazienti trattati con carboplatino." Atti XVII
Congresso Nazionale SIPDTT, Monduzzi Ed. Catania November 13-16, 1991.
28. Incoronato P, Gridelli C, Airoma G, Pepe R, Rossi A, Palazzolo G, Bianco AR. "Il
dolore nel paziente neoplastico." AGGIORNAMENTO DEL MEDICO, 18:312-320,
1994.
29. Gridelli C, Airoma G, Incoronato P, Pepe R, Rossi A, Bianco AR. "Nuove
prospettive terapeutiche nel microcitoma polmonare." AGGIORNAMENTO DEL
MEDICO, 19:73-78, 1995.
30. Bianco AR, Gridelli C, Rossi A. "Ruolo della chemioterapia nel paziente anziano
affetto da carcinoma polmonare." Atti IV Congresso Nazionale Società Italiana di
Chirurgia Geriatrica, pp. 471-472. Naples September 23-26, 1992.
31. Scoppa GF, Bruni GS, Guida C, Posca T, Gridelli C, Daniele B, Rinaldi L, Celiento
G, Ruffolo P, Pergola M. "La radio-chemioterapia concomitante nel carcinoma
polmonare non a piccole cellule (CPNPC) stadio IIIA-IIIB: dati preliminari di uno
studio di fase II non randomizzato." Atti IV Congresso Nazionale Associazione
Italiana di Radioterapia Oncologica. Taormina September 14-17, 1994.
32. Smaltino F, Ruggiero R, Fortunato F, Gridelli C, Catalano O. "Radiochirurgia
stereotassica e farmaci antitumorali nella terapia dei gliomi maligni." Atti IV
Congresso Nazionale Associazione Italiana di Radioterapia Oncologica. Taormina
September 14-17, 1994.
33. Gridelli C, Rossi A. "La chemioterapia nel paziente anziano affetto da carcinoma
polmonare non a piccole cellule avanzato." Atti III Simposio Nazionale G.O.I.M.
(Gruppo Oncologico Italia Meridionale). Vietri sul Mare (Sa) July 4-7, 1996.
34. Gridelli C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D’Aprile
M, Rossi A, Perrone F, Migliorino R, Pergola M, Bianco AR. "Studio di fase II con
vinorelbina in pazienti anziani affetti da carcinoma polmonare non a piccole cellule
(CPNPC) stadio IIIB-IV." MINERVA MEDICA, 87 (suppl 1):397, 1996.
35. Rossi A, Gridelli C, Lamaida E, Daniele B, Caputi F, Palazzolo G, Bianco AR.
“Leptomeningeal Carcinomatosis: report of 3 cases”. GIORNALE EUROPEO DI
ONCOLOGIA, 1:199-202, 1996.
36. Bruni GS, Posca T, Gridelli C, Celiento G, Montella M, Ruffolo P, Scognamiglio F,
Di Giacomo R, Guida C, Scoppa GF. “A phase II study of daily carboplatin and
radiation therapy in stage IIIA-IIIB non small cell lung cancer (NSCLC)."
GIORNALE EUROPEO DI ONCOLOGIA, 2:19-22, 1997
92
37. Gridelli C. “Il ruolo dei nuovi farmaci nel trattamento del carcinoma polmonare non a
piccole cellule avanzato". Atti IV° Simposio Nazionale GOIM (Gruppo Oncologico
Italia Meridionale). Palermo June 4-7, 1998.
38. Gridelli C. “La potenzialità nel paziente anziano”. Atti Simposio Satellite
“Gemcitabina: un approccio attuale alla terapia del tumore polmonare non a piccole
cellule.” VII ° Congresso Nazionale FONICAP. Bari June 11, 1998.
39. Rossi A, Gridelli C. “La cachessia neoplastica.” MEDICINA & TERAPIA, 4 (suppl
2):17-33, 1998.
40. Gridelli C. “Efficacia della chemioterapia nel trattamento del tumore del polmone
avanzato non microcitoma (NSCLC).” FARMACI, 23 (suppl 4):1-8, 1999.
41. Gridelli C. “La chemioterapia del carcinoma polmonare non a piccole cellule nel
paziente anziano.” MEDICINA & TERAPIA, 5 (suppl 2):5-17, 1999.
42. Gridelli C, Barzelloni ML, Barletta E, Guida C, Gatani T, Fiore F, Scognamiglio F.
“The role of granulocyte growth factors in the treatment of non small cell lung
cancer.” LA CLINICA TERAPEUTICA,150, 1999.
43. Gava A, Zagonel V, Repetto L, Granetto C, Conca S, Ferrarese F, Gridelli C.
“Carcinomi del polmone.” ARGOMENTI DI ONCOLOGIA, 20:127-135, 1999.
44. Gridelli C. “Update sul ruolo del topotecan nel trattamento del carcinoma polmonare
a piccole cellule e del carcinoma ovarico.” EDIZIONI SCIENTIFICHE CUZZOLIN,
5-14, 1999.
45. Gridelli C. “Il trattamento chemioterapico delle neoplasie polmonari non a piccole
cellule nel paziente anziano.” GERIATRIA, 11 (suppl 4):33-34, 1999.
46. Gava A, Zagonel V, Repetto L, Granetto C, Conca S, Ferrarese F, Gridelli C.
“Carcinomi del polmone.” ARGOMENTI DI ONCOLOGIA, 20:127-135, 1999.
47. Gridelli C. “Il trattaemnto del carcinoma polmonare non a piccole cellule in fase
avanzata nel paziente anziano.” AURA, 1:1-6, 1998.
48. Gridelli C. “L’emesi da chemioterapia.” LA QUALITA’ DELLA VITA IN
ONCOLOGIA, Supplemento al GIORNALE ITALIANO DI ONCOLOGIA, 1:9-10,
2000.
49. Gridelli C. “Nuove prospettive nel trattamento chemioterapico del carcinoma
polmonare non a piccole cellule avanzato.” ONCONEWS, 3:10-11, 2000.
50. Gridelli C. “Raccomandazioni sull’impiego degli antiemetici nella pratica clinica:
linee guida dell’American Society of Clinical Oncology.” CUZZOLIN EDITORE, 115, 2000.
51. Gridelli C. “L’emesi da chemioterapia.” GIORNALE ITALIANO DI ONCOLOGIA,
3 (suppl):21, 2000.
93
52. Gridelli C. “Esperienze innovative con vinorelbine nel NSCLC.” ADIS
INTERNATIONAL, 12-16, 2000.
53. Gridelli C, Maione P. “Il trattamento del carcinoma polmonare a piccole cellule
nell’anziano.” Congress report: “Anziani e cancro: qualità di vita e qualità di cura.”
Genoa October 28-29, 2000.
54. Gridelli C. “Impiego della chemioterapia nella pratica clinica del carcinoma
polmonare non a piccole cellule.” RASSEGNA DI ONCOLOGIA TORACICA, 3
(suppl 4):12-16, 2001
55. Gridelli C. “Mono vs polichemioterapia con gemcitabina nel trattamento del
carcinoma polmonare non a piccole cellule avanzato.” MEDICAL
INTERNATIONAL REVIEW, 5:16-21, 2001.
56. Gridelli C. “Il trattamento chemioteraico nel paziente anziano affetto da carcinoma
polmonare non a piccole cellule avanzato.” ONCOLOGY NEWS, 1:33-39, 2001.
57. Gridelli C. “L’emesi da chemio e radioterapia: problematiche e prospettive.”
BASELIFE ONCOLOGY, 1:4:7, 2001.
58. Gridelli C. “Editoriale.” BASELIFE ONCOLOGY, 1:2-4, 2002.
59. Gridelli C. “Carcinoma polmonare non a piccole cellule. Docetaxel nel trattamento
chemioterapico di seconda linea.” EXCERPTA MEDICA, 3-23, 2004.
60. Gridelli C. “La terapia medica del paziente anziano affetto da carcinoma polmonare
non a piccole cellule avanzato: significato e possibilità.” TUMORI, 2 (suppl 13):S36S37, 2004.
61. Maione P, Rossi A, Gridelli C. “Il trattamento del tumore polmonare non
microcitoma localmente avanzato ed avanzato nell’anziano.” CANCER AND
AGING, 2:5-10, 2004.
62. Gridelli C. “Vinorelbine e il paziente oncologico anziano. Il carcinoma polmonare
non a piccole cellule.” CURRENT THERAPEUTICS, 8-18, 2004.
63. Gridelli C. “Il carcinoma polmonare non a piccole cellule nell’anziano.” TRENDS IN
MEDICINE, 4:285-294, 2004.
64. Gridelli C, Maione P, Rossi A. “Il trattamento del carcinoma polmonare non a
piccole cellule avanzato nel paziente con performance status ECOG 2.” ON
Oncology News, 1/2006:16-23, 2006.
65. Rossi A, Gridelli C. “Il trattamento del carcinoma polmonare nel paziente anziano”.
ONCOFORM, 9 :34-48,2006.
66. Gridelli C. “Il problema: l’emesi ritardata”. ONCOLOGICAL FORUM,1:9,2006.
94
67. Gridelli C. “Emesi e chemioterapia neoadiuvante in paziente anziano affetto da
carcinoma polmonare non a piccole cellule”. ONCOLOGICAL FORUM,2:20,2006.
68. Gridelli C, Rossi A. “Le nuove prospettive di terapia medica per il tumore al
polmone”. MEDICO E PAZIENTE,5:23-26,2009.
69. Sgambato A, Casaluce F, Maione P, Rossi A, Gridelli C. “La terapia del paziente
anziano con carcinoma del polmone non a piccole cellule”.
GERIATRIC
MEDICAL INTELLIGENCE,22:20-30, 2013.
70. Gridelli C, Riccardi F, Piantedosi F, Di Lullo L, Lorusso V, Galetta D. “ Terapia con
gli inibitori della somatostatina e terapia biologica nei tumori neuroendocrini
polmonari”. Select, 3:13-14, 2013.
95
ARTICLES ON INDEXED INTERNATIONAL JOURNALS
1. Palmieri G, Gridelli C, Vitale A, Bianco AR. "Contemporary chemotherapy and
radiotherapy for inguinal metastases of carcinoma of the penis: a case report."
TUMORI, 74:585-586, 1988.
2. Palmieri G, Stefani S, Gridelli C, Conte A, Airoma G, Contegiacomo A, Bianco AR.
"Irradiation of the hypothalamic-hypophyseal area induces complete remission of
mucocutaneous lesions in disseminated Histiocytosis X: a case report." CANCER,
64:29-31, 1989.
3. Palmieri G, Gridelli C, Airoma G, Balestrino M, Bisogno A, Incoronato P, Bianco
AR. "Clinical trials with 5-Fluorouracil and leucovorin." JOURNAL OF
CHEMOTHERAPY, 2 (suppl 1):41-46,1990.
4. Palmieri G, Gridelli C, Pepe R, Airoma G, Iaffaioli RV, Frasci G, Caponigro F,
Bianco AR. "Partial regression of metastatic hepatocellular carcinoma after treatment
with thymostimolin." TUMORI, 76:61-63, 1990.
5. Gridelli C, Palmieri G, Airoma G, Incoronato P, Pepe R, Barra E, Bianco AR.
"Complete regression of laryngeal involvement by classic Kaposi's sarcoma with low
dose 2b-interferon." TUMORI, 76:292-293, 1990.
6. Palmieri G, Lauria R, Caponigro F, Montesarchio V, Nuzzo F, Gridelli C, Bianco
AR. "Salvage chemotherapy for non-Hodgkin lymphoma of unfavorable histology
with a combination of CCNU and vinblastine." HAEMATOLOGICAL
ONCOLOGY, 8:179-183, 1990.
7. Palmieri G, Caponigro F, Iaffaioli RV, Contegiacomo A, Lauria R, Montesarchio V,
Gridelli C, Bianco AR. "CAVBP/DEP alternating chemotherapy for intermediate and
high grade non-Hodgkin lymphoma. Final results of a pilot study."
HAEMATOLOGICAL ONCOLOGY, 8:313-322, 1990.
8. Palmieri G, Gridelli C, Airoma G, Pepe R, Incoronato P, Caponigro F, Bianco AR.
"Second-line chemotherapy of advanced colorectal cancer with sequential high-dose
methotrexate and 5-fluorouracil." JOURNAL OF CHEMOTHERAPY, 3:55-60,
1991.
9. Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G,
Palmieri G, Russo A, Incoronato P, De Placido S, Perrone F, Basilico L, Rausa L,
Ferrante G, Bianco AR. "Phase II study of mitomycin C, etoposide and vindesine
(MEV) in metastatic, stage IV, non small cell lung cancer." CANCER
CHEMOTHERAPY AND PHARMACOLOGY, 28:405-407, 1991.
10. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinelli F, Bianco AR. "Ondansetron
nella profilassi della nausea e del vomito nei pazienti trattati con carboplatino:
risultati preliminari. Nuove acquisizioni sul ruolo dei 5-HT3 antagonisti." ADIS
INTERNATIONAL, 59-62, 1991.
96
11. Bianco AR, Stefani S, Gridelli C, Gentile M, Contegiacomo A, Giampaglia F, Lauria
R, Conte A, Ferrante G. "Intensive alternating chemotherapy and high dose chest
radio-therapy in small cell lung cancer." TUMORI, 77:437-441, 1991.
12. Gridelli C, Contegiacomo A, Lauria R, Gentile M, Airoma G, De Placido S, Perrone
F, Ferrante G, Bianco AR. "Salvage chemotherapy with CCNU and methotrexate for
small cell lung cancer resistant to CAV/PE alternating chemotherapy." TUMORI,
77:506-510, 1991.
13. Gridelli C, Airoma G, Incoronato P, Pepe R, Palazzolo G, Rossi A, Bianco AR.
"Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated
patients with symptomatic advanced non small cell lung cancer." CANCER
CHEMOTHERAPY AND PHARMACOLOGY, 30:212-214, 1992.
14. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinelli F, Bianco AR. "Ondansetron
in the prophylaxis of nausea and vomiting induced by carboplatin combination
chemotherapy." EUROPEAN JOURNAL OF CANCER, 4:651, 1993.
15. Gridelli C, Iacobelli S, Martino T, Natoli C, Ferrante G, Gentile M, Irtelli L,
Beltrami V, Rossi A, Bianco AR. "Neoadjuvant chemotherapy with cisplatin,
epirubicin and VP-16 for stage IIIA-IIIB non small cell lung cancer: a pilot study."
TUMORI, 78:377-379, 1992.
16. Gridelli C, Pepe R, Airoma G, Incoronato P, Rossi A, Palazzolo G, Bianco AR.
"Mitomycin C and vindesine: an ineffective combination chemotherapy in the
treatment of malignant pleural mesothelioma." TUMORI, 78:380-382, 1992.
17. Perrone, De Placido S, C. Carlomagno, Nuzzo F, A. Ruggiero, M. De Laurentis,
Gridelli C, C .Pagliarulo, Bianco AR. "Chemotherapy with mitomycin C and
vinblastine in pretreated metastatic breast cancer." TUMORI, 79:254-257, 1993.
18. Gridelli C, Incoronato P, Rossi A, Palazzolo G, Bianco AR. "Skeletal muscle
metastases from non small cell lung cancer." ACTA ONCOLOGICA, 14:425-427,
1993.
19. Gridelli C, Ianniello G, Maiorino A, Curcio C, D’Aprile M, Brancaccio L, Palmeri S,
Gentile M, Comella G, Pedicini T, Airoma G, Veltri E, Gebbia V, Russo A, Casaretti
R, Giampaglia F, Ferrante G, Rausa L, Iacobelli S, Arcangeli G, De Placido S,
Bianco AR."Carboplatin, epirubicin and VP-16 chemotherapy, in the treatment of
small cell lung cancer." AMERICAN JOURNAL OF CLINICAL ONCOLOGY,
17:160-162, 1994.
20. Perrone F, De Placido S, Carlomagno C, Gravina G, De Laurentiis M, Del Mastro L,
Gridelli C, Pagliarulo C, Bianco AR. "Mitomycin C and mitoxantrone in
anthracycline pretreated advanced breast cancer. A phase II study." AMERICAN
JOURNAL OF CLINICAL ONCOLOGY, 17:218-222, 1994.
21. Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G,
Bianco AR. "Phase I study of epirubicin plus vinorelbine with or without G-CSF in
97
advanced non small cell lung cancer." EUROPEAN JOURNAL OF CANCER,
29A:1729-1731, 1993.
22. Gridelli C, Rossi A, Palazzolo G, Pepe R, Airoma G, Incoronato P, Bianco AR.
"Mitomycin C, etoposide and vinorelbine (MEV II) in the treatment of metastatic
stage IV non small cell lung cancer." TUMORI, 80:128-130, 1994.
23. Gridelli C, D’Aprile M, Curcio C, Brancaccio L, Palmeri S, Comella G, Veltri E,
Ferrante G, Gentile M, Rossi A, Arcangeli G, Montella M, Bianco AR. "Carboplatin
plus epirubicin plus VP-16, concurrent split-course radiotherapy and adjuvant surgery
for limited small cell lung cancer." LUNG CANCER, 11:83-91,1994.
24. Gridelli C. "Treatment of small cell lung cancer: a critical review." CANCER
REPORT, 41 (1-4):25:31, 1994.
25. Gridelli C, Perrone F, D’Aprile M, Rossi A, Palmeri S, Curcio C, Veltri E, Ianniello
G, Lorusso V, Palmieri G, Rinaldi L, De Placido S, Gallo C, Bianco AR. "Phase II
study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF in extensive
small cell lung cancer." EUROPEAN JOURNAL OF CANCER, 31A:2424-2426,
1995
26. Gridelli C, Rossi A, Incoronato P, Bruni GS, Scognamiglio F, Ruffolo P, Rinaldi L,
Bianco AR. "Phase I study of ifosfamide plus high dose epirubicin in advanced non
small
cell
lung
cancer."
CANCER
CHEMOTHERAPY
AND
PHARMACOLOGY, 37:613-615, 1996.
27. Gridelli C, D’Aprile M, Palmeri S, Curcio C, Rossi A, Gebbia V, Veltri E, Pepe R,
Pistillucci G, Bianco AR. “Phase I study of chemotherapy with carboplatin,
epirubicin and escalating dose of VP-16 with G-CSF support in extensive small cell
lung cancer.” AMERICAN JOURNAL OF CLINICAL ONCOLOGY, 19:589591, 1996.
28. Gridelli C, Rossi A, Pergola M. "Chemotherapy of advanced non small cell lung
cancer in elderly patients." CANCER REPORT, 42 (1-2):13:17, 1995.
29. Gridelli C, Perrone F, Palmeri S, D’Aprile M, F. Cognetti, Rossi A, Gebbia V, Pepe
R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali C,
Leonardi V, Gallo C, De Placido S, Bianco AR. "Mitomycin plus vindesine plus
etoposide (MEV) vs mitomycin plus vindesine plus cisplatin (MVP) in stage IV non
small cell lung cancer: a phase III multicentre randomised trial." ANNALS OF
ONCOLOGY, 7:821-826, 1996.
30. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di
Costanzo F, D’Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola
M, Monfardini S. "Vinorelbine is well tolerated and active in the treatment of elderly
patients with advanced non small cell lung cancer. A two-stage phase II study."
EUROPEAN JOURNAL OF CANCER, 33:392-397, 1997.
31. Gridelli C, Ianniello G , Ambrosini G, Mustacchi G, Pedicini T, Farris A, Iacobelli S,
Rossi G, Moretti G, Angelini F, De Lena M, Di Carlo A, Bonsignori M, Sabbatini R,
98
Catalano G, Rossi A, Olivieri A, Fina P, Bianco AR. "A multicentre, double-blind,
randomised trial comparing ondansetron versus ondansetron plus dexamethasone in
the prophylaxis of cisplatin-induced delayed emesis." INTERNATIONAL
JOURNAL OF ONCOLOGY, 10:395-400, 1997.
32. Tonato M, Crinò L, Mosconi AM, ...... Gridelli C ........ “Rationale of a phase III
study comparing a standard cisplatin regimen (mitomycin /ifosfamide/cisplatin) with
cisplatin and gemcitabine in non-small cell lung cancer.” SEMINARS IN
ONCOLOGY, 24 (suppl 8):S31-S35, 1997.
33. Gridelli C, De Marinis F, Rossi A, Tucci E, D’Aprile M, Cioffi R, Cortesi E,
Migliorino R, Pisano A, Scognamiglio F, Di Giacomo R, Bianco AR. "A phase II
study of VM-26 plus lonidamine in pretreated small cell lung cancer."
ANTICANCER RESEARCH, 17:1277-1280, 1997.
34. Gregor A, Cull A, Stephens RJ,Kirkpatrick JA, Jarnold JR, Girling DJ .... Gridelli C
..... “Prophylactic cranial irradiation following complete response to induction
therapy in small cell lung cancer: results of a multicentre randomised trial.”
EUROPEAN JOURNAL OF CANCER, 33:1754-1760, 1997.
35. Gridelli C, Perrone F, Monfardini S. “Lung Cancer in the Elderly.” EUROPEAN
JOURNAL OF CANCER, 33:2313-2314, 1997.
36. Ruckdeschel R, Gridelli C, Perrone F, Monfardini S, Giaccone G. “Are platinum
compounds mandatory in the treatment of metastatic non small cell lung cancer?”
EUROPEAN JOURNAL OF CANCER, 34:1993-1999, 1998.
37. Gridelli C, Rossi A, Scognamiglio F, Guida C, Fiore F, Gatani T, Scoppa GF,
Pergola M. “Carboplatin plus oral etoposide in elderly patients with advanced non
small cell lung cancer. A phase II study.” ANTICANCER RESEARCH, 17:47554758, 1997.
38. Gridelli C, Perrone F, Ianniello G, Brancaccio L, Iaffaioli RV, Curcio C, D’Aprile M,
Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo
C, Monfardini S, Bianco AR. “Carboplatin plus vinorelbine, a new well tolerated and
active regimen for the treatment of extensive-stage small cell lung cancer: a phase II
study.” JOURNAL OF CLINICAL ONCOLOGY, 16:1414-1419, 1998.
39. Crinò L, Mosconi AM, Scagliotti G, Selvaggi G, Rinaldi M, Della Giulia M, Gridelli
C, Calandri C, De Marinis F, Noseda M, Tonato M. “Gemcitabine as second-line
treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II
trial.” SEMINARS IN ONCOLOGY, 25 (suppl 9):23-26, 1998.
40. Rosell R, Tonato M, Sandler A, ..... Gridelli C, ....... “The Activity of gemcitabine
plus cisplatin in randomized trials in untreated patients with advanced Non - Small
Cell Lung Cancer.” SEMINARS IN ONCOLOGY, 25 (suppl 9):27-34, 1998.
41. Lorusso V, Pollera C, Antimi M, Luporini G, Gridelli C, Frassinetti GL, Oliva C,
Pacini M and De Lena M. “A phase II study of gemcitabine in patients with
99
transitional cell carcinoma of the utinary tract previously treated with platinum.”
EUROPEAN JOURNAL OF CANCER, 34:1208-1212, 1998.
42. The Elderly Lung Cancer Vinorelbine Italian Study Group. “Effects of vinorelbine on
quality of life and survival of elderly patients with advanced non-small cell lung
cancer”. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 91:66-72,
1999.
43. Italian Study Group for the Di Bella multitherapy trials ........ Gridelli C, ........
“Evaluation of an unconventional cancer treatment (the Di Bella multitherapy):
results of a phase II trials in Italy.” BRITISH MEDICAL JOURNAL, 318:224-228,
1999.
44. The Italian Multicentre Study Group. “A double-blind randomized study comparing
intramuscolar granisetron with intramuscolar granisetron plus dexamethasone in the
prevention of delayed emesis induced by cisplatin.” ANTICANCER DRUGS,
10:465-470, 1999.
45. van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A,
Gridelli C, van Marck E, Lentz M, Giaccone G. “A phase II study of gemcitabine in
patients with malignant pleural mesothelioma.” CANCER, 85:2577-2582, 1999.
46. Crinò L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia
M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M.
“Gemcitabine as second line treatment for advanced non small cell lung cancer: a
phase II trial.” JOURNAL OF CLINICAL ONCOLOGY, 17:2081-2085, 1999.
47. Gridelli C, Barletta E, Barzelloni ML. “Chemotherapy of advanced non small cell
lung cancer in the elderly.” RAYS, 24 (suppl 2):58-62, 1999.
48. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S,
Gatani T, Fiore F, Guida C, Scognamiglio F. “Single-agent gemcitabine as second
line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase
II trial.” ANTICANCER RESEARCH, 19:4535-4538, 1999.
49. Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A,
Bianco AR, Marangolo M, Di Costanzo F, Sari M, Barni S, Ravaioli A, AdamoV,
Portalone L, Cruciani G, Masotti A, Ferrara F, Gozzelino F, Tonato M. “Gemcitabine
and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non small cell
lung cancer: a randomized phase III study of the Italian Lung cancer Project.”
JOURNAL OF CLINICAL ONCOLOGY, 17:3522-3530, 1999.
50. Gava A, Zagonel V ,Repetto L, Gravetto C, Ferrarese F, Gridelli C. “Guidelines for
radiation therapy of lung cancer in the elderly.” RAYS, 24 (suppl 2):79-81, 1999.
51. Gridelli C. “Topotecan, recenti acquisizioni e prospettive nel trattamento dei tumori
del polmone.” TUMORI, 85 (suppl 1):S16-S22, 1999.
52. Traversa G, Maggini M, Menniti-Ippolito F, Bruzzi P, Chiarotti F, Greco D, SpilaAlegiani S, Raschetti R, Benagiano G, ......... Gridelli C, ......... “The unconventional
100
Di Bella Cancer Treatment a reflection on the italian experience.” CANCER,
86:1903-1911, 1999.
53. Gridelli C, Cigolari S, Maiorino A, Ianniello G, Brancaccio L, Rossi A, De Cataldis
G, Pedicini T, Maiorino L, Barletta E, M. Di Lanno M, Bilancia D, Crispino C,
Barzelloni ML, Masullo P, D’Aniello R, Manzione L. “Amifostine plus cisplatin plus
vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter
phase II study.” LUNG CANCER, 28:237-244, 2000.
54. Perrone F, Gridelli C, Gallo C. “Vinorelbine + best supportive care vs best supportive
care in the treatment of elderly patients with advanced non-small-cell lung cancer.
Results of the ELVIS randomized trial.” ALC, ADVANCES IN LUNG CANCER,
2:2-5, 2000.
55. De Luca A, Pignata S, Casamassimi A, D’Antonio A, Gridelli C, Rossi A, Cremona
F, Parisi V, De Matteis A, Normanno N. “Detection of circulating tumor cells in
carcinoma patients by a novel epidermal growth factor receptor reverse transcrptionPCR assay.” CLINICAL CANCER RESEARCH, 6:1439-1444, 2000.
56. Castiglione F, Porcile G, Gridelli C. ”The role of amifostine in the treatment of nonsmall cell lung cancer.” LUNG CANCER, 29:57-66, 2000.
57. The Italian Group for Antiemetic Research. “Dexamethasone alone or in combination
with ondasetron for the prevention of delayed nausea and vomiting by
chemotherapy.” NEW ENGLAND JOURNAL OF MEDICINE, 342:1554-1559,
2000.
58. Gridelli C, Frontini L, Perrone F, Gallo C, Gulisano M, Cigolari S, Castiglione F,
Robbiati SF, Gasparini G, Ianniello GP, Farris A, Locatelli MC, Felletti R, Piazza E.
“Gemcitabine plus vinorelbine in advanced non-small cell lung cancer, a phase II
study of three different doses.” BRITISH JOURNAL OF CANCER, 83:707-714,
2000.
59. Gridelli C. “Chemotherapy of advanced non small cell lung cancer in the elderly: an
update.” CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 35:219-225,
2000.
60. Gridelli C, Frontini L, Barletta E, Rossi A, Barzelloni ML, Scognamiglio F, Guida C,
Gatani T, Fiore F, De Bellis M, Marfella A, Manzione L. “Single agent docetaxel
plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients
with advanced non small cell lung cancer. A phase II study and review of the
literature.” ANTICANCER RESEARCH, 20:1077-1084, 2000.
61. Gridelli C, Guida C, Barletta E, Gatani T, Fiore F, Barzelloni ML, Rossi A, de Bellis
M, D’Aniello R, Scognamiglio F. “Thoracic radiotherapy and daily vinorelbine as
radiosensitizer in locally advanced non small cell lung cancer: a phase I study.”
LUNG CANCER, 29:131-137, 2000.
62. Rinaldi M, Crinò L, Scagliotti G, Mosconi AM, De Marinis F, Gridelli C, Selvaggi
G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A, Bartolucci R, Calandri
101
C, Tonato M. “A three-week schedule of gemcitabine-cisplatin in advanced nonsmall cell lung cancer with two different cisplatin dose levels: a phase II randomized
trial.” ANNALS OF ONCOLOGY, 11:1295-300, 2000.
63. Gridelli C, Daniele B. “Originality, benefits and difficulties of clinical research
performed by cooperative groups: the experience of an Italian Lung Cancer Study
Group.” CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 36:3-8,
2000.
64. Illiano A, Barletta E, De Marino V, Battiloro C, Barzelloni ML, Scognamiglio F,
Rossi N, Zampa G, de Bellis M, Gridelli C. “New triplet chemotherapy combination
with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced
non small cell lung cancer: a phase II study.” ANTICANCER RESEARCH,
20:3999-40041, 2000.
65. Gridelli C, Perrone F, Gallo C. “Activity and toxcity of gemcitabine + vinorelbine in
advanced non-small-cell lung cancer elderly patients. Phase II data from the MILES
(Multicenter Italian Lung cancer in the Elderly Study) randomized trial.” LUNG
CANCER, 31:277-284, 2001.
66. Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi
A, E.Barletta, Barzelloni ML, Bilancia D, Gallo C. “Carboplatin plus paclitaxel in
extensive small cell lung cancer: a multicenter phase II study.” BRITISH
JOURNAL OF CANCER, 84:38-41, 2001.
67. Gridelli C. “The ELVIS trial: a phase III study of single-agent vinorelbine as firstline treatment in elderly patients with advanced non-small cell lung cancer.” THE
ONCOLOGIST, 6 (suppl 1):4-7, 2001.
68. Gridelli C, Maione P, Barletta E. “Introduction” in “New Perspectives in the
Treatment of Non-Small Cell Lung Cancer.” TUMORI, 86 (suppl 1):31-32, 2000.
69. Gridelli C, De Vivo R, Monfardini S. “Management of small cell lung cancer in the
elderly.” CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 41:79-88,
2002.
70. Daniele B, Rossi GB, Losito S, Gridelli C, de Bellis M. “Ischemic colitis associated
with paclitaxel”. J CLIN GASTROENTEROLOGY, 33:159-160, 2001.
71. Gridelli C, Cortesi E, Roila F. “Editorial” in “Survival and quality of life: comparing
end points in oncology”. ANNALS OF ONCOLOGY, 12 (suppl 3): S1, 2001.
72. Gridelli C, Perrone F, Nelli F, Ramponi S, De Marinis F. “Quality of life in lung
cancer patients.” ANNALS OF ONCOLOGY, 12 (suppl 3):S21-25, 2001.
73. Gridelli C, Di Maio M. “Indication for venous ports in oncology: comparino different
experiences in Europe.” TUMORI, 87:S69-S70, 2001.
74. Gridelli C, Curcio C, Iaffaioli RV, Brancaccio L, D’Aprile M, Gebbia V, Rossi A,
Tortoriello A, Veltri E, Maione P, Barbarisi A, Gallo C, Perrone F. “Carboplatin +
epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as
102
radiosensitizer in localized small cell lung cancer. A multicenter phase II study.”
ANTICANCER RESEARCH, 21:4179-4184, 2001.
75. Gridelli C. “Overview of major trias on the treatment of advanced non-small cell lung
cancer.” THERAPY PERSPECTIVES (ADIS INTERNATIONAL):3-7, 2001.
76. Gridelli C, De Vivo R. “Vinorelbine in the treatment of non small cell lung cancer.”
CURRENT MEDICINAL CHEMISTRY, 9:1867-1880, 2002.
77. Puozzo C, Gridelli C, Jaworski M. “Pharmacokinetics of navelbine oral in elderly
patients”. TUMORI, 88 (suppl 1):S75-S76, 2002.
78. Gridelli C, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Colantuoni G, Rossi A.
“Chemotherapy of advanced NSCLC in the elderly.” TUMORI, 88 (suppl 1):S143S144, 2002.
79. Gridelli C. “Focus on vinorelbine: Lung Cancer”. EXCERPTA MEDICA, 20-40,
2002.
80. Gridelli C, Maione P, Barletta E. “Individualized chemotherapy for elderly patients
with non small cell lung cancer.” CURRENT OPINION IN ONCOLOGY, 14:199203, 2002.
81. Gridelli C, Rossi A, Barletta E, Panza N, Brancaccio L, Cioffi R, Pedicini T,
Ianniello GP, Piazza E, Rossi N, Iaffaioli RV, Maione P, Di Maio M, Gallo C,
Perrone F. ”Carboplatin plus vinorelbine plus G-CSF in elderly patients with
estensive-stage small cell lung cancer: a poorly tolerated regimen.” LUNG
CANCER, 36:327-332,2002.
82. Perrone F, Gallo C, Gridelli C. “Re: Cisplatin-based therapy for elderly patients with
advanced non small cell lung cancer: implication of Eastern Cooperative Oncology
Group 5592, a randomized trial.” JOURNAL OF NATIONAL CANCER
INSTITUTE, 94:62-63, 2002.
83. Gridelli C, Maione P, Colantuoni C, Rossi A. “Chemotherapy of non small cell lung
cancer in elderly patients.” CURRENT MEDICINAL CHEMISTRY, 9:14871495, 2002.
84. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù
F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C,
Gasparini G, Daletta D, iaffaioli RV, Gebbia V. “Chemotherapy for elderly patients
with advanced non small cell lung cancer. The MILES (Multicenter Italian Lung
cancer in the Elderly Study) phase 3 randomized trial.” JOURNAL OF NATIONAL
CANCER INSTITUTE, 95:362-72, 2003.
85. Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N,
Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G. “Vinorelbine plus cisplatin
versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non small cell lung
cancer: a prospective randomized study.” LUNG CANCER, 37: 179-187, 2002.
103
86. Gridelli C, Maione P, Airoma G, Rossi A. “Selective cyclooxygenase-2 inhibitors
and non small cell lung cancer.” CURRENT MEDICINAL CHEMISTRY, 9:18511858, 2002..
87. Montella M, Gridelli C, Crispo A, Scognamiglio F, Ruffolo P, Gatani T, Boccia V,
Maione P, Fabbrocini G. “Has lung cancer in the elderly different characteristics at
presentation?” ONCOLOGY REPORTS, 9:1093-1096, 2002.
88. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E,
Barni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di
Costanzo F, Frontini L, Tonato M. “Phase III randomized trial comparino three
platinum doublets in advanced non small cell lung cancer.” JOURNAL OF
CLINICAL ONCOLOGY, 20:4285-4291 2002.
89. Gridelli C. “How to combine cytotoxic and cytostatic agents.” LUNG CANCER,
38:S39, 2002.
90. Gridelli C. “Quality of life in lung cancer patients.” QUALITY OF LIFE IN
ONCOLOGY, 5:7-9, 2002.
91. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G,
Gridelli C, Iaffaioli RV. “CD40 activations as potential tool in malignant neoplasms.”
TUMORI, 88:361-366, 2002.
92. Gridelli C. “Does chemotherapy have a role as palliative for unfit or elderly patients
with non small cell lung cancer?” LUNG CANCER, 38 (suppl):245-250, 2002.
93. Gridelli C. “Chemotherapy of non small cell lung cancer in the elderly.” LUNG
CANCER, 38:67-70, 2002.
94. Gridelli C, Cortesi E, Roila F. “Survival and quality of life: comparing end points in
oncology. Two years later.” TUMORI, 2:S3, 2003.
95. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G,
Gridelli C, Iaffaioli RV. “CD40 activation as potential tool in malignant neoplasms.”
TUMORI, 88:361-366, 2002.
96. Gridelli C, Hainsworth J. “Meeting the chemotherapy needs elderly and poor
performance status patients with NSCLC.” LUNG CANCER, 38 (suppl 1):37-41,
2002.
97. Ottaiano A, Barletta E, Maione P, Fiore F, Pisano C, Di Maio M, Iaffaioli RV,
Gridelli C. “Pancreatic involvement from heavily pretreated small cell lung cancer
successfully treated with transcatheter intra-arterial chemotherapy: a case report with
local and systemic disease control.” TUMORI, 88:535-537, 2002.
98. Akehurst RL, Beinert T, Crawford J, ……………, Gridelli C,……….”Consensus on
medical treatment of non-small cell lung cancer.“ LUNG CANCER, 38:S3-S7,
2002.
104
99. Colantuoni G, Rossi A, Ferrara C, Nicolella D, Del Gaizo F, Guerriero C, Airoma G,
Barzelloni ML, Maione P, Salerno V, Gridelli C. “Chemotherapy in elderly patients
with advanced breast cancer.” CANCER THERAPY, 1:71-79, 2003.
100. Gridelli C, Rossi A, Guerriero C, Ferrara C, Del Gaizo F, Colantuoni G, Salerno
V, Nicolella D. “Carcinoma polmonare non a piccole cellule stadio IIIA, cosa fare?
Pro.” TUMORI, 2 (suppl) :S103-S105, 2003.
101. Rossi E, Perrone F, Labonia V, Landi G, Nuzzo F, Amabile G, Gridelli C, Di
Maio M, D’Aiuto G, De Matteis A. “Is gemcitabine plus vinorelbine active in second
line chemotherapy of metastatic breast cancer? A single center phase II study.”
ONCOLOGY, 64:479-480, 2003.
102. Gridelli C. “Multicednter Italian Lung Cancer in the Elderly Study: phase III
randomized trial.” ALC – ADVANCES IN LUNG CANCER, 5:11-14, 2003.
103. Rossi A, Gridelli C, Gebbia V, Rosati G, Tortoriello A, Maione P, Borsellino N,
Rossi N, Pisano A, Colantuoni G, Iaffaioli RV, Castaldo V, Manzione L. “Single
agent vinorelbine as first line chemotherapy in elderly patients with advanced breast
cancer.” ANTICANCER RESEARCH, 23:1657-1664, 2003.
104. Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Cigolari S, Gridelli C.
“Supportive care in patients with advanced non small cell lung cancer.” BRITISH
JOURNAL OF CANCER, 89:1013-1021, 2003.
105. Gridelli C, Gallo C. Shepherd F, Illiano A, Piantedosi FV, Robbiati SF, Manzione
L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP,
Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F.
“Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin
plus gemcitabine for advanced non small cell lung cancer: a phase III trial of the
Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical
Trial Group.” JOURNAL OF CLINICAL ONCOLOGY, 21:3025-34, 2003.
106. Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni
M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F. “Prolonged
gemcitabine infusion in advanced non small cell lung carcinoma randomized phase II
study of two different schedules in combination with cisplatin.” CANCER, 98:337343, 2003.
107. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo T, Calandri
C, Bartolini S, Santoro A, Crinò L. “Epidermal growth factor receptor targated
therapy by ZD 1839 (Iressa) in patients with brain metastases from non small cell
lung cancer (NSCLC).” LUNG CANCER, 41:227-231, 2003.
108. Gridelli C. “5-HT3 receptor antagonists in the control of delayed onset emesis.”
ANTICANCER RESEARCH, 23:2773-2782, 2003.
109. Nicolella D, Maione P, Gridelli C. “Targeted therapies: focus on a new strategy
for gastrointestinal tumours.” CRITICAL REVIEW IN ONCOLOGY /
HEMATOLOGY, 47:261-271, 2003.
105
110. Gridelli C, Rossi A, Maione P. “Treatment of non small cell lung cancer: state of
the art and development of new biologic agents.” ONCOGENE, 22:6629-6638,
2003.
111. De Marinis F, Nelli F, Migliorino MR, Martelli O, Cortesi E, Treggiari S,
Portalone L, Crispino C, Brancaccio L, Gridelli C. “Gemcitabine, paclitaxel, and
cisplatin as induction chemotherapy for patientswith biopsy-proven stage IIIA(N2)
non small cell lung carcinoma. A phase II multicenter study.” CANCER, 98:170715, 2003.
112. Gridelli C, Maione P, Rossi A. “Corticosteroids underemployment in delayed
chemotherapy induced nausea and emesis with poor adherence to American Society
of Clincal Oncology Guidelines: is this a reasonable clinical choice for the elderly?”
JOURNAL OF CLINICAL ONCOLOGY, 21:4066-4067, 2003.
113. Gridelli C, Maione P, Castaldo V, Rossi A. “Gefinitib in elderly and unfit patients
affected by advanced non small cell lung cancer.” BRITISH JOURNAL OF
CANCER, 89:1827-9, 2003.
114. Gridelli C. “5-HT3 reeptor antagonists: should we be treating elderly cancer
patients differently.” CANCER TODAY, suppl:3-15, 2003.
115. Stahel R, Rossi A, Petruzelka L, Kosmidis P, de Braud F, Bernerdo MM, Souquet
P-J, Soto Parra H, Gridelli C. “Lessons from the Iressa expanded access programme:
gefitinib in special non small cell lung cancer patient populations.” BRITISH
JOURNAL OF CANCER, 89 (suppl 2):19-23, 2003.
116. Gridelli C. “Elderly patient: definition and therapeutic approaches.” REV
PNEUMOL CLIN, 59:53-55, 2003.
117. Puozzo C, Gridelli C. “Non small cell lung cancer in elderly patients: influence of
age on vinorelbine oral pharmacokinetics.” CLINICAL LUNG CANCER, 5:23742, 2004.
118. Gridelli C, Ardizzoni A., Le Chavalier T., Manegold C., Perrone F, Thatcher N,
van Zandwijk N, Di Maio M, Martelli O, De Marinis F. “Treatment of advanced non
small cell lung cancer patients with ECPG performance status 2: results of an
European Experts Panel.” ANNALS OF ONCOLOGY, 15:419-426, 2004.
119. Gridelli C, Aapro M. “Factors influencing the choice of 5-HT(3) receptor
antagonist antiemetics: focus on elderly cancer patients.” SUPPORTIVE CARE
CANCER, 12:487-496, 2004.
120. Gridelli C, Maione P, Rossi A, Colantuoni G, Barzelloni ML, Salerno V, Airoma
G. “Management of non small cell lung cancer in elderly patients.” EUROPEAN
JOURNAL OF CANCER, 4 (suppl 2):15-25, 2004.
121. Rossi A, Colantuoni G, Cantore N, Panico L, De Chiara G, Ferbo U, Gridelli C.
“Complete response of severe symptomatic bone marrow metastases from heavily
106
pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case.”
ANTICANCER RESEARCH, 24:317-320, 2004.
122. Gridelli C. “Targeted therapies in the treatment of non small cell lung cancer:
realtà and hopes.” CURRENT OPINION IN ONCOLOGY, 16:126-129, 2004.
123. Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera Robbiati SF,
Ianniello GP, Ferrau F, Piazza E, Frontini L, Rosetti F, Carozza F, Bearz A,
Spatafora M, Adamo V, Isa L, Iaffaioli RV, Di Savo E, Perrone F. “Prevalence and
management of pain in Italian patientswith advanced non small cell lung cancer.”
BRITISH JOURNAL OF CANCER, 90:2288-2296, 2004.
124. Rossi A, Maione P, Colantuoni G, Guerriero C, Gridelli C. “The role of new
targeted therapies in smal cell lung cancer.” CRITICAL REVIEW IN
ONCOLOGY/HEMATOLOGY, 51:45-53, 2004.
125. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C. “The role of
targeted therapy in non small cell lung cancer.” CRITICAL REVIEW IN
ONCOLOGY/HEMATOLOGY, 51:29-44, 2004.
126. Gridelli C. “Targeted therapies in cancer treatment.” HOSPITAL PHARMACY
EUROPE, 69-70, 2004.
127. Gridelli C, Rossi A, Maione P, Guerriero C, Airoma A, Colantuoni G, Barzelloni
ML. “Gefitinib as salvage therapy in pre-treated patients with advanced non small
cell lung cancer. Dta from acompassionate use program.” ANTICANCER
RESEARCH, 24:1873-1877, 2004.
128. Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F.
“Potential role of molecularly targeted therapy in the management of advanced non
small cell lung carcinoma in the elderly.” CANCER, 101:1733-1744,2004.
129. Gridelli C. “Same old story? Do we need to modify our supportive care treatment
of elderly cancer patients? Focus on antiemetics.” DRUGS AGING, 21:825-832,
2004.
130. Gridelli C, Manegold C, Mali P, Reck M, Portalone L, Castelnau O, Betticher D,
Pless M, Pons JT, Aubert D, Burillon JP, Parlier Y, De Marinis F. “Oral Vinorelbine
given as monotherapy to advanced elderly patients: a multicenter phase II trial”.
EUROPEAN JOURNAL OF CANCER, 40:2424-31, 2004.
131. De Luca A, Grassi M, Macello MR, Di Maio M, Mancino M, De Maio E, Gridelli
C, Perrone F, Normanno N. “Does the sequenze of gemcitabine and vinorelbine
affect their activity in non-small cell lung cancer in vitro?” ANTICANCER
RESEARCH, 24:2985-9, 2004.
132. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvo S,
Piantedosi FV, Palazzolo G, Caffo O, Cerebelli A, Falcone A, Mazzeo P, Brancaccio
L, Captano MA, Iisa L, Barbera S, Perrone F. “A randomised clinical trial of two
107
docetaxel regimens in the second-line treatment of non small cell lung cancer. The
DISTAL 01 study.” BRITISH JOURNAL OF CANCER, 91:1996-2004, 2004.
133. Perrone F, Di Maio M, Gallo C, Gridelli C. “Outcome of patients with a
performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study
(MILES).” JOURNAL OF CLINICAL ONCOLOGY, 22:5018-20, 2004.
134. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P,
Rudd RM, Vansteenkiste J, Thatcher N, Mmanegold C, Puj van Zandwijk N, Gridelli
C, van Meerbeeck JP, Crinò L, Brown A, Fitzgerald P, Aristides M, Schiller JH.
“Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum
containing regimens in advanced non small cell lung cancer: a meta-analysis of
survival outcomes.” LUNG CANCER, 47:69-80, 2004.
135. De Marinis F, Nelli F, Lombardo M, Ferraù F, Barbera S, Bertetto C, Barni S,
Michetti G, Labianca R, Gridelli C. “A multicenter, randomized phase II study of
cisplatin etoposide and gemcitabine or cisplatin plus gemcitabine as first-line
treatment in patients with poor-prognosis small cell lung carcinoma.” CANCER,
103:772-779, 2005
136. Rossi A, Maione P, Gaizo FD, Guerriero C, Castaldo V, Gridelli C. “Safety
profile of gefitinib in advanced non small cell lung cancer in elderly patients with
chronic failure: two clinical cases.” LUNG CANCER, 47:421-3, 2005.
137. Rossi A, Colantuoni G, Maione P, Ferrara C, Aroma G, Balzelloni ML, Castaldo
V, Gridelli C. “Chemotherapy of breast cancer in the elderly.” CURRENT
MEDICINAL CHEMISTRY, 12:297-310, 2005.
138. Gridelli C, Maione P, Rossi A, Ciardiello F, Raben D. “Treatment of locally
advanced non small cell lung cancer in the elderly.” CURRENT OPINION IN
ONCOLOGY, 17:130-134, 2005.
139. Gridelli C, Rossi A, Maione P. “Treatment of non small cell lung cancer targeted
therapies: where are we?” CURRENT OPINION IN ONCOLOGY, 17:114-117,
2005.
140. Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le
Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Pretis L, Di Maio M,
Langer C. “Treatment of advanced non small cell lung cancer in the elderly: results
of an international expert panel.” JOURNAL OF CLINICAL ONCOLOGY,
23:3125-3137, 2005.
141. Gridelli C, Maione P, Rossi A, Di Maio M, Perrone F. “Chemotherapy of stage I
to III Non-Small Cell Lung Cancer in the Elderly Patients”. AMERICAN
SOCIETY OF CLINICAL ONCOLOGY, EDUCATIONAL BOOK 41ST
ANNUAL MEETING 13-17 MAY 2005.
142. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. “Trying to
compose the puzzle with all pieces: Epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer.” J CELL PHYSIOL, 13 (MAY), 2005.
108
143. Gridelli C, Rossi A, Galetta D, Maione P, Ferrara C, Guerriero C, Del Gaizo F,
Nicolella D, Colantuoni G, Gebbia V, Colucci G. “Italian clinical research in non
small cell lung cancer.” ANNALS OF ONCOLOGY, 16:110-115, 2005.
144. Rossi A, Maione P, Colantuoni G, Guerriero C, Ferrara C, Del Gaizo F, Nicolella
D, Gridelli C. “Treatment of small cell lung cancer in the elderly.” THE
ONCOLOGIST, 10:399-411, 2005.
145. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S,
Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP,
Veltri E, Castiglione F, Rosetti F, gebbia V, Seymour L, Chiodini P, Perrone F.
“Chemotherapy-induced neutropenia and treatment efficacy in advanced non small
cell lung cancer: a pooled analysis of three randomised trials.” LANCET
ONCOLOGY, 6:669-677, 2005.
146. Gridelli C, Shepherd FA. “Chemotherapy for elderly patients with non small lung
cancer: a review of the evidence.” CHEST, 128:947-57, 2005.
147. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi FV, Barbera S, Cigolari S,
Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A,
Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. “Pretreatment
quality of life and functional status assessment significantly predict survival of
elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a
prognostic analysis of the multicenter italian lung cancer in the elderly study.”
JOURNAL OF CLINICAL ONCOLOGY, 23:6865-6872, 2005.
148. Normanno N, De Luca A, Macello MR, Gridelli C. “Modulation of epidermal
growth factor receptor positive circulating tumor cells by chemotherapy in non small
cell lung cancer patients.” JOURNAL OF CLINICAL ONCOLOGY, 23:7746-8,
2005.
149. Aapro MS, Macciocchi A, Gridelli C. “Palonosetron improves prevention of
chemotherapy induced nausea and vomitino in elderly patients.” JOURNAL OF
SUPPORTIVE ONCOLOGY, 3:369-74, 2005.
150. Rossi A, Manto A, Maione P, Gridelli C. “Synochronous bilateral metastases
from adenocarcinoma.” TUMORI, 91:287-9, 2005.
151. Zielinski CC, Krainer M, Pirker R, Tomek S, Zochbauer-Muller S, Beinert T,
Crawford J, Fischer JR, Georgoulias V, Gridelli C, Hirsch F, Jassem J, Herold CH,
Kosmidis P, Krzakowski M, Manegold CH, Pujol JL, Thatcher N, Zandwick N,
Zwitter M. “Meeting report – Consensus on medical treatment of non small cell lung
cancer – update 2004.” LUNG CANCER, 50:129-137, 2005.
152. Rossi A, Maione P, Gridelli C. “Safety profile of platinum-based chemotherapy
in the treatment of advanced non-small cell lung cancer in elderly patients.”
EXPERT OPINION ON DRUG SAFETY, 4:1051-67, 2005.
109
153. Rossi A , Maione P , Colantuoni G , Del Gaizo F , Guerriero C , Nicolella D ,
Ferrara C , Gridelli C. “ Screening for lung cancer: new horizons?” CRITICAL
REVIEW IN ONCOLOGY/HEMATOLOGY, 56:311-320, 2005.
154. Di Maio M, Gridelli C, Gallo C, Perrone F. “Chemotherapy-induced neutropenia:
a useful predictor of treatment efficacy?” NATURE CLINICAL PRACTICE,
3:114-115, 2006.
155. Maione P, Gridelli C , Troiani T, Ciardiello F. ”Combining targeted therapies and
drugs with multiple targets in the treatment of NSCLC.” THE ONCOLOGIST,
11:274-284, 2006.
156. Gridelli C, Maione P, Rossi A, Ferrara C, Colantuoni G, Del Gaizo F, Nicolella
D, Guerriero C. “Targeted therapies in the treatment of advanced non small cell lung
cancer elderly patients.” TARGETED ONCOLOGY, 1:13-22, 2006.
157. Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Nicolella D, Guerriero C,
Colantuoni G. “Erlotinib in previously treated advanced non small cell lung cancer
elderly patient: a clinical case.” TARGETED ONCOLOGY , 1:56-58, 2006.
158. De Pretis L, Crinò L, Scagliotti GV, Gridelli C, Galetta D, Metro G, Novello S,
Maione P, Colucci G, de Marinis F. “Treatment of advanced non small cell lung
cancer.” ANNALS OF ONCOLOGY , 17 (suppl 2):36-41, 2006.
159. Rossi A, Gridelli C. “Chemotherapy of advanced non small cell lung cancer in
elderly patients.” ANNALS OF ONCOLOGY, 17 (suppl 2):58-60, 2006.
160. Gridelli C, Maione P, Rossi A. “Treatment of stage I-III non small cell lung
cancer in the elderly.” ONCOLOGY, 20:373-380, 2006.
161. Ciardiello F, Troiani T, Caputo F, De Laurentis M, Tortora G, Palmieri G, De
Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido
S, Bianco AR. “Phase II study of gefitinib in combination with docetaxel as first-line
therapy in metastatic breast cancer.” BRITISH JOURNAL OF CANCER, 94:16041609, 2006.
162. Gridelli C. “Antiemetic therapy in older cancer patients.” AGING HEALTH,
2:449-459, 2006.
163. Rossi A, Maione P, Gridelli C. “Cetuximab in advanced non small cell lung
cancer”. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 59:139-149,
2006.
164. Rinaldi M, Cauchi C, Gridelli C. “First-line chemotherapy in advanced or
metastatic non small cell lung cancer”. ANNALS OF ONCOLOGY, 17 (Suppl
5):v64-v67, 2006.
165. Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del Gaizo F, Colantuoni
G, Nicolella D, Napolitano L. “Chemotherapy of advanced non small cell lung cancer
110
in special patient population”. ANNALS OF ONCOLOGY, 17 (Suppl 5):v72-v78,
2006.
166. Gridelli C, Rossi A, Maione P. “New antiangiogenetic agents and non small cell
lung cancer”. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 60:7686, 2006.
167. Gridelli C. “Targeted therapy and non small cell lung cancer: work in progress?”.
CURRENT OPINION IN ONCOLOGY, 18:132-134, 2006.
168. Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. “ Antiangiogenic
drugs in non small cell lung cancer treatment “. CURRENT OPINION IN
ONCOLOGY, 18:152-155, 2006.
169. Gridelli C, Maione P, Comunale D, Rossi A. “Adjuvant chemotherapy in elderly
patients with non small cell lung cancer”. CANCER CONTROL, 14:57-62, 2007.
170. Gridelli C.
“The use of biphosphonate in elderly cancer patients”
ONCOLOGIST, 12:62-71, 2007.
171. Gridelli C. “Targeted therapies and non small cell lung cancer:new
developments”. CURRENT OPINION IN ONCOLOGY, 19:75-77, 2007.
172. Cascone T, GridelliC, Ciardiello F. “Combined targeted therapies in non small
cell lung cancer: a winner strategy?”. CURRENT OPINION IN ONCOLOGY,
19:98-102, 63:53-64, 2007.
173. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C,
Nicolella D, Comunale D, De Vita A, Rossi A. “ Sorafenib and sunitinib in the
treatment of advanced non small cell lung cancer” . ONCOLOGIST, 12:191-200,
2007.
174. Gridelli C, Kankel E, Gregor V, Migliorino R, Muller T, Manegold C, Favaretto
A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Munoz M, Reck
M. “Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line
treatment of advanced non small cell lung cancer in elderly patients or patients
inelegible for platinum-based chemotherapy:a multicenter, randomised, phase II
trial”. JOURNAL OF THORACIC ONCOLOGY, 2:221-229, 2007.
175. Gridelli C, Maione P, Galetta D, Rossi A. “Safety profile of erlotinib in patients
with advanced non small cell lung cancer with chronic renal failure.” JOURNAL OF
THORACIC ONCOLOGY, 2:96-98, 2007.
176. Gridelli C. “Does palliative chemotherapy beyond three courses benefit patients
with non small cell lung cancer?”. NATURE CLINICAL PRACTICE
ONCOLOGY, 4:274-275, 2007.
177. Gridelli C, Aapro M, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L,
Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F. “Role of colony
stimulating factors (CSFs) in solid tumors: results of an experts panel”. CRITICAL
REVIEW IN ONCOLOGY/HEMATOLOGY, 2007.
111
178. Rossi A, Maione P, Colantuoni G, Ferrara C, De Vita A, Guerriero C, Nicolella
D, Del Gaizo F, Gridelli C. “The role of chemotherapy in the treatment of advanced
non small cell lung cancer elderly patients”. CANCER THERAPY, 5:77-88, 2007.
179. Di Maio M, Perone F, Chiodini P, Gallo C, Camps C, Schuttle W, Quoix E, Tsai
CM, Gridelli C. “Individual data meta-analysis of docetaxel administered once every
3 weeks compared with once every week second-line treatment of advanced non
small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 25:1377-1382,
2007.
180. Gridelli C, Maione P, Rossi A.” Single agent chemotherapy for the treatment of
elderly patients with advanced non small cell lung cancer: what is the best drug?
JOURNAL OF CLINICAL ONCOLOGY, 25:1444-1445, 2007.
181. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta
E, Cortinovis D, Barbieri F, Gebbia V, Grossi F, Novello S, Baldini E, Gasperini G,
Latino W, Durante E, Giustini L, Negrini C. “Informal caregiver burden in advanced
non small cell lung cancer: the HABIT study”. JOURNAL OF THORACIC
ONCOLOGY, 2:475-480, 2007.
182. Gridelli C, Langer C, Maione P, Rossi A, Schild S. “Lung cancer in the elderly”.
JOURNAL OF CLINICAL ONCOLOGY, 25:1898-1907, 2007.
183. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carrozza F,
Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti
F, Testa A, Di Maio M, Perrone F on the behalf of the GECO Investigators.
.”Factorial phase III randomised trial of rofecoxib and prolonged costant infusion of
gemcitabine in advanced NSCLC: the GEmcitabine ad COxib in NSCLC (GECO)
study”. LANCET ONCOLOGY, 8:500-512, 2007.
184. Gridelli C, Rossi A, Mongillo F, BareschinoM, Maione P,Ciardiello.
“A randomised phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for
advanced non small cell lung cancer in elderly patients or patients with Performance
Status
of
2:
treatment
rationale
and
protocol
dynamics.
CLINICAL LUNG CANCER, 8:396-398, 2007.
185. Gridelli C, Maione P, Galetta D, Colantuoni G, Del gaizo F, Ferrara C, Guerriero
C, Nicolella D, Rossi A. “Brief report: three cases of lasting-tumor control with
erlotinib after progression with gefitinib in advanced non small cell lung
cancer”.JOURNAL OF THORACIC ONCOLOGY, 2:758-761, 2007.
186. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F.
“Erlotinib in non small cell lung cancer treatment: current status and future
development”. ONCOLOGIST, 12:840-849, 2007.
187. Ceresoli GL, Gridelli C, Santoro A.”Multidisciplinary treatment of malignant
pleural mesothelioma”. ONCOLOGIST, 12: 850-863 ,2007.
112
188. Gridelli C, Maione P, Iliano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati
SF, Filipazzi V, Lo Russo V,Carozza F, Iaffaioli RV, Manzione L, Gallo C,
Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients
with advanced non small cell lung cancer: the MILES phase II study. JOURNAL OF
CLINICAL ONCOLOGY, 10:4663-4669, 2007.
189. Gridelli C, Rossi A, Maione P, Colantuoni G, Del Gaizo F, Ferrara C, Nicolella
D, Guerriero C. “ Erlotinib in non small cell lung cancer”. EXPERT OPINION ON
PHARMACOTHERAPY, 8:2579-2592, 2007.
190. Gridelli C. Editorial. Elderly lung cancer patients: what treatment strategy?.
EXPERT REVIEW IN ANTICANCER THERAPY, 7:1331-1334, 2007.
191. Gridelli C, Maione P, Rossi A, De Marinis F. The Role of Bevacizumab in the
Treatment of Non-Small Cell Lung Cancer: Current Indications and Future
Developments. ONCOLOGIST, 12:1183-1193, 2007.
192. Rossi A, Maione P, Ferrera C, Del Gaizo F, Guerrriero C, Nicolella D, Palazzolo
G, Falanga M, Colantuoni G, Gridelli C. New angiogenic agents and non small cell
lung cancer: current results and future development. TARGETED ONCOLOGY,
2:211-223, 2007.
193. Schettino C, Baraschino M, Maione P, Rossi A, Ciardiello F. Gridelli C. Small
molecule Epidermal Growth Factor Receptors (EGFR) Tyrosine Kinase Inhibitors in
non small cell lung cancer treatment. CURRENT CANCER THERAPY REVIEW,
3:226-235, 2007.
194. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi
E, De Marinis F, Di Pietro FA; Grossi F, Innocenzi D, Micali G Piantedosi FV,
Scarrozzi M. Clinical significance and treatment of skin rash from erlotinib in non
small cell lung cancer patients: results of an Experts Panel Meeting. CRITICAL
REVIEW IN ONCOLOGY/HEMATOLOGY, 66:155-162,2008.
195. Gridelli C, Rossi A, Morvillo F, Baraschino M, Maione P, Di Maio M, Ciardiello
F. A randomised phase II trial of pemetrexed or RAD001 as second-line treatment of
advanced non small cell lung cancer in elderly patients:treatment rationale and
prtocol dynamics. CLIN LUNG CANCER, 8:568-571,2007.
196. Gridelli C, Maione P, Palazzolo G, Rossi A. New targeted therapies and SCLC.
CURRENT MEDICAL LITERATURE LUNG CANCER, 1:37-44, 2007.
197. Gridelli C. Editorial. Treatment of advanced non small cell lung cancer in the
elderly: from best supportive care to the combination of platin-based chemotherapy
and targeted therapies. JOURNAL OF CLINICAL ONCOLOGY. 26:13 -16 ,
2008.
198. Rossi A, Bria E, Gridelli C. Thalidomide in small cell lung cancer: is it a
tombstone? JOURNAL OF CLINICAL ONCOLOGY, 26:160,2008.
113
199. Perrone F, Gallo C, Ciardiello F, Gridelli C. TKIs before chemotherapy in
advanced NSCLC. ANNALS OF ONCOLOGY, 564vi-564,2007.
200. Monfardini S, Gridelli C, Pasetto LM, Soubeyran P, Droz JP, Basso U.
Vulnerable and frail elderly: an approach to the management of the main tumor types.
EUROPEAN JOURNAL OF CANCER, 44:488-493, 2008.
201. Grossi F, Gridelli C, Aita M, De Marinis F. Identifying an optimum tratment
strategy for patients with advanced non small cell lung cancer. CRITICAL
REVIEW IN ONCOLOGY HEMATOLOGY, 67:16-26, 2008.
202. Gridelli C. Targeted therapy developments in the treatment of non small cell lung
cancer: a promising but long and winding road. CURRENT OPINION IN
ONCOLOGY, 20:145-147, 2008.
203. Gridelli C, Maione P, Rossi A. The potential role of m-TOR inhibitors in non
small cell lung cancer. ONCOLOGIST, 13:139-147, 2008.
204. Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach J, Perrone F, Rosell R,
Shepherd F, Thatcher N, Vansteenkiste J, De Pretis L, Di Maio M, De Marinis F.
Second-line treatment of advanced non small cell lung cancer.
JOURNAL OF THORACIC ONCOLOGY, 3:430-440, 2008.
205. Rossi A, Torri V, Gridelli C. “Paclitaxel plus bevacizumab for metastatic breast
cancer”. NEW ENGLAND JOURNAL OF MEDICINE, 358:1637-1638, 2008.
206. Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Gueriero C, Nicolella D,
Palazzolo G, Falanga M, Colantuoni G. New insights in drug development for non
small cell lung cancer therapy.
.
FRONTIERS IN BIOSCIENCE, 13:5108-5119, 2008.
207. Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C, Ciardiello F.
Sequenze-dependent,synergistic antiproliferative and proapoptotic effects of the
combination of cytotoxic drugs and enzastaurin,a protein kinase Cbeta inhibitor,
in
non
small
cell
lung
cancer.
MOLECULAR CANCER THERAPEUTIC, 7:1698-1707, 2008.
208.
Gridelli C. Perspective in lung cancer. TUMORI, 7 (suppl) 41-58, 2008.
209. Guida C, Maione P, Rossi C, Bareschino M, Schettino C, Barzaghi D, Elmo M,
Gridelli C. “Combined chemo-radiotherapy for locally advanced non small cell lung
cancer:
current
status
and
future
developments.
CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 68:222-232, 2008.
210. Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T,
Mancuso G, Di Maio M, Galo C, Perrone F, Morabito A. “Weekly docetaxel vs
docetaxel-based combination chemotherapy as second-line treatment of advanced
non small cell lung cancer patients. LUNG CANCER, 63:251-258, 2008.
114
211. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Olivera AC,
santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten
TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Gianniris T, Shan M, Moscovici M,
Voliotis D, Bruix J; SHARP Investigators Study Group….Gridelli C…. “Sorafenib in
advanced hepatocellular carcinoma”. NEW ENGLAND JOURNAL OF
MEDICINE, 359:378-390, 2008.
212. Rossi A, Bria E, Maione P, Palazzolo G, Falanga M, Gridelli C. “The role of
cetuximab and other epidermal growth factor receptor monoclonal antibodie in the
treatment of advanced non small cell lung cancer. REVIEW RECENT CLINICAL
TRIALS. 3:217-227, 2008.
213. Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. “An International,
multicenter , randomized phase III study of first-line erlotinib followed by secondline cisplatin/gemcitabine versus first-line cisplatin-gemcitabine followed by secondline erlotinib in advanced non small cell lung cancer: treatment rationale and protocol
dynamics of the TORCH trial”. CLINICAL LUNG CANCER,9:235-238, 2008.
214. NSCLC Meta-analyses Collaborative Group …..(Gridelli C). “Chemotherapy in
addition to supportive care improves survival in advanced non small cel lung cancer:
a systematic review and meta-analysis of individual-patient data from 16 randomized
controlled trials.” JOURNAL OF CLINICAL ONCOLOGY,26:1-9, 2008.
215. Grossi F, De Marinis F, Frontini L, Gridelli C. “ The dilemma of first-line
chemotherapy in advanced non small cell lung cancer : are third-generation drugs all
the same?”. TUMORI, 94:5-14, 2008.
216. Bareschino M, Schettino C, Maione P, Rossi A, Nicolella D, Ciardiello F,
Gridelli C. “The role of panitumumab in metastatic colorectal cancer”.
CANCER THERAPY, 6:477-490, 2008.
217. Gridelli C, Rossi A, Maione P. Challanges treating older non small cell lung
cancer patients”. ANNALS OF ONCOLOGY, 19 (suppl 7): vii109-vvi113, 2008.
218. Tiseo M, Gridelli C, Cascinu S, crinò L, Piantedosi FV, Grossi F, Brandes AA,
Labianca R, Siena R, Amoroso D, belvedere O, Valentino B, Bearz A, Venturino P,
Ardizzoni A. An expanded access program of erlotinib (Tarceva) in patients with
advanced non small cell lung cancer (NSCLC). Data report from Italy.
LUNG CANCER, 2:199-206, 2009.
219.
Rossi A, Maione P, Palazzolo G, Sacco PC, Ferrara M, Falanga M, Gridelli C.
“New targeted therapies and non small cell lung cancer”.
CLINICAL LUNG CANCER, 9:271-279, 2008.
220. Gridelli C. Treatment of patients with advanced non small cell lung cancer and
PS of 2: un unsolved issue.
CLIN LUNG CANCER, 9:324-325, 2008.
221. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors
in the treatment of non small cell lung cancer.
115
CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 68:29-36, 2008.
222. Gridelli C, De Maio E, Barbera S, Sannicolò M, Piazza E, Piantedosi FV,
Brancaccio L, Morabito A, Maione P, Renda F, Signoriello G, Perrone F.The Miles2G phase II study of single agent gemcitabine with prolonged constant infusion for
advanced NSCLC elderly patients.
LUNG CANCER, 61:67-72,2008.
223. Gridelli C, Maione P, Rossi A, Falanga M, Bareschino M, Schettino C,
Colantuoni G, Guerriero C, Nicolella D, Rossi E, Ferrara ML, Palazzolo G. “New
avenues for second-line treatment of metastatic non small cell lung cancer”.
EXPERT REVIEW ANTICANCER THERAPY, 9:115-124. 2009.
224. Gridelli C, Maione P, Rossi A, Ferara ML, Bareschino M, Schettino C,Sacco
PC, Ciardiello F. “Potential treatment options after first-line chemotherapy for
advanced
NSCLC:
maintenance
treatmentor
early
second-line?”.
ONCOLOGIST, 14:137-147, 2009.
225. Gridelli C. “Histology-based treatment: a new era in the management of advanced
non small cell lung cancer. CURRENT OPINION IN ONCOLOGY, 21:97-98,
2009.
226. Bevilacqua S, Gallo M, Franco R, Rossi A, De Luca A, Rocco G, Botti G,
Gridelli C, Normanno N. “A live biopsy in a small cell lung cancer patient by
detection of circulating tumor cells”. LUNG CANCER , 65:123-125, 2009.
227. Di Maio M, Chiodini P, Georgouilas V, Hatzidaki D. Wachter FM, Gebbia V,
Smit EF, Morabito A, Gallo C; Perrone F, Gridelli C. “Meta-analysis of single agent
chemotherapy compared with combination chemotherapy as second-line treatment of
advanced non small cell lung cancer”.
JOURNAL OF CLINICAL ONCOLOGY, 27:1836-1843, 2009.
228. Maione P, Rossi A, Di Maio M, Gridelli C. “Tumor-related leucocytosis and
chemotherapy-induced neutropenia : linked or indipendent prognostivc factors for
advanced non small cell lung cancer”.
LUNG CANCER, 66:8-14, 2009.
229. Gridelli C, Rossi A, Maione P. Chemotherapy and targeted therapy for older
patients with advanced non small cell lung cancer.
AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2009 EDUCATIONAL
BOOK, 283-287, 2009.
230. Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F, Gridelli C. The
potential role of pharmacogenomic and genomic in the adjuvant treatment of early
stage non small cell lung cancer.
CURRENT GENOMICS, 9:252-262, 2009.
231. Gridelli C, Maione P, Rossi A, Palazzolo G, Colantuoni, Rossi E.Management of
unfit older patients with advanced non small cell lung cancer.
CANCER TREATMENT REVIEW, 35.517-521, 2009.
116
232. Gridelli C, Maione P, Ferrara M, Rossi A. Cetuximab and other anti-epidrmal
growth factors receptor monoclonal antibodies in the treatment of non small cell lung
cancer. ONCOLOGIST, 14:601-611, 2009.
233. Gridelli C, Rossi A,Maione P, Rossi E, Castaldo V, Sacco PC, Colantuoni G.
Vascular disrupting agents: a novel mechanism of action in the battle against non
small cell lung cancer. ONCOLOGIST, 14:612-620, 2009.
234. Gridelli C, Rossi A, de Marinis F.
Pattern of care for advanced non-small cell lung cancer in the era of histology-based
treatment: A survey of the Italian Association of Thoracic Oncology (AIOT).
LUNG CANCER,68:319-331, 2009.
235. Schettino C, Bareschino MA, Rossi A, Maione P, Castaldo V, Mazzeo N, Sacco
PC, Ferrara LM, Palazzolo G, Ciardiello F, Gridelli C. The potential role of
bevacizumab in early stages and locally advanced non small cell lung cancer.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2009.
236. Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D,
Falanga M, Palazzolo G, Gridelli C. Recent developement of targeted terapies in the
treatment of non small cell lung cancer.
CURRENT DRUG DISCOVERY TECHNOLOGY, 6:91-102, 2009.
237. Gridelli C. Histology-based treatment: a new scenario in the management of
advanced non small cell lung cancer.
CURRENT OPINION IN ONCOLOGY,21:97-98, 2009.
238. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the
treatment of advanced non-squamous lung cancer.
LUNG CANCER, 66:141-149, 2009.
239. Pallis AG, Serfass L,Dziadziusko Rm van Meerbeeck JP, Fennel D, Lacombe D,
Welch J, Gridelli C. Targeted therapies in the treatment of advanced/metastatic
NSCLC. EUROPEAN JOURNAL OF CANCER, 45:2473-2487, 2009.
240. Gridelli C, Maione P, Rossi A, Ferrara ML, Bareschino M, Schettino C, Sacco
PC, Ciardiello F. Potential treatment option after first-line chemotherapy for
advanced NSCLC: maintenance treatment or early second-line?
ONCOLOGIST, 14:137-147, 2009.
241. Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C. Second and third line
treatment in non small cell lung cancer.
CRITICAL REVIEW IN ONCOLOGY HEMATOLOGY, 2:117.126, 2009.
242. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, Sacco PC.Vaccines for
the treatment of non small cell lung cancer: a renewed anticancer strategy.
ONCOLOGIST, 14:909-920, 2009.
243. Rossi A, Maione P, Ferrara ML, Sacco PC, Schettino C, Bareschino M, Gridelli
C. Angiogenesis inhibitors and vascular disrupting agents in non small cell lung
117
cancer.
CURRENT MEDICAL CHEMISTRY, 16:3019-3030, 2009.
244. Gridelli C, Maione P, Rossi A, Ferrara M, Castaldo V, Palazzolo G, Mazzeo N.
Treatment in advanced non small cell lung cancer in the elderly.
LUNG CANCER, 66: 282-286, 2009.
245. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao
YD,Liepa AM, Peterson P, Tonato M. The role of histology with common first-line
regimens for advanced non small cell lung cancer: a brief report of the retrospective
analysis of a three-arm randomized trial.
JOURNAL OF THORACIC ONCOLOGY, 12:1568-1571, 2009.
246. Mattioli R, Gridelli C, Castellanos J,Dunque A, falcone A, Massutti M, Bacon P,
Lawrinson S, Skacel T, Casas A. “Use of pegfilgastrim support on day 9 to maintain
dose intensity of chemotherapy in breast cancer patients receiving day 1 and 8 CMF
regimen”.
CLIN TRANSL ONCOL ,11:842-848, 2009.
247. Rossi A, Galetta D, Gridelli C. “Biological prognostic and predictive factors in
lung cancer”. ONCOLOGY, 77 (suppl 1):90-96, 2009.
248. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R,
Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F. Recent issues in firstline treatment of advanced non small cell lung cancer: results of an International
Expert Panel Meeting of the Italian Association of Thoracic Oncology.
LUNG CANCER, 68:319-331, 2010.
249. Gridelli C, Haiderali AM, Russo MW, Blackburn LM, Lykopoulos K. “Casopitant
improves quality of life in patients receiving highly emetogenic chemotherapy.
SUPPORTIVE CARE IN CANCER, 18:1437-1444, 2010.
250. Gridelli C, Morabito A, Gebbia V,Mencoboni M, Carroozza F, Viganò MG,
Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A,
Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F.
“Catuximab and gemcitabine in elderly or adult patients with advanced non small cell
lung cancer: the Cetuximab in advanced lung cancer (CALC-1E and CALC,PS2)
randomized phase II trials”.
LUNG CANCER, 67:86-92, 2010.
251. Pallis A, Shepherd FA, Lacombe D, Gridelli C. “Treatment of snmall cell lung
cancer in elderly patients”.
CANCER, 116:1192-2000, 2010.
252. Pallis AG, Gridelli C. “Is age a negative prognostic factor for the treatment of
advanced/metastatic non small cell lung cancer?”
CANCER TREATMENT REVIEW, 36:436-441, 2010.
118
253. Gridelli C, Di Maio M. “The role of pemetrexed as maintenance treatment in
advanced NSCLC: a phase III randomized trial”.
EXPERT OPINION IN PHARMACOTHERAPY, 11:321-324, 2010.
254. Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazieres J, Cappuzzo F,
Fruh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O’Byrne K, Rosell R.
“Meeting report: 2 meeting of the European Thoracic Oncology Platform (ETOP)”.
LUNG CANCER, 68:121-124, 2010.
255. Rossi A, Maione P, Bareschino MA, Schettino C, Sacco PC, Ferrara ML, Castaldo
V, Gridelli C. “The emerging role of histology in the choice of first-line treatment of
advanced non small cell lung cancer: implication in the clinical decision-making.
CURRENT MEDICINE CHEMISTRY, 17:1030-1038, 2010.
256. Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, Perrone
F. Methodological aspects of lung cancer clinical trials in the era of targeted terapie.
LUNG CANCER, 67:127.135, 2010.
257. Gridelli C. “Can a decisional alghorithm be used in first-line treatment of advanced
non small cell lung cancer?”.
CURRENT OPINION IN ONCOLOGY, 22:77-78, 2010.
258. Rocco G, Perrone F, Rossi A, Gridelli C. “Surgical management of non small cell
lung cancer with mediastinal lymphadenopathy”.
CLINICAL ONCOLOGY, 22:325-333, 2010.
259. Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C,
Torri V. “Maintenance or consolidation therapy in small cell lung cancer: a systematic
review and meta-analysis”.
LUNG CANCER, 70:119-128, 2010.
260. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E,
Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P,
Piccirillo MC, Perrone F, Gallo C, Gridelli C. “Clinical assessment of patients with
advanced non small cell lung cancer eligible for second-line chemotherapy: a
prognostic score from individual data of nine randomized trials”.
EUROPEAN JOURNAL OF CANCER,46:735-743, 2010.
261. Barni S, Maltoni M, Tuveri G, Pronzato P, Cortesi E, Masidda B, Colucci G, Iacono
C, Lorusso V, Gridelli C, Aitini E, Simoni L, Torta R. “Attitude of Italian medical
oncologist toward palliative care for patients with advanced cancer:results of the SIO
project”.
SUPPORTIVE CARE CANCER, 19:381-389, 2010.
262. Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D,
Welch J, Belani CP, Aapro M. “EORTC Elderly Task Force and Lung Cancer Group
and International Society for Geriatric Oncology (SIOG) experts opinion for the
treatment of non small cell lung cancer in an elderly population”.
ANNALS OF ONCOLOGY, 21:692-706, 2010.
119
263. Gridelli C, Rossi A, Bareschino M Schettino C, Sacco PC, Maione P. “The
potential role of insulin-like growth factor receptor inhibitors in the treatment of
advanced non small cell lung cancer”.
EXPERT OPIN INVESTIG DRUGS, 19:631-639, 2010.
264. Rossi A, Maione P, Ambrosio R, Falanga M, Gridelli C. “Vascular Endothelial
Growth factor Receptor as target for advanced non small cell lung cancer”.
CURRENT DRUG TARGETS, 11:865-878, 2010.
265. Gridelli C, Maione P, Bareschino M, Schettino C, Sacco PC, Ambrosio R,
Barbato V, Falanga M, Rossi A. “Erlotinib in the treatment of non small cell lung
cancer: current status and future developments.
ANTICANCER RESEARCH, 30:1301-1310, 2010.
266. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Gridelli C.
“Advances in chemotherapy in advanced non small cell lung cancer”.
EXPERT OPIN PHARMACOTHER, 11:2992-3007, 2010.
267. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowoski
M, Heigener D. “Erlotinib in advanced non small cell lung cancer: efficacy and
safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment
Study”.
JOURNAL OF THORACIC ONCOLOGY, 5:1616-1622, 2010.
268. Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Doillard
JY.”Future scenario for the treatment of advanced non small cell lung cancer:focus
on taxanes.containing regimens”.
ONCOLOGIST, 15:1102-1115, 2010.
269. Gridelli C, Rossi A, Maione P, Ambrosio R, Barbato V, Bareschino MA,
Schettino C, Palazzolo G, Saco PC. “The role of maintenance treatment in advanced
non small cell lung cancer: reality or early second-line?”.
CLINICAL LUNG CANCER, 11:374-382, 2010.
270. Gridelli C, Rossi A.”Unsewered questions: monoclonal antibodies in the
treatment of advanced non small cell lung cancer”.
ONCOLOGY, 24:1216-1223, 2010.
271. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Ferrara ML, Falanga
M, Ambrosio R, Gridelli C. “Treating advanced non small cell lung cancer in the
elderly”.
THER ADVAN MED ONCOL,2:251-60, 2010.
272. Gridelli C, Morgillo F. Favaretto A, De Marinis F, Chella A, Cerea G, Mattioli
R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M,
Ciardiello F. “Sorafenib in combination with erlotinib or with gemcitabine in elderly
patients with advanced non small cell lung cancer: a randomized phase II study.
ANNALS OF ONCOLOGY, 22:1528-1534, 2011.
120
273. Maione P, Rossi A, Bareschino MA, Sacco PC, Schettino C, Falanga M, Barbato
V, Ambrosio R, Gridelli C. “Factors driving the choice of the best second-line
treatment of advanced NSCLC”.
REV RECENT CLIN TRIALS, 6:44-51, 2011.
274. Gridelli C, de Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.
“Gefitinib as first-line treatment for patients with advanced non small cell lung
cancer with activating epidermal growth factor receptor mutation: review of the
evidence.
LUNG CANCER , 71:249-257,2011.
275. Gridelli C, de Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.
“Gefitinib as first-line treatment for patients with advanced non small cell lung
cancer with activating epidermal growth factor receptor mutation: implication for
clinical practice and open issues”.
LUNG CANCER,72:3-8, 2011.
276. Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, Sacco PC, Zeppa R.
“Pemetrexed in advanced non small cell lung cancer”.
EXPERT OPINION ON DRUG SAFETY, 10:311-317, 2011.
277. Gridelli C, Rossi A, Venturino P, de Marinis F. “Treatment, rationale, and study
design of TALISMAN study: a randomized phase II open-label study of second-line
erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former
smoker men affected by recurrent squamous non small cell lung cancer.
CLINICAL LUNG CANCER, 12:70-73, 2011.
278. Gridelli C. “First-line treatment for advanced non small cell lung cancer
harboring activating epidermal growth factor receptor mutation: epidermal growth
factor receptor tyrosine kinase inhibitors or chemotherapy?
CURRENT OPINION IN ONCOLOGY, 23:131-132, 2011.
279. Sacco PC, Maione P, Rossi A, Bareschino MA, Schettino C, Guida C, Elmo M,
Ambrosio R, Barbato V, Zeppa R, Palazzolo G, Gridelli C. “Combination of
chemotherapy and targeted terapie in the treatment of locally advanced non small cell
lung cancer”.
TARGETED ONCOLOGY, 3:171-180, 2011.
280. De Marinis F, Rossi A, Di Maio M,Ricciardi S, Gridelli C. “Treatment of
advanced non small cell lung cancer: Italian Association of Thoracic Oncology
(AIOT) clinical practice guidelines”.
LUNG CANCER, 73:1-10, 2011.
281. Felip E, Gridelli C, Baas P, Rosell R, Stahel R & Panel Members “Metastatic non
small cell lung cancer: consensus on pathology and molecular tests, first-line, second121
line, and third-line therapy.” 1 ESMO Consensus Conference in Lung Cancer;
Lugano 2010.
ANNALS OF ONCOLOGY, 22:1507-1519, 2011.
282.
Gridelli C, Ardizzoni A, Barni S, Crinò L, Caprioli A, Piazza E, Lorusso V, Barbera S,
Zilembo N, Gebbia V, Adamo V, Pela R, Marangolo M, Morena R, Filippelli G, Buscarino C,
Alabiso O, Maione P, Venturino P, De Marinis F. “ Medical treatment choices for patients
affected by advanced NSCLC in routine clinical practice: results from the Italian observational
SUN (Survey on the lUng cancer maNagement) study.
LUNG CANCER, 74:462.468, 2011.
283. Rossi A, Maione P, Schettino C, Bareschino MA, Sacco PC, Ambrosio R,
Barbato V, Zeppa R, Palazzolo G, Gridelli C. “Non small cell lung carcinoma
vaccine in clinical trials”.
EXPERT REV VACCINES, 10:887-987, 2011.
284. Gridelli C, Rossi A, Maione P, Schettino C, Bareschino MA, Palazzolo G, Zeppa
R, Ambrosio R, Barbato V, Sacco PC. “Non small cell lung cancer therapy in the
elderly”.
CLINICAL ADVANCE HEMATOLOGY ONCOLOGY, 9:375.383, 2011.
285. Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F,
Rossi A, Thatcher N, Wong EK, Langer C. “Randomized phase IIIb trial evaluating
the continuation of bevacizumab beyond disease progression in patients with
advanced non-squamous non small cell lung cancer after first-line treatment with
bevacizumab plus platin-based chemotherapy: treatment rationale and protocol
dynamics of the AvaALL (MO22097) trial.
CLINICAL LUNG CANCER, 12:407-411, 2011.
286. Rossi A, Torri V, Gridelli C. “Switch maintenance versus early second-line
treatment in advanced non samll cell lung cancer”.
JOURNAL OF THORACIC ONCOLOGY, 6:1298, 2011.
287. Brodowicz T, Cialeanu T, Crawford G, Filipts M, Fischer JR, Georgoulias V,
Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold C, Pujol JL,
Stahel R, Thatcher N, Vansteenkiste, Minichsdorfer C, Zochbauer-Muller S, Pirker
R, Zielinski CC. “Third CECOG Consensus on the systemic treatment of non small
cell lung cancer”. ANNALS OF ONCOLOGY, 23:1223-1229, 2012.
288. Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P,
Rossi A, De Marinis F. “Treatment decision-making for advanced non small cell lung
cancer and differencies among European countries: 1st AIOT/ETOP meeting”.
LUNG CANCER, 74:544.548, 2011.
289. Gridelli C, Rossi A, Maione P. 2010 Conseunsus on lung cancer:new clinical
recommendations and current status of biomarkers assessment- fist-line therapy.
EUROPEAN JOURNAL OF CANCER, 47 (suppl3):S248-S257, 2011.
122
290. Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S,
Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello G,
De Maio E, Di Maio M, Rocco G, Vecchione A, Perrone F. “ Phase I-II trial of
gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly
patients with performance status 0-2: the G-STEP trial.
JOURNAL OF THORACIC ONCOLOGY, 7:233-242, 2011.
291. Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P,
Ciardiello F, Gridelli C. “The role of antiangiogenetic agents in the treatment of
breast cancer”.
CURRENT MEDICAL CHEMISTRY, 18:5022-5032, 2011.
292. Gridelli C, Felip E. “Targeted therapies development in the treatment of advanced
non small cell lung cancer”.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY,11:1-2, 2011.
293. Gridelli C, Brodowicz T, Langer CJ, Peterson P, Islam M, Guba SC, Moore P,
Visseren-Grul CM, Scagliotti G. “Pemetrexed therapy in elderly patients with good
performance status: analysis of two phase III trials of patients with nonsquamous non
small cell lung cancer”.
CLINICAL LUNG CANCER, 13.340-346, 2012.
294. Gridelli C, De Marinis F, Di Maio M, Ardizzoni A, Belani C, Cappuzzo F,
Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R.
“Maintenance treatment of advanced non small cell lung cancer : Results of an
International Expert Panel Meeting of the Italian Association of Thoracic Oncology”.
LUNG CANCER, 76:269-279, 2012.
295. Schettino C, Bareschino M, Rossi A, Maione P, Sacco PC, Colantuoni G, Rossi
E, Gridelli C. “Targeting angiogenesis for treatment of NSCLC brain metastases”.
CURRENT CANCER DRUG TARGETS, 12:289-299, 2012.
296. Bareschino M, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, Gridelli C.
“Treatment of advanced non small cell lung cancer”.
JOURNAL OF THORACIC DISEASE,3:122-133, 2012.
297. Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi FV,
Bilancia D, Cigolari S, Barbera S, Gebbia V, Daniele B, Robbiati SF, Illiano A,
Ceribelli A, Carrozza F, Favaretto A, Piazza E, Piccirillo MC, Daniele G, Giordano
P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C. “Prognostic
impact of education level of patients with advanced non small cell lung cancer
enrolled in clinical trials”. LUNG CANCER, 76:457-464, 2012.
298. Gridelli C. “Personalized medicine in the treatment of advanced non small cell
lung cancer: a step-by-step progress”.
CURRENT OPINION IN ONCOLOGY, 24:115-116, 2012.
123
299. Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O,
Sahoo TP, Laack E, Reck M, Corral J, Chouaki N, Zimmemrmann AH,
Visseren.Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best
supportive care versus placebo plus best supportive after induction therapy with
pemetrexed plus cisplatin for advanced non-squamous non small cell lung cancer
(PARAMOUNT): a double blind, phase III randomized controlled trial.
LANCET ONCOLOGY, 13:247-255, 2012.
300. Di Maio M, Krzakowski M, Fougeray D, Kowalski M, Gridelli C. “Prognostic
score for second-line chemotherapy of advanced non small cell lung cancer: external
validation in a phase III trial comparing vinflunine with docetaxel.
LUNG CANCER, 77:116-120, 2012.
301. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Sklaros DV, Fruh M,
Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli
O, Lee S-M. “Carboplatin or cisplatin-based chemotherapy in first-line treatment of
small cell lung cancer: the COCIS meta-analysis of individual patient data”.
JOURNAL OF CLINICAL ONCOLOGY, 30:1692-1698, 2012.
302. Gridelli C, Rossi A. “ EURTAC first-line phase III randomized study in advanced
non small cell lung cancer: erlotinib works also in European population”.
JOURNAL OF THORACIC DISEASE, 4:219-220, 2012.
303. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhard G, Bruix for the SHARP
Investigators ….Gridelli C…… “Plasma biomarkers as predictors of outcome in
patients with advanced hepatocellular carcinoma.
CLINICAL CANCER RESEARCH, 18:2290-2300, 2012.
304. Sgambato A, Casaluce F, Maione P, Rossi A, Napolitano A, Palazzolo G,
Bareschino M, Schettino C, Sacco PC, Ciardiello F, Grideli C. “The role of EGFR
tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung
cancer patients harbouring EGFR mutation”.
CURRENT MEDICINE CHEMISTRY, 19:3337-3352, 2012.
305. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo
F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S,
Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Contile F, Tsao M, da Cumba
Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. “First-line erlotinib
follone by second-line cisplatin-gemcitabine chemotherapy in advanced non small
cell lung cancer: the TORCH randomized trial.
JOURNAL OF CLINICAL ONCOLOGY, 30:3002-3011, 2012.
306. Gridelli C, Rossi A, Airoma G, Bianco R, Costanzo R, Daniele B, De Chiara G,
Grimaldi G, Irtelli L, Maione P, Morabito A, Piantedosi FV, Riccardi F. “Treatment
of pulmonary neuroendocrine tumors: state of the art and future development”.
CANCER TREATMENT REVIEWS, 39:466-472, 2012.
124
307. Gridelli C. “Locally advanced NSCLC in the elderly: which treatment?”
NATURE REVIEWS CLINICAL ONCOLOGY, 9:434-435, 2012.
308. Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G,
Bareschino M, Schettino C, Sacco PC, Ciardiello F, Gridelli C. “The c-Met inhibitors: a
new class of drugs in the battle against advanced non small cell lung cancer”.
CURRENT PHARMACEUTICAL DESIGN, 18:6155-6168, 2012.
309. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E on behalf of the ESMO
Guidelines Working Group” “Metastatic non small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up”.
ANNALS OF ONCOLOGY, 23(suppl 7):vii56-vii64, 2012.
310. Rossi A, Gridelli C, Ricciardi S, de Marinis F. “Bone metastases and lung cancer:
from biphosphonates to targeted therapies”.
CURRENT MEDICAL CHEMISTRY, 19:5524-5535, 2012.
311. Bearz A, Passalacqua R, Alabiso O, Cinieri S, Gridelli C, Cravesana C, Crinò L.
“First-line bevacizumab-based therapy in advanced nons-quamous non small cell lung
cancer; analysis of the Italiean patients enrolled in the SAil study”.
CLINICAL DRUG INVESTIGATION, 32:755-760, 2012.
312. Gridelli C, de Marinis F, Pujol J-L, Reck M, Rampau R, Parente B, Pieters T.
Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer G,
Chouaki N, Visseren-Grul C, Paz-Ares L.”Safety, resource use and quality of life in
PARAMOUNT: a phase III study of maintenance pemetrexed versus placebo after
induction pemetrexed plus cisplatin for advanced non-squamous non small cell lung
cancer”.
JOURNAL OF THORACIC ONCOLOGY, 7:1713-1721, 2012.
313. Di Maio M, Leigh NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V,
Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi
F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G,
Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C. “Quality of life
analysis of TORCH, a randomised trial testing first-line erlotinib follone by second-line
cispaltin/gemcitabine chemotherapy in advanced non small cell lung cancer.”.
JOURNAL OF THORACIC ONCOLOGY,7:1830-1844, 2012.
314. Santoro A, Rimassa L, Barbath I, Daniele B, Salvagni S, Van Laetherm JL, Van
Vlieberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Cicalese L,
Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personemi N,
Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, ChenY, Porta
C. “Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a
randomized, placebo-controlled phase II study”.
LANCET ONCOLOGY, 14:55-63, 2012.
125
315. Gridelli C, Gallo C, Butts C, Ciardiello F, Feld R, Perrone F. “Reply to V.
Lorusso et al.”. JOURNAL OF CLINICAL ONCOLOGY, 31:289-299, 2012.
316. Gridelli C. “Maintenance therapy: a new treatment paradigm in advanced non
small cell lung cancer”.
CURRENT OPINION IN ONCOLOGY, 25:105-106, 2013.
317. Gridelli C, Maione P, Rossi A. “The PARAMOUNT trial: a phase III randomized
study of maintenance pemetrexed versus placebo immediately following induction
first-line treatment with pemetrexed plus cisplatin for non squamous non small cell
lung cancer”.
REVIEWS RECENT CLINICAL TRIALS, 8:23-28, 2013.
318. Casaluce F, Sgambao A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo
G, Ciardiello F, Gridelli C. “ALK inhibitors: a new targeted therapy in the treatment
of advanced NSCLC”.
TARGETED ONCOLOGY, 8:55-67, 2013.
319. Schettino C, bareschino M, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato
A, Gridelli C. “New molecular targets in the treatment of NSCLC”.
CURRENT PHARMACEUTICAL DESIGN, 19:5333-5343, 2013.
320. Marchetti A, Ardizzoni A, Papotti M, Crinò L, Rossi G, Gridelli C, Barberis M,
Maiorano E, Normanno N, Taddei GL, Scagliotti G, Clemente C, Pinto C.
“Recommendations for the analysis of ALK gene rearrangement in non small cell
lung cancer: a consensus of the Italian Association of Medical Oncology and the
Italian Society of Pathology and Cytopathology”.
JOURNAL OF THORACIC ONCOLOGY, 8:352-358, 2013.
321. Casaluce F, Sgambato Am Maione P, Ciardiello F, Gridelli C. “Emerging mitotic
inhibitors for non small cell lung cancer”.
EXPERT OPINION ON EMERGING DRUGS,18:97-107, 2013.
322. Gridelli C, Paz-Ares L. The PARAMOUNT study and the re-challange
chemotherapy issue in advance non small cell lung cancer”.
EUROPEAN JOURNAL OF CANCER, 2013.
323. Morabito A, Gebbia V, Di Maio M, Conieri S, Viganò MG, Bianco R, Barbera S,
Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino
A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G,
Gridelli C, Gallo C, Perrone F. “Randomized phase III trial of gemcitabine and
cisplatin vs gemcitabine alone in patients with advanced non small cell lung cancer
and performance status of 2: the CAPPA-2 study”.
LUNG CANCER, 81:77-83, 2013.
324.
Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N,
Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli
C, Caraglia M, Tassone P, Tagliaferri P, Correale P. “Systemic inflammatory status
at baseline predictc bevacizumab benefit in advanced non small cell lung cancer
126
patients”.
CANCER BIOLOGIC THERAPY, 14:469-475, 2013.
325. Groen HJM, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts C,
Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC,
Blumenschein GR.”A randomiozed, doubl-blind, phase II study of erlotinib with or
without sunitinib for the second-line treatment of metastatic non small cell lung
cancer”. ANNALS OF ONCOLOGY, 2013.
326. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O,
Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N,
Zimmermann A, Visseren-Grul C, Gridelli C. “PARAMOUNT: final overall survival
results of the phase III study of maintenance pemetrexed versus placebo immediately
after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous
non small cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY, 31:2895-2902, 2013.
327. Gridelli C. “Lung cancer: defining standard of care for performance status2- don’t
rush”. NATURE REVIEW CLINICAL ONCOLOGY, 10:490-492, 2013.
328. Sgambato A, Casaluce F, Maione P, Rossi A, Sacco PC, Panzone F, Ciardiello F,
Gridelli C.” Medical treatment of small cell lung cancer: state of the art and new
development”. EXPERT OPINION PHARMACOTHERAPY, 14:2019-2031,
2013.
329. Reaume MN, Leigh NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D,
Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans
WK. “Economic analysis of a randomized phase III trial of gemcitabine plus
vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for
advanced non small cell lung cancer (ItalianGEMVIN3/NCIC CTG BR14 trial).
LUNG CANCER, 82:115-120, 2013.
330. Di Maio M, Gridelli C, Grossi F, Novello S, de Marinis F. “Afatinib in advanced
non small cell lung cancer”.
LUNG CANCER MANAGEMENT, 2:493-504,2013.
331. Maione P, Gridelli C, Rossi A, Sacco PC, Bareschino MA, Schettino C, Casaluce
F, Sgambato A. “Selumetinib in advanced non small cell lung cancer (NSCLC)
harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.”
REVIEW RECENT CLINICAL TRIALS, 2013.
332. Maione P, Rossi A, Bareschino M, Sacco PC, Schettino C, Casaluce F, Sgambato
A, Gridelli C. “Irreversible EGFR inhibitors in the treatment of advanced NSCLC”.
CURRENT PHARMACEUTICAL DESIGN, 2013.
127
333. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei A, Ciardiello F. “ALK
inhibithors in the treatment of advanced NSCLC”.
CANCER TREATMENT REVIEW,40:300-306, 2014.
334. Paz-Ares L, de Marinis F, Visseren-Graal C, Gridelli C. Reply to S Barni et al,
KR Dearing and N Murray. JOURNAL OF CLINICAL ONCOLOGY, 2014.
335. Gridelli,C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch F, Mok T, Morgillo F,
Rosell R, Spigel D, Yang J, Ciardiello F. Treatment of advanced non small cell lung
cancer with Epidermal Growth Factor receptor (EGFR) mutation or ALK gene
rearrangement: results of an International Expert Panel Meeting of the Italian
Association of Thoracic Oncology.
CLINICAL LUNG CANCER, 2014.
336. Sacco PC, Maione P, Rossi A, Bareschino MA, Sgambato A, Casaluce F,
Napolitano A, Palazzolo G, Rossi E, Ferrara C, Gridelli C. “The PI3K inhibitors: new
hopes in the battle against advanced NSCLC”.
FRONTIERS BIOSCIENCE, 19:259-271, 2014.
337. Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA,
Cinieri S, Bianco R, Ciardiello F,Cavanna L, Bordonaro R, Costanzo R,
Sandomenico C, Gallo C, Perrone F, MorabitoA. “Rationale and design of MILES-3
and MILES-4 studies: two randomized phase 3 trials comparing single agent
chemotherapy versus cisplatin-based doublets in elderly patients with advanced non
small cell lung cancer.
CLINICAL LUNG CANCER, 2014.
338. Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W,
Zimmermann AH, Visseren-Grul C, Gridelli C. “PARAMOUNT: descripetive
subgroup analyses of final overall survival for the phase III study of maintenance
pemetrexed versus placebo following induction treatment with pemetrexed plus
cisplatin for advanced nonsquamous non small cell lung cancer.
JOURNAL OF THORACIC ONCOLOGY, 2014.
339. Krzakowski M, Lucas C, Gridelli C. “Fractionated scheme of oral vinorelbine as
single agent or in combination with cisplatin concomitantly with thoracic
radiotherapy in stage III non small cell lung cancer: escalation-dose phase I trial.
CLINICAL LUNG CANCER, 2014.
340. Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M,
Luciani A, O’Brien M. “Management of elderly patients with NSCLC; updated
ecpert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and
International Society for Geriatric Oncology”.
ANNALS OF ONCOLOGY, 2014.
128
341. Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, de Marinis F,
Genestreti G, Crinò L, Grossi F, Caffo O, Ferraù F, Cruciani G, Brandes AA, Galetta
D, Barni S, Fasola G, Cerea G, Ferrari S, Iannaccone C, Ciardiello F. “Phase II
randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as
first-line treatment of advanced non small cell lung cancer in elderly patients”.
JOURNAL OF THORACIC ONCOLOGY,9:733-737, 2014.
342. Di Maio M, de Marinis F, Hirsch F, Gridelli C. “ Diagnostic and therapeutic
issues for patients with advanced non small cell lung cancer harboring anaplastic
lymphoma kinase rearrangement: European vs US perspective”.
INTERNATIONAL JOURNAL OF ONCOLOGY, 45:509-515, 2014.
343. Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo
G, Ciardiello F, Gridelli C. “ALK inhibitors and advanced NSCLC”.
INTERNATIONAL JOURNAL OF ONCOLOGY, 45:499-508, 2014.
344. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F,
Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini
A, Iurlaro M, Caprioli A. “Advanced non small cell lung cancer management in
patients progressing after first-line treatment: results of the cross-sectional phase of
the italian LIFE observational study”.
CANCER RES CLIN ONCOL, 2014.
345. De Marinis F, Ardizzoni A, Fonatnini G, Grossi F, Cappuzzo F, Novello S, Santo
A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C. “Management of
italian patients with advanced non small cell lung cancer after second-line treatment:
results of the ongitudinal phase of the LIFE observational study”.
CLINAL LUNG CANCER, 2014.
346. Gridelli C, De Marinis F, Thomas M, Prabhash K, El Kouri C, Blackhall F,
Bustin F, Pujol JL, Jhon WJ, San Antonio B, Zimmermann A, Choulaki N, VisserenGrul C, Paz-Ares L. “Final efficacy and safety results of pemetrexed continuation
maintenance therapy in the elderly from the PARAMOUNT phase III study”.
JOURNAL OF THORACIC ONCOLOGY, 9:991-997, 2014.
347. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab
in advanced non small cell lung cancer (NSCLC): the showdown? JOURNAL OF
THORACIC DISEASE, 6:578-580, 2014.
348. Maione P, Sgambato A, Rossi A, Sacco PC, Bareschino M, Schettino C, Casaluce
F, Ciardiello F, Gridelli C. Selumetinib in advanced non small cell lung cancer
(NSCLC) harboring KRAS mutation: endless clinical challenge to KRAS mutant
NSCLC. REVIEW ON RECENT CLINICAL TRIALS, 2014.
349.
129
CITATION INDEX
12.878 citations on international indexed journal and h Index 55
(Publish or Perish 4 )
130